AIDS/LifeCycle 8 to Raise $10.5 Million to Fight AIDS

2,150 cyclists to start San Francisco-to-Los Angeles ride May 31

SAN FRANCISCO and LOS ANGELES, May 31 /PRNewswire-USNewswire/ -- More than 2,150 bicyclists from 41 states and 14 nations will stream out of San Francisco on May 31 en route to Los Angeles as participants in the colorful and emotional AIDS/LifeCycle, the world's largest annual HIV/AIDS fundraiser.

The 545-mile trek is expected to raise $10.5 million to support vital HIV/AIDS-related services at the L.A. Gay & Lesbian Center and the San Francisco AIDS Foundation. The event also raises awareness about the disease, particularly significant this year following a recent survey* revealing a dramatic drop in the sense of urgency about HIV/AIDS and persistent misconceptions about HIV transmission and treatment among Americans.

Participants on the weeklong ride include cyclists and a volunteer support crew of hundreds of "roadies" who range in age from 18 to 78. Whether gay or straight, HIV-positive or HIV-negative, expert cyclists or novices, they share a commitment to reducing new infections and the suffering caused by AIDS.

"People come to AIDS/LifeCycle to fight a disease," said Mark Cloutier, CEO of the San Francisco AIDS Foundation and one of the cyclists. "But the event is also a celebration of health. Participants have the physical strength to complete a challenging course, and the emotional connectedness to help others succeed on an exhausting, yet exhilarating journey."

Riders train for months to prepare for the rigorous ride, and raise a minimum of $3,000 each to support the work of the two sponsoring organizations. The event has raised approximately $50 million to fight AIDS since it began in 2002.

"The economic recession has deeply impacted HIV/AIDS service providers on all fronts. Charitable giving and government funding of HIV/AIDS support services are dropping while the number of people who need free or low-cost services is going up," said Lorri L. Jean, CEO of the L.A. Gay & Lesbian Center. "Our participants and their supporters recognize the urgent need for HIV prevention. I'm proud of the AIDS/LifeCycle community, and I'm deeply grateful."

This year's ride is the first since federal health officials reported that new HIV infections are much higher than previously thought.** During the seven days of AIDS/LifeCycle, an estimated 1,080 Americans will become infected with HIV. There are 1.1 million Americans living with HIV--the highest number in the history of the epidemic--1 in 6 of whom are Californians. Gay and bisexual men bear the brunt of the disease, representing 73 percent of all HIV/AIDS cases in California and 53 percent nationally. Communities of color are also disproportionately affected; although African Americans comprise 6 percent of the state's population, they account for nearly 19 percent of those living with HIV/AIDS.

AIDS/LifeCycle's presenting sponsors are Shopoff Properties Trust, FedEx Corporation, and Gilead Sciences.

* In April 2009, the Kaiser Family Foundation released survey findings that showed that only 6 percent of Americans call HIV/AIDS the most urgent health problem facing the nation, down from 44 percent in 1995; see: http://www.kff.org/kaiserpolls/posr042809nr.cfm

** In July 2008, the U.S. Centers for Disease Control and Prevention released a study that the annual HIV infection rate in the U.S. is 40 percent higher than previously estimated. See: http://cdc.gov/hiv/topics/surveillance/resources/factsheets/incidence.htm

FACTS AND VISUALS:

As they make their way through eight California counties, the cyclists collectively consume 420 gallons of coffee, 6,200 pounds of vegetables and 5,400 Pop Tarts. But they likely end up somewhat lighter, according to event organizers, because a 170-pound cyclist burns an average of 3,410 calories a day during AIDS/LifeCycle.

Each day of the ride, 500 roadies set up and break down tents, kitchens, and mobile bathroom and shower facilities. They provide riders with directional signage, first aid and bicycle repair services. They serve snacks to weary riders at rest stops and ensure a steady stream of entertainment by flamboyantly costumed performers. And they drive "sag wagons" that scoop up riders whose energy runs out before the road does.

Many riders stop at hills to cheer on other cyclists. They're often joined by locals, who turn out at many points along the route to applaud, offer refreshments, and hold signs bearing the names of loved ones lost to AIDS.

Beginning June 1, event photos and journals can be viewed at http://experience.aidslifecycle.org. Additional information about the history of the event, a list of sponsoring organizations and profiles of several participants can be found in AIDS/LifeCycle's online pressroom at www.aidslifecycle.org/press-room/.

DETAILS OF THE RIDE:

The route of the ride and the location of overnight campsites are as follows:

Sunday, May 31: Opening Ceremony at the Cow Palace, 2600 Geneva Ave., Daly City. Ride 79.4 miles to Santa Cruz and camp at Harvey West Park, 326 Evergreen Street.

Monday, June 1: Ride 107.6 miles to King City and camp at San Lorenzo County Park, 1160 Broadway.

Tuesday, June 2: Ride 63.4 miles to Paso Robles and camp at the Mid-State Fairgrounds, 2198 Riverside Avenue.

Wednesday, June 3: Ride 94.1 miles to Santa Maria and camp at Preisker Park, 2301 Preisker Lane.

Thursday, June 4: Ride 67.7 miles to Lompoc and camp at River Park, Sweeney Road & Highway 246.

Friday, June 5: Ride 85.5 miles to Ventura and camp at San Buenaventura State Beach, 901 San Pedro Street.

Saturday, June 6: Ride 61.5 miles to Los Angeles. Closing Ceremony at the VA Center, 11301 Wilshire Boulevard.


SOURCE AIDS/LifeCycle

Pain-Free, Hair-Free System Set to Transform Hair Removal

Near Infra Red technology (NIR) delivers revolutionary pain free hair removal. Glasgow clinic is one of the first in UK to offer genuine groundbreaking hair removal laser technology - the innovative Pain-Free, Hair-Free system.

MANCHESTER, England, May 31 /PRNewswire/ -- Transform, the UK's largest group of plastic surgery clinics, announces that its Glasgow clinic is one of the first in the UK to install the ground-breaking system that uses NIR (near infra red) technology to deliver super fast, pain-free hair removal. This step-forward in cosmetic treatments means Scottish women and men will be amongst the first to trial the gentlest hair removal treatment available to the UK.

Intense Pulsed Light to Near Infra Red hair Removal

Unlike traditional laser and IPL (Intense Pulsed Light) technologies on the market, NIR does not cause any of the stinging or discomfort associated with laser treatments and electrolysis and removes the need for daily shaving, painful plucking and expensive waxing to provide silky smooth hair free skin.

Fastest hair removal treatment in UK

The Pain-Free, Hair-Free treatment visibly reduces hair re-growth within the first two sessions, making it the fastest acting hair removal treatment on the market. A typical NIR hair removal course can produce hair-free skin within seven sessions meaning the next generation laser system can half treatment times normally associated with IPL.

Pain-Free, Hair-Free's effective treatment offers the ideal solution to modern day time-precious lifestyles by removing unwanted hair on the face, legs, back, bikini line and any other body area.

Revitalises Dull Skin and Reduces Wrinkles

The NIR system can also be used to rejuvenate and revitalize dull skin, remove uneven colour and pigments and stimulate collagen production to reduce fine lines and wrinkles, the perfect way to brighten skin during the long Scottish winter. This new addition to Transform's Glasgow premises promises to refine, pamper and rejuvenate skin of any age.

Other non surgical treatments available at Transform include the popular CACI Non-surgical face lift, Microdermabrasion, rhinoplasty, abdominoplasty, breast reduction and Botox. Transform is the UK's leading plastic surgery provider. All types of cosmetic surgical treatments are undertaken from breast augmentation to gastric band surgery.

For further information or to arrange sample treatment for press purposes please contact:
Laura Duncan on 0141 222 2266 or email laura.duncan@dada.co.uk
Julie MacSporran on 0141 222 2266 or email julie.macsporran@dada.co.uk
http://www.transform.co.uk

Notes to the editor

Transform Cosmetic Surgery Group is Britain's largest and most popular cosmetic surgery group network with over 30 years experience and 24 clinics across the UK
http://www.transform.co.uk / http://www.transforminglives.co.uk/hair/hair_removal.aspx
Transform offers a comprehensive and extensive post-operative care programme, which is included in the cost of the treatments. The programme serves to ensure that recovery is as swift and problem free as possible.
Transform works with highly qualified and specialist cosmetic surgeons and nursing staff.
Transform is a member of the Covenant Healthcare Group

This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.


SOURCE Transform Cosmetic Surgery Group

Zeus to Present at Digestive Disease Week in Chicago

Zeus Research & Development will be one of the presenters at Digestive Disease Week, addressing the topic of invention of new devices in interventional gastroenterology

ORANGEBURG, S.C., May 29 /PRNewswire/ -- Zeus, Inc., a leader in polymer extrusions and material science, announces it has been invited to present at Digestive Disease Week in Chicago on June 1, 2009. Zeus presenters Dr. Bruce Anneaux, Ph.D. and GI Endoscopy Specialist Aubrey Sanders will address possible polymer selection for building new and innovative medical devices for interventional procedures in gastrointestinal endoscopy and Natural Orifice Translumenal Endoscopic Surgery (NOTES).

Digestive Disease Week is the world's largest meeting of researchers, physicians, and other professionals in the fields of gastroenterology, endoscopy, gastrointestinal surgery, and hepatology.

When Dr. Naomi Nakao, a prolific inventor of 20 years extended her invitation to Zeus to speak at the conference, she prefaced her invitation as follows: "Being an inventor can be a lonely journey, but Zeus has faithfully stood by me for these many years. Zeus engineers have generously helped me during my research and development of the many prototypes of my inventions. I was gently brought down to earth by Zeus engineers, learning what is, and is not, possible in building my devices. Sharing their company's varied capabilities, I learned from Zeus' engineers that things I did not think possible could be built because of the enormous imagination that Zeus puts into its colossal ensemble of shapes, forms, colors, and sizes of the catheters and other sub-components that it has to offer."

The Zeus presentation will focus primarily on developing industry advancements in polymer science with an emphasis on gastroenterology and endoscopy of the present and future. At the conclusion of the presentation, Dr. Anneaux and Ms. Sanders will participate in an open panel discussion.

Commenting on his presentation Dr. Bruce Anneaux, Corporate Manager, Research & Development for Zeus, said, "We are excited about the opportunity to present at a gathering of this scope and significance. Both the Zeus presentation and open panel discussion seek to enhance attendees' understanding of polymer selection and create an open dialogue among the innovators in gastroenterology/endoscopy medical device industry."

Bob Jennings, Vice President for Medical Sales and Marketing, said, "Zeus has an evolving history of exploring and advancing innovative concepts and processes in the medical device industry. It is this commitment that allows us to serve as a resource for inventors, physicians, and other professionals who strive to enhance medical applications and ultimately, improve patient care."

About Zeus, Inc.:

Zeus, Inc. is headquartered in Orangeburg, SC, USA. Zeus is a world leader in material science and the development of high-performance polymer tubing used in demanding applications, operating multiple facilities in North America and internationally. Zeus products and services are preferred by companies in medical, automotive, electrical, fluid handling, and mechanical markets. For more information, visit http://www.zeusinc.com.

Press Contact:

Samantha D. Farlow
Zeus, Inc.
Communications Coordinator
publicrelations@zeusinc.com
(803) 268-9505

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


SOURCE Zeus, Inc.

New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanc

COLLEGEVILLE, Pa., May 29 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced preliminary data from two ongoing studies, one evaluating neratinib (HKI-272) in combination with trastuzumab (Herceptin(R), Roche) in HER-2 positive (ErbB-2 positive) breast cancer, and a separate study investigating neratinib safety and efficacy when given with paclitaxel (Taxol(R), Bristol-Myers Squibb) in patients with HER-2 dependent solid tumors. The data gathered from both trials are scheduled to be presented at the 45th Annual Meeting of the American Society of Clinical Oncology Annual Meeting in Orlando, Florida, from May 29 to June 2, 2009. Neratinib is an investigational orally administered irreversible inhibitor of the HER-2 and EGFR kinases.

"The data gathered from these studies provide additional evidence suggesting that neratinib, when combined with these therapies, is an active agent in HER-2 positive breast cancer," says Ramona Swaby, M.D., Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA. "While improvements have been made in treating HER-2 positive breast cancer, there remains an unmet medical need for more therapies for patients with metastatic breast cancer. These data warrant ongoing and future investigations to further understand and evaluate the utility of neratinib against this aggressive disease."

Neratinib (HKI-272) in Combination with Trastuzumab for the Treatment of Advanced Breast Cancer

This ongoing phase 1/2 study of neratinib in combination with trastuzumab evaluated patients with advanced ErbB-2 positive breast cancer that progressed following therapy with trastuzumab, the standard of care in this disease setting. The primary endpoint of the two-part study is 16-week progression-free survival (PFS). The first part of the study includes patients being administered neratinib (160 mg or 240 mg) daily plus weekly trastuzumab (4 mg/kg IV loading dose then 2 mg/kg). In the second part of the study, patients receive a weekly dose of trastuzumab with daily neratinib (240 mg).

To date, 45 patients have been enrolled and 28 patients were evaluable for efficacy. The 16-week PFS rate (for part 2) was 45 percent (95 percent CI, 26 percent to 62 percent); median PFS was 16 weeks (95 percent CI, 15 to 31 weeks). The complete response rate was 7 percent, while 21 percent of evaluable patients showed partial response. The objective response rate was 29 percent (95 percent CI, 13 percent to 49 percent).

In this study, adverse events of any grade were diarrhea, nausea, anorexia, vomiting, asthenia, rash and fatigue. In the 45 patients enrolled in this study, diarrhea was the most common adverse event, observed in 91 percent of patients, and was the most significant grade 3 or 4 adverse event, occurring in 16 percent of patients. Two patients receiving neratinib 240 mg reported adverse events leading to discontinuation of therapy.

Safety and Efficacy of Neratinib (HKI-272) in Combination with Paclitaxel in Patients with Solid Tumors

In a separate phase 1/2, open-label, 2-part study, ascending multiple daily oral doses of neratinib (160 mg, 240 mg) were administered in combination with IV paclitaxel 80 mg/m2, if tolerable, or 70 mg/m2 on days 1, 8 and 15. Patients with solid tumors (endometrial, cervical, colorectal and esophageal cancers) were entered in the phase 1 portion (part 1), and only patients with metastatic ErbB-2 positive breast cancer were enrolled in part 2. Safety and efficacy were investigated in patients with ErbB-2 positive metastatic breast cancer.

A total of 102 patients were enrolled in part 2 of the study and 97 patients were evaluable for efficacy. The overall response rate at 16-weeks (for part 2) was 63 percent (80 percent CI, 55.9 percent to 69.4).

In this preliminary analysis, the adverse event profile of the combination of neratinib (240 mg) plus paclitaxel (80 mg/m2) was similar to that reported with both agents as monotherapy. Adverse events of any grade were diarrhea, alopecia, infection, peripheral neuropathy, leucopenia, anemia, nausea, rash, fatigue and vomiting. The most common adverse event was diarrhea, observed in 89 percent of the 102 patients enrolled in part 2 and was the most significant grade 3 or 4 adverse event, occurring in 25 percent of patients. Fourteen patients had dose reductions and one patient withdrew from the study due to an adverse event.

"Emerging clinical data continue to suggest that neratinib, in combination with these therapies is tolerable and active in treating HER-2 positive disease, even in those women who have progressed while on other targeted therapies," says Gary L. Stiles, M.D., Chief Medical Officer, Wyeth Pharmaceuticals. "These additional data build upon results presented at the 2008 San Antonio Breast Cancer Symposium, and Wyeth is committed to evaluating further the potential of this investigational therapy."

In 2008, the American Cancer Society estimated that more than 182,000 women in the United States would be diagnosed with breast cancer, and more than 40,000 would die from the disease. The HER-2 receptor is over-expressed in 25 percent to 30 percent of patients with breast cancer.

About Wyeth

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In particular, clinical trial data are subject to differing interpretations, and the views of regulatory agencies, medical and scientific experts and others may differ from ours. There can be no assurance that neratinib will ever receive regulatory approval or be successfully developed and commercialized. Other risks and uncertainties that could cause actual results to differ materially from those expressed or implied by forward-looking statements include, among others, risks related to our proposed merger with Pfizer, including satisfaction of the conditions of the proposed merger on the proposed timeframe or at all, contractual restrictions on the conduct of our business included in the merger agreement, and the potential for loss of key personnel, disruption in key business activities or any impact on our relationships with third parties as a result of the announcement of the proposed merger; the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; the outcome of government investigations; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; global economic conditions; interest and currency exchange rate fluctuations and volatility in the credit and financial markets; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2008, which was filed with the Securities and Exchange Commission on February 27, 2009. The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.


SOURCE Wyeth Pharmaceuticals

Association Wants One Million People to Commit to CPR Training

DALLAS, May 29 /PRNewswire-USNewswire/ -- Senior offensive tackle Matt Nader felt like his chest exploded when he collapsed on the sidelines at his high school football game. Quick action by his parents who knew cardiopulmonary resuscitation (CPR) and the availability of an onsite automated external defibrillator (AED) saved his life.

The American Heart Association wants a million people to learn CPR as part of National CPR & AED Awareness Week, June 1-7, to help save cardiac arrest victims like Matt. The week encourages the public to get CPR training and learn how to use an AED. It also encourages them to log their training on the association's Web site. The site will feature a live map that will update in real time when people submit their information.

It could happen on the football field, during a bike ride or while dropping off the kids for an after-school activity. Every year, EMS treats about 300,000 victims of out-of-hospital sudden cardiac arrest. More than 92 percent of people who suffer cardiac arrest outside the hospital will die from it. Without immediate CPR, the chance of surviving out-of-hospital cardiac arrest drops 7 percent to 10 percent for each minute that passes without defibrillation. Unfortunately, less than one third of out-of-hospital cardiac arrest victims receive bystander CPR.

There is a great need for more CPR and AED training. Seventy percent of bystanders who respond to a cardiac emergency have either never received CPR and AED training or their training was more than five years ago, according to a 2008 American Heart Association survey. To keep skills current, training should occur at least every two years, the association says.

"By learning CPR, you are taking care of yourself and your family with just a small time commitment," said Michael Sayre, M.D., chair-elect of the American Heart Association's Emergency Cardiovascular Care Committee. "The more you practice, the more confident your skills will be in a real emergency. We want people to keep their CPR skills current and see learning and practicing CPR as critical health maintenance."

There are two ways to become CPR trained: take a traditional classroom-based course, or get a self-paced CPR Anytime kit, which includes an inflatable manikin and instructional DVD.

People can also learn the steps for Hands-Only CPR by viewing free videos online. Hands-Only CPR is for people who are unsure of their CPR skills and who witness an adult suddenly collapse. The steps are simple: Call 9-1-1 and push hard and fast in the center of the chest until help arrives.

Since 1995, the American Heart Association has recommended the development of lay rescuer AED programs to improve outcomes from out-of-hospital cardiac arrest. To maximize the effectiveness of these programs, the AHA emphasizes the importance of organization, planning, training, linking with the EMS system, and establishing a process of continuous quality improvement.

For more information about National CPR & AED Awareness Week and to find out more about training, visit www.cprweek.org or call 1-877-AHA-4CPR.

About the American Heart Association

Founded in 1924, we're the nation's oldest and largest voluntary health organization dedicated to building healthier lives, free of heart disease and stroke. To help prevent, treat and defeat these diseases--America's No. 1 and No. 3 killers--we fund cutting-edge research, conduct lifesaving public and professional educational programs, and advocate to protect public health. To learn more or join us in helping all Americans, call 1-800-AHA-USA1 or visit americanheart.org.


SOURCE American Heart Association

Join Men's Health Network in Celebration of Men's Health Month

WASHINGTON, May 29 /PRNewswire-USNewswire/ -- June is Men's Health Month and groups across the country and around the globe are joining Men's Health Network (MHN) in celebration of this awareness period. The purpose of Men's Health Month is to heighten the awareness of preventable health problems and encourage early detection and treatment of disease among men and boys.

The month is anchored by National Men's Health Week, June 15-21, the week ending on Father's Day, a special awareness period recognized by Congress each year, and signed into law by President Clinton in 1994. Additional support comes from the more than 45 governors who declare Men's Health Week in their states.

Men's Health Month is celebrated with screenings, health fairs, media appearances, and other health education and outreach activities. These events help ensure a healthier future for men and their families. For a partial listing of events, visit: http://www.menshealthnetwork.org/calendar.htm.

"While men continue to live sicker and die younger," Scott Williams, Vice President for MHN explained, "awareness and outreach efforts like those conducted in June reach men and their families where they live, work, play, and pray."

Mark Pitts, President of Urban Music for Zomba Label Group (ZLG) said, "I'm blessed to be able to give back and be a part of the men's health initiative. Since being diagnosed with Bell's Palsy, my life has definitely changed but I am now stronger than before and am giving back to help inspire not only those around me but others on a global level. Men's Health Network is important because they are helping men understand how important it is to be proactive about keeping up on our healthcare and not just for ourselves but for our families and communities; I hope I can be an example to many young men through my support of MHN."

Additionally, Men's Health Network has developed a new program called Wear BLUE, designed to raise awareness and educate men, women, and their families of the need to end the silent crisis in men's health. Workplaces, community groups, places of worship, and others are encouraged to host a Wear BLUE event in their community. Information, tools, and resources can be found at www.wearblueformen.com.

Health care providers, public policy makers, the media, and individuals can use Men's Health Month and the Wear BLUE program to encourage men and boys to seek regular medical advice and early treatment for disease. In celebration of Men's Health Month, MHN is launching a number of larger awareness campaigns including ones focused on fibromyalgia, incontinence, fertility, bladder cancer, uninsured issues, public service announcements, and prostate health.

"With prostate, cardiovascular, mental, and other health issues adversely impacting the lives of our men, awareness periods like this help end the silence surrounding men's health and make it OK for men and boys to talk and take action about their health," shared Theresa Morrow, Program Director for Women Against Prostate Cancer (www.womenagainstprostatecancer.org).

"This Father's Day we all should try to help the men we love take charge of their health. MHN has resources and programs that can help them do that," added Dr. S. J. Giorgianni, Asst. Professor Pharmacy, Belmont University School of Pharmacy, Nashville.

For interviews or to learn more about Men's Health Month contact info@menshealthweek.org or 202-543-6461x101 or visit us online at www.menshealthmonth.com.

Men's Health Network (www.menshealthnetwork.org) is a national non-profit organization whose mission is to reach men and their families where they live, work, play, and pray with health prevention messages and tools, screening programs, educational materials, advocacy opportunities, and patient navigation.


SOURCE Men's Health Network

Family Health International Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research Project Led by David Sokal, M.

RESEARCH TRIANGLE PARK, N.C., MAY 28 /PRNewswire-USNewswire/ -- Family Health International announced today that it has received a US$100,000 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation. The grant will support an innovative global health research project led by David C. Sokal, M.D., studying a novel approach to inactivate HIV with minimal interference during breastfeeding.

Dr. Sokal's project is one of 81 grants announced by the Gates Foundation in the second funding round of Grand Challenges Explorations, an initiative to help scientists around the world explore bold and largely unproven ways to improve health in developing countries. The grants were provided to scientists in 17 countries on six continents.

To receive funding, Dr. Sokal and his team showed in a two-page application how their idea falls outside current scientific paradigms and might lead to significant advances in global health. The initiative is highly competitive, receiving more than 3,000 proposals in this round.

The idea for the "Just Milk" project was born in the summer of 2008 when Dr. Sokal and a team of young engineers at an MIT workshop explored various alternatives for preventing mother-to-child transmission of HIV during breastfeeding. The team focused on modifying an existing nipple shield by putting a porous felt-like material in its tip and saturating the material with a commonly used compound that can inactivate HIV without harming the child. The researchers for the project are also looking into other potential applications of the device including delivery of nutritional supplements and pediatric medicine. Carol Joanis and Mary Lynn Baniecki, Ph.D. of Family Health International have joined the initial team to work on acceptability and laboratory aspects of the project, respectively. External partners on the grant include Sandra Urdaneta Hartmann, M.D., Ph.D. at Drexel University College of Medicine and Renaissance Scientific, LLC, and Stephen Gerrard, a graduate student in chemical engineering at Cambridge University, UK. Additional background information is at the team's web site, www.justmilk.org.

In leading the Just Milk team, Dr. Sokal, a scientist in Family Health International's Health and Development Sciences group, is building on past successes in developing new reproductive health technologies. Dr. Sokal has invented a device for delivery of vaginal microbicides using low-cost non-woven materials, and has obtained two patents for this novel vaginal device. He also has a patent for a new method of nonsurgical fallopian tube occlusion, and a patent pending on an innovative vasectomy device. He is also currently working on several research projects within Family Health International and with teams at the University of North Carolina on various forms of male contraception.

Al Siemens, Chief Executive Officer, Family Health International, stated, "Every year, approximately 50,000 babies are infected with HIV AIDS while trying to obtain from their mothers the natural nutrition they to need to live and thrive. With the Just Milk project, Dr. David Sokal and his team are beginning development of a device that could potentially prevent thousands of these cases of mother-to-child transmission with a simple device that is low-cost, accessible and easy to use. This research is yet another example of how Family Health International is extending its scientific leadership to offer hope for vulnerable people around the world."

"The winners of these grants are doing truly exciting and innovative work," said Dr. Tachi Yamada, president of the Gates Foundation's Global Health Program. "I'm optimistic that some of these exploratory projects will lead to life-saving breakthroughs for people in the world's poorest countries."

About Grand Challenges Explorations

Grand Challenges Explorations is a five-year, $100 million initiative of the Gates Foundation to promote innovation in global health. The program uses an agile, streamlined grant process - applications are limited to two pages, and preliminary data are not required. Proposals are reviewed and selected by a committee of foundation staff and external experts, and grant decisions are made within approximately three months of the close of the funding round.

Applications for the next round of Grand Challenges Explorations are being accepted through May 28, 2009. Grant application instructions, including the list of topic areas in which proposals are currently being accepted, are available at the Grand Challenges Explorations website.


About Family Health International
Family Health International (FHI), a leading global health and development organization, improves the lives of the world's most vulnerable families through its unique approach of delivering sustainable programs based on scientific research. Since 1971, FHI continues to lead the global response to HIV/AIDS and is making major contributions to address reproductive health, malaria, tuberculosis, and other infectious and chronic diseases. Beyond immediate care and treatment programs, FHI engages staff scientists in research, testing, and developing new treatments to advance public health and development. FHI's community-building and service delivery model responds to the most pressing and anticipated needs in developing countries. With more than 2,300 employees working in over 55 countries, FHI is a partner of choice for funders, local governments, nongovernmental agencies, research institutions, and community-based groups. For more information, visit www.fhi.org

CONTACT:
Matthew Matassa
Family Health International
703-647-1909
mmatassa@fhi.org


SOURCE Family Health International

Raptiva Withdrawal Offers Upside for Enbrel and Humira According to Latest BioTrends Survey of U.S. Dermatologists

EXTON, Pa., May 28 /PRNewswire/ -- BioTrends Research Group today released its syndicated report TreatmentTrends(R): Psoriasis, the fourth annual survey of U.S. Dermatologists (n=150). The report, based on results of an on-line survey fielded in April, highlights shifting trends in the management of psoriasis and psoriatic arthritis. This comprehensive report covers treatment approaches for mild, moderate, and severe patients with an emphasis on the evolving use of biologic agents.

The vast majority of psoriasis patients across all disease severity categories are prescribed topical agents. The most important attributes for topical agents, according to the respondents, are "Safe when used long term", "Efficacy", and "Covered by insurance plans". Galderma's Vectical, which was approved in February, is the only vitamin D3 ointment indicated for psoriasis and already has a perceived advantage on one of the most important attributes. 61% of the Dermatologists surveyed had prescribed Vectical, but market share is less than 3%. Taclonex and Clobex are the market share leaders for topical agents.

Use of oral agents to treat moderate and severe psoriasis declined for the second year in a row. Use of oral agents is divided primarily between methotrexate and Steifel's (now owned by GSK) Soriatane. Almost half of the surveyed Dermatologists identify methotrexate as the first line oral choice whereas 43% choose Soriatane.

On April 8th, 2009, Genentech and Roche announced the voluntary withdrawal of Raptiva from the U.S. market. Among the Dermatologists surveyed, 41% had patients on Raptiva at the time of the announcement, but only 11% had prescribed the product for a new patient in the past year. While 15% of the patients being treated with Raptiva are expected to be discontinued from biologic therapy, it appears that Enbrel (Amgen/Wyeth) and Humira (Abbott) stand to gain the most for patients being switched to other agents. Roughly 20% of the respondents feel that the withdrawal of Raptiva will result in an overall decline in biologic use in their practices, but a majority do not anticipate a negative impact.

On the horizon? Only 27% of the respondents reported being satisfied with current treatment options for psoriasis. Dermatologists report that the most desired attributes in new products for psoriasis include "Safe when used long term" and "Improved efficacy". Familiarity with new products in development is not particularly high. The highest interest levels are associated with Centocor's STELARA which could be approved later this year. With 39% of the respondents agreeing with the statement "The withdrawal of Raptiva will make me more hesitant to use new biologics in the future," increased use of these agents and rapid adoption of newly approved brands may be tempered.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


SOURCE BioTrends Research Group, Inc.

New Therapy Enlists Immune System to Boost Cure Rate in a Childhood Cancer

--In a First, Immunotherapy Works Against Neuroblastoma--

PHILADELPHIA, May 28 /PRNewswire-USNewswire/ -- A multicenter research team has announced encouraging results for an experimental therapy using elements of the body's immune system to improve cure rates for children with neuroblastoma, a challenging cancer of the nervous system.

John M. Maris, M.D., chief of Oncology at The Children's Hospital of Philadelphia, co-authored the phase 3 clinical trial, which was led by Alice Yu, M.D., Ph.D., of the University of California, San Diego. Maris chairs the committee supervising the trial for the Children's Oncology Group, a cooperative organization that pools resources from leading medical centers to study and devise new treatments for pediatric cancers.

Neuroblastoma, a cancer of the peripheral nervous system, usually appears as a solid tumor in the chest or abdomen. Neuroblastoma accounts for 7 percent of all childhood cancers, but due to its often aggressive nature, causes 15 percent of all childhood cancer deaths.

Yu will present the neuroblastoma study results on June 2 at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Fla. In advance of the meeting, ASCO published the findings online on May 14.

Maris explained that immunotherapy for cancer involves triggering the body's immune system to attack cancer cells. Monoclonal antibodies are molecules customized to target particular cancers, while cytokines are naturally occurring signaling proteins that regulate the body's immune responses.

In the current study, Children's Oncology Group researchers studied 226 children with high-risk neuroblastoma. Half received the immunotherapy, while half received standard therapy (chemotherapy and stem cell transplantation). The patients who received the immunotherapy were 20 percent more likely than those in the standard therapy group to live disease-free two years after treatment. "This 20 percent improvement in preventing relapse led to a greater cure rate -- the first substantial increase in cure rate for neuroblastoma for more than a decade," said Maris.

The researchers halted the trial earlier than expected after early results showed the benefits of immunotherapy. "This experimental immunotherapy is poised to become part of the new standard of care for children with the aggressive form of neuroblastoma," said Maris.

Maris added that the supply of the antibodies and cytokines used in the trial was limited, and that pediatric oncologists were seeking biotechnology companies to move the biological agents into commercial production to make the treatment readily available to children with neuroblastoma.

The Children's Hospital of Philadelphia has one of the nation's largest clinical and research programs in neuroblastoma. In 2008, Maris led a study that was the first to identify the gene location at which neuroblastoma originates. His laboratory continues to investigate how genes contribute to the disease, using that knowledge to devise new treatments.

Maris served as an oncologist for Alex Scott, the child with neuroblastoma who started a lemonade stand in 2000 to raise money for programs in childhood cancer. Now operated through the Scott family, the Alex's Lemonade Stand Foundation supports ongoing research by members of the Children's Oncology Group.

About The Children's Hospital of Philadelphia: The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking second in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 430-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu.

Contact: Rachel Salis-Silverman
Phone: (267) 426-6063
Salis@email.chop.edu

SOURCE The Children's Hospital of Philadelphia

Enlarged Prostate and Erectile Dysfunction Are Subjects of Free Men's Health Seminar

TUCSON, Ariz., May 27 /PRNewswire/ -- Dr. Peter Burrows from the Arizona Center-Vasectomy/Urology, a specialist in men's health issues, will be leading a free Men's Health Seminar on Saturday June 6th. The program, to be held at 8:30 AM at El Dorado Hospital, will explain the latest treatment options for two of the most common conditions affecting men today: Benign Prostate Hyperplasia (also known as Enlarged Prostate) and Erectile Dysfunction. A question and answer period will follow the program.

At the June 6th presentation, Dr. Burrows will bring clarity to two topics that together affect well over half of all men above the age of 60 in the United States. Benign Prostate Hyperplasia, or BPH, is a natural, non-cancerous enlargement of the prostate. Symptoms of BPH include frequent urination, weak flow, and interrupted sleep--factors that can significantly impact a man's quality of life.

Many men are commonly offered two treatment options for BPH: prescription medication, or a surgical procedure known as Transurethral Resection of the Prostate, or TURP. Both options can be effective, yet both have potential side effects. Dr. Burrows will explain a new procedure involving a minimally invasive laser surgery, from American Medical Systems, that equals the benefits of TURP with fewer potential complications; it can also be performed on an outpatient basis.

Erectile Dysfunction, or ED, is the inability to maintain an erection firm enough for sexual intercourse. Diabetes, heart disease, prostate surgery and medications for other conditions are among the most common physical causes. The good news is that nearly every case is treatable today. Options range from lifestyle changes to medications, as well as more permanent solutions such as penile implants, from American Medical Systems.

Spouses or partners are invited to accompany attendees. The seminar, which is free and open to the public, will last approximately one hour. Refreshments will be served. Space is limited and reservations are strongly advised.

All surgical treatments have inherent and associated risks. The most common risks associated with GreenLight are hematuria, short term dysuria and urinary track infections.

Implanting a penile prosthesis is likely to damage or destroy any remaining natural ability to have an erection. This product is contraindicated for patient with the following conditions:

Active urinary infections or active skin infections in the region of surgery.
A known sensitivity to silicone or the antibiotic rifampin or tetracyclines.
Lupus erythematosus.
Taking warfarin, thionamides, isoniazid and halothane
Renal disease.

You should talk with your doctor about benefits and risks before moving forward with any treatment option.

To reserve a space, call 866-432-5274 toll-free. (Men's health seminar will be held at El Dorado Hospital in the ground floor cafeteria. Hospital is located at 1400 North Wilmot Rd. Tucson, AZ 85712).


SOURCE American Medical Systems

Access Pharmaceuticals Provides Update on Global Launch of MuGard(TM)

NEW FDA-APPROVED TREATMENT FOR ORAL MUCOSITIS

DALLAS, May 27 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), (http://www.accesspharma.com) announced today that MuGard(TM), its proprietary oral mucositis product has been launched in Germany, Italy, UK, Greece and the Nordic countries by its European commercial partner, SpePharm, a pan-European specialty pharmaceutical company dedicated to the provision of high medical value medicines in supportive and critical care. The Company has previously announced commercialization agreements in North America, China and eight Southeast Asian countries and Korea, and is actively seeking additional marketing partners in other regions; MuGard expects commercial launches in these regions throughout the remainder of 2009 as manufacturing and reimbursement gets established regionally.

MuGard is a ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 40% of all patients receiving chemotherapy and/or radiation therapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.

"Access is pleased with the commercial launch of MuGard in Europe, and the progress made by our partners in other regions of the world," said Phillip Wise, Vice President of Business Development at Access. "Access is also working with its partners outside of Europe to establish GMP manufacturing and secure necessary approvals and/or reimbursement from the individual governmental regulators, which we believe will greatly enhance initial product adoption and ongoing marketing efforts to reach and penetrate the target population of patients requiring this important treatment option," he continued.

MuGard forms a protective coating over the oral mucosa when swirled gently around the mouth. In a comparison of cancer patients receiving standard mucositis care with those patients receiving MuGard, the incidence and severity of mucositis was significantly lower in the MuGard treated group using a validated scale for the assessment of oral mucositis.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; and Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer. Access recently announced completed the acquisition of MacroChem Corporation. This acquisition provides Access with Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for ProLindac and other product candidates, our ability to execute licensing agreements in the future, Access' plans to continue and initiate clinical trials, the value of its products in the market (including MuGard and the size of the overall market for mucositis products), its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.


SOURCE Access Pharmaceuticals, Inc.

Feeding America and Abbott Partner For Hurricane Relief

Abbott Donates Relief Supplies to Expedite Immediate Hurricane Response

CHICAGO, May 27 /PRNewswire-USNewswire/ -- Feeding America today announced that it is working with the global health care company, Abbott, to pre-position nutritional products in 20 food banks throughout the Southeast United States and Puerto Rico in preparation for the 2009 hurricane season, which officially arrives on June 1. Feeding America is the nation's largest domestic hunger-relief organization.

Food banks will receive pre-packaged disaster relief packs containing both adult and pediatric nutritionals that are designed specifically for families of different sizes. These disaster relief packs will serve more than 20,000 people in the aftermath of a natural disaster. Food banks were selected based on vulnerability to hurricanes, their capacity to assist in disaster response and recovery, and on population coverage.

Volunteers within organizations such as The East Texas Food Bank in Tyler, Texas and America's Second Harvest of South Georgia in Valdosta, Georgia, have agreed to create 5,200 disaster relief packs containing 232,000 pounds of Abbott-donated nutritionals for distribution across U.S. food banks by the start of hurricane season.

"Our goal, in partnering with Feeding America, is to empower communities to ensure that critical products are immediately available to those who need them when a disaster strikes. Pre-positioned products can be distributed quickly and reliably by working through Feeding America's established network of food banks," said Kathy Pickus, divisional vice president, Global Citizenship and Policy, Abbott.

"We are extremely grateful to Abbott for donating to us and helping us pre-position relief supplies at our food banks in strategically important locations," said Vicki Escarra, president and CEO of Feeding America. "We certainly hope that there aren't any hurricanes this season, but we can now take some small comfort in the fact that should a hurricane hit, we will be ready to immediately provide food, water and other supplies to people in need. These supplies are intended to help bridge the gap until the rest of our Network can aid the food banks serving affected communities."

"If the donated supplies are not needed for disaster use this season," said Escarra, "they will be rolled into the food bank's regular inventory, providing extra assistance to those in need on an everyday basis."

The Abbott/Feeding America disaster relief packs will be pre-staged at the following food banks:

Texas

Beaumont-Southeast Texas Foodbank
Food Bank of Corpus Christi
Houston Food Bank
McAllen-Food Bank of the Rio Grande Valley, Inc.
Tyler-East TX Foodbank
Victoria--Food Bank of the Golden Crescent

Louisiana

Alexandria-Food Bank of Central Louisiana
Greater Baton Rouge Food Bank
Monroe-Food Bank of Northeast Louisiana
Second Harvest Food Bank of Greater New Orleans & Acadiana
Shreveport-Food Bank of Northwest Louisiana

Alabama/Mississippi

Theodore, AL--Bay Area Food Bank

Florida

Ft Myers--Harry Chapin Food Bank of Southwest Florida
Miami--Daily Bread Food Bank
Sarasota-All Faiths Food Bank
Tallahassee--America's Second Harvest of the Big Bend, Inc.

Georgia

Savannah--America's Second Harvest of Coastal Georgia, Inc.
Valdosta--America's Second Harvest of South Georgia, Inc.

South Carolina

Charleston-Lowcountry Food Bank

North Carolina

Elizabeth City-Food Bank of the Albemarle

Puerto Rico

Bayamon-Banco de Alimentos de Puerto Rico

Feeding America provided more than 25.6 million pounds of food and grocery products to food banks throughout Louisiana, Texas and other Gulf Coast states in 2008, following the devastation caused by Hurricanes Gustav and Ike.

Feeding America is now in its 20th year of providing disaster relief services. The network of 206 food banks has worked in recent years to improve its disaster response capability with enhanced disaster planning, by developing and training national support teams, and with the staging supplies in advance of disaster.

About Feeding America

Feeding America provides low-income individuals and families with the fuel to survive and even thrive. As the nation's largest domestic hunger-relief charity, our network members supply food to more than 25 million Americans each year, including 9 million children and 3 million seniors. Serving the entire United States, more than 200 member food banks support 63,000 agencies that address hunger in all of its forms. For more information on how you can fight hunger in your community and across the country, visit www.feedingamerica.org.


SOURCE Feeding America

The Pennsylvania Breast Cancer Coalition Showcases Its Traveling Photo Exhibit in McKean County at Kane Area Community Center

EPHRATA, Pa., May 26 /PRNewswire-USNewswire/ -- The Pennsylvania Breast Cancer Coalition (PBCC) is pleased to work with the McKean County Exhibit Committee and the Kane Area Community Center to bring its traveling photo exhibit "67 Women, 67 Counties: Facing Breast Cancer in Pennsylvania," to McKean County from May 28 - June 8. The photo exhibit will be displayed in the Kane Area Community Center.

An opening reception is scheduled for Thursday, May 28 at 6:00 p.m. The exhibit and reception are free and open to the public. To RSVP for the opening reception, please call 1-800-377-8828 x304.

This work of art features women from each of Pennsylvania's 67 counties, along with a message about how breast cancer has touched their lives. The women reflect the diversity of Pennsylvania, and their stories reflect the impact of breast cancer on themselves, their families and their communities. The exhibit encourages women to learn about early detection and celebrates life, courage, hope and dignity of women and families who have battled breast cancer. "67 Women, 67 Counties: Facing Breast Cancer in Pennsylvania" is sponsored by the PBCC and funded by the Pennsylvania Department of Health.

Pat Halpin-Murphy, President and Founder of the PBCC, encourages everyone to visit the exhibit. "Breast cancer is not a rare event separate from the fabrics of our everyday lives. It impacts our mothers, daughters and friends. We must educate ourselves about this disease and fight to find a cure now...so our daughters won't have to."

Susan Coulter, committee chair said, "In October I organized Kane Pink Power Day through Adagio Health to promote Breast Cancer Awareness. This exhibit is a continuation of the cause. I am very excited to work with the women of our community to bring the traveling photo exhibit "67 Women, 67 Counties: Facing Breast Cancer in Pennsylvania" to McKean County."

The PBCC, founded in 1993, is a non-profit organization and the only statewide grassroots organization that speaks to and for breast cancer survivors. The PA Breast Cancer Coalition represents, supports and serves breast cancer survivors and their families in Pennsylvania through educational programming, legislative advocacy and breast cancer research grants.

For more information please call 1-800-377-8828 x101 or visit the website at www.pabreastcancer.org.


SOURCE Pennsylvania Breast Cancer Coalition

International Cooperation to Save Drug-Addicted Kids

TROIS-RIVIERES, Quebec, May 26 /PRNewswire/ -- Over an eight-day period, during the first week of May, the Executive Director of Narconon Nepal was able to deliver nine drug education lectures to over three-thousand Nepali children living in the United Kingdom. "Our kids brought their drug problem along with them and found new ones here," comments Basanta Raj Kunwar, executive director, Narconon Nepal.

In 1997, a UK court finalized a decision allowing former Gurkha soldiers to seek citizenship for themselves and their families within the United Kingdom. After that decision was made, more then 100,000 Gurkha people immigrated to the UK. Unfortunately, like any culture immigrating to different countries, drug problems do tend to follow. Originally from Nepal, Gurkhas take their name from an eighth-century Hindu warrior named Guru Gorakhnath. Throughout history, Gurkhas are best known for their bravery and strength within the British Army's Brigade and the Indian Army.

Mr. Kunwar was invited to the United Kingdom by the UK Nepali Association and gave drug education lectures across the greater London area. Basanta was a 23-year veteran of the Nepali police force and was also the former superintendent of the Nepal police force. He came all the way from Kathmandu, Nepal to deliver his drug education lectures, and was also able to reach 525,000 people through Nepali radio, TV, and newspapers. "Drug abuse and addiction miseries migrate with populations," says Mr. Kunwar, "and with our growing Narconon network, we have workable solutions; I should know."

Mr. Kunwar has been dedicated to the cause of eradicating drug addiction for quite some time; in fact, prior to him opening a Narconon center, he was researching solutions for better drug rehabs in Kathmandu. When he retired from the police force, he was able to provide a drug rehab to Nepali youth through his own charitable foundation, Pratigya; however, it struggled to see any real results. Basanta then discovered the Narconon program and took the time to learn about what it had to offer. He was so amazed by the workable solutions, he opened a 100-bed program in Kathmandu, and is continuing his dedication to save lives and terminate the drug problem in Nepal.

Photo: http://www.ereleases.com/pr/2009-Narconon.jpg

If you or someone you know is battling a drug or alcohol addiction, call our toll-free line at 1-877-782-7409, or visit our website at http://www.narcononrehab.com.

NARCONON is a trademark and service mark owned by Association for Better Living and Education and is used with its permission.

Press Contact:

Clark Carr
Narconon International
1-323-962-2404

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


SOURCE Narconon International

Schools and Cities Send 9.7 Million Messages During Swine Flu Outbreak with Blackboard Connect(TM) Platform

Notification technology helps schools communicate more quickly and consistently

WASHINGTON, May 26 /PRNewswire-FirstCall/ -- As the world waited for news about the swine flu outbreak, many U.S. school and government leaders used notification technology to proactively reach parents and residents with important updates and information - the latest example of the way that time-sensitive communication has advanced far beyond the days when it might have taken officials days to reach all of their constituents with little or no way to confirm that important messages were received.

In just eight days, from April 27 to May 4, Blackboard Connect(TM) sent some 9.79 million messages direct to users in support of school and government outreach efforts, according to Blackboard Inc. (Nasdaq: BBBB), a global leader in education technology.

Approximately 40 percent of the messages dealt with the flu outbreak and helped officials quickly reach parents, staff and residents. Officials communicated a wide range of information through email, voicemail and text messages, including updates on potential cases and precautionary measures being taken to help control the spread of disease and eliminate undue panic in communities. Experts cite the importance of rapid and consistent communication of accurate information in minimizing the impact of a public threat.

For the Los Angeles Unified School District (LAUSD), the Blackboard Connect platform plays a key role in their emergency preparedness plan. On Monday, April 27, within the first hours of public concern over the flu, Dr. Kimberly Uyeda, LAUSD's Director of Student Medical Services recorded and sent the following message to 713,000 unique recipients, in both English and Spanish (to hear the actual recorded messages, see the links at the end of this release):

"We want to inform you, at this time, there are no known cases of the Swine Flu in our schools. The school district is working closely with the Los Angeles County Department of Public Health to protect the health of students and staff. More than 600 school nurses are monitoring student absences and custodians are washing down common areas at school sites more frequently, on an as needed basis. Schools are currently open and we are urging everyone to follow these simple steps: cover your mouth when you cough or sneeze, wash your hands frequently, if you are sick stay home, if your child is sick please do not send him or her to school."

"Because California borders Mexico and so many of our students have family ties to cities in Mexico where the outbreak first hit, it was imperative that we quickly and effectively addressed the issue," Dr. Uyeda said. "On the morning of April 27, our phone lines were swamped by concerned parents who wanted to know if schools were closed, and most importantly, if their children would be safe. From my office phone, we were able to record and send an assuring message, in English and Spanish, to parents, students and staff. The incoming calls quickly subsided and we were able to focus on keeping our students safe."

In addition to outreach surrounding the Swine Flu outbreak, LAUSD officials regularly use the Blackboard Connect platform to communicate information on student attendance, activities and testing schedules and volunteer programs. The outreach has helped to increase student achievement, parental involvement and overall enrollment.

A number of other school and government leaders used the Blackboard Connect platform to report suspected flu cases and quickly communicate campus closures. Among the first to respond was Dr. Max Riley, Superintendent of Port Jefferson Union Free School District in New York.

"After the Governor issued a state of awareness, it was crucial that we communicate with parents quickly and directly to inform them of the health and safety precautions our school district was actively taking," Riley said. "With the Blackboard Connect platform, we were able to effectively convey those important messages directly to parents in a matter of minutes."

Drawing on the experience gained in delivering hundreds of millions of messages for nearly 2,500 K-12 organizations, college campuses and cities nationwide, as well as government and military organizations, the Blackboard Connect platform enables officials to quickly reach their organizations and communities through voice, text and email messages to a variety of communication platforms and devices. The Blackboard Connect platform allows officials to send an unlimited number of messages, requires no additional hardware, and can be used from any computer with Internet access or telephone. This ensures that administrators can send vital messages from wherever they are located--even if they are evacuated.

To listen to Blackboard Connect messages sent by LAUSD, please visit: http://www.blackboardconnect.com/samples/SwineFluMessageLAUSD.wav (English) and http://www.blackboardconnect.com/samples/SwineFluMessageSpanishMessageLAUSD.wav (Spanish). For more information about Blackboard Connect solutions, please visit http://www.blackboard.com/Alert-Notification/Connect-Platform.aspx.

About Blackboard Inc.

Blackboard Inc. (NASDAQ: BBBB) is a global leader in enterprise technology and innovative solutions that improve the experience of millions of students and learners around the world every day. Blackboard's solutions allow thousands of higher education, K-12, professional, corporate, and government organizations to extend teaching and learning online, facilitate campus commerce and security, and communicate more effectively with their communities. Founded in 1997, Blackboard is headquartered in Washington, D.C., with offices in North America, Europe, Asia and Australia.

Any statements in this press release about future expectations, plans and prospects for Blackboard and other statements containing the words "believes," "anticipates," "plans," "expects," "will," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the factors discussed in the "Risk Factors" section of our Form 10-Q filed on May 7, 2009 with the SEC. In addition, the forward-looking statements included in this press release represent the Company's views as of May 26, 2009. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to May 26, 2009.


SOURCE Blackboard Inc.

Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Art

- Fifth International Phase III ACTEMRA Study Meets its Primary Endpoints -

NUTLEY, N.J., May 25 /PRNewswire/ -- Roche today announced that two-year data from the LITHE (TociLIzumab Safety and THE Prevention of Structural Joint Damage) study demonstrated that ACTEMRA(R) (tocilizumab) continued to inhibit the progression of structural damage to joints in patients with rheumatoid arthritis (RA). The study also showed that patients receiving ACTEMRA experienced improved physical function, as measured by the Health Assessment Questionnaire Disability Index (HAQ-DI) scores(1). The LITHE study is the fifth international Phase III study in the extensive ACTEMRA clinical development program to successfully meet its primary endpoints in patients with moderately to severely active RA.

"The one-year LITHE results demonstrated that ACTEMRA significantly inhibited the progression of structural joint damage, which is a major cause of disability and loss of physical function for RA patients," said Kenneth Bahrt, M.D., Global Medical Director, Autoimmunity, Roche. "We are extremely pleased by these two-year LITHE data as they confirm the previous study findings, and also suggest that the effect of ACTEMRA actually improves over time."

The two-year data from the LITHE study showed that patients treated with ACTEMRA maintained consistently high disease remission rates according to DAS28 criteria, which measures disease activity in RA patients(2). The study also showed that a greater proportion of patients treated with ACTEMRA (8 mg/kg and 4 mg/kg) plus methotrexate achieved a significant reduction in the progression of structural joint damage during 24 months of treatment compared with patients receiving placebo plus methotrexate. The outcome was determined by X-ray evidence of the progression of bone erosion and narrowing of joint spaces, as measured by the Genant-modified Sharp score(3).

In the study, ACTEMRA was generally well-tolerated and the overall safety profile after two years of treatment with ACTEMRA was consistent with previously reported data. Full data from this two-year study will be submitted to the U.S. Food and Drug Administration (FDA) and for presentation at a future international scientific meeting.

One-year LITHE data have been accepted for presentation at the 10th Annual Congress of the European League Against Rheumatism (EULAR), which will take place June 10-13, 2009, in Copenhagen, Denmark.

About the LITHE Study

The LITHE study was a three-arm, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of ACTEMRA (8 mg/kg and 4 mg/kg) plus methotrexate compared with placebo plus methotrexate in RA patients. Patients in the LITHE study received either ACTEMRA intravenously every four weeks plus methotrexate weekly or placebo infusions every four weeks plus methotrexate weekly. The LITHE study included nearly 1,200 patients from 137 sites in 15 countries, including the United States. The study aimed to show the inhibition of structural damage at the joints, as demonstrated by changes in validated radiographic parameters. The study also examined the improvement in physical function and disease signs and symptoms.

One-year data from the study showed the mean change in the combined Genant-modified Sharp score(3), which assesses progression of both joint erosion and joint space narrowing, was lower among ACTEMRA (8 mg/kg and 4 mg/kg) plus methotrexate-treated patients versus methotrexate plus placebo-treated patients (0.3, 0.3 versus 1.1, respectively; p<0.001). In addition, the one-year study results showed that 85 percent and 81 percent of patients treated with ACTEMRA (8 mg/kg or 4 mg/kg, respectively) experienced no progression of either joint erosion or joint space narrowing, as measured by the Genant-modified Sharp score, compared with 67 percent of patients treated with placebo plus methotrexate.

ACTEMRA was generally well tolerated; the most common adverse events reported most frequently in the ACTEMRA arms of the LITHE study were serious infections.

About ACTEMRA(R) (tocilizumab)

ACTEMRA is the first humanized interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody being studied for the treatment of RA. Studies demonstrate that reducing the activity of IL-6, one of several key cytokines involved in the inflammatory process, relieves both inflammation of the joints and certain systemic effects of RA. The extensive clinical development program conducted by Roche includes five Phase III clinical studies and has enrolled more than 4,000 patients in 41 countries, including the United States. The five Phase III studies are completed and have reported meeting their primary endpoints. ACTEMRA is currently under review by the FDA in the United States.

ACTEMRA is part of a co-development agreement between Roche and Chugai Pharmaceutical Co. In June 2005, ACTEMRA was launched by Chugai in Japan as a therapy for Castleman's disease; in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and systemic-onset juvenile idiopathic arthritis were also approved in Japan. ACTEMRA (known as RoACTEMRA in Europe), was also recently approved in the European Union, Switzerland and India.

The serious adverse events reported in ACTEMRA clinical studies include serious infections, gastrointestinal perforations and hypersensitivity reactions including anaphylaxis. The most common adverse events reported in clinical studies were upper respiratory tract infection, nasopharyngitis, headache, hypertension and increased ALT. Increases in liver enzymes (ALT and AST) were seen in patients; these increases were generally mild and reversible, with no evidence of hepatic injuries. Laboratory changes, including increases in lipids (total cholesterol, LDL, HDL, triglycerides) and decreases in neutrophils and platelets, were seen in patients without association with clinical outcomes. Treatments that suppress the immune system, such as ACTEMRA, may cause an increase in the risk of malignancies.

About IL-6

IL-6 is a common protein found in all joints in the body and is a natural substance that can raise inflammation. Everyone has IL-6 in their body, but people with RA may have too much. When approved, ACTEMRA will be the first and only medication to specifically target IL-6 in patients with RA.

About Rheumatoid Arthritis

RA is a progressive, systemic autoimmune disease characterized by inflammation of the membrane lining in the joints. This inflammation causes a loss of joint shape and function, resulting in pain, stiffness and swelling, ultimately leading to irreversible joint destruction and disability. Characteristics of RA include redness, swelling, pain and movement limitation around joints of the hands, feet, elbows, knees and neck that leads to loss of function. In addition, the systemic symptoms of RA include fatigue, decreased hemoglobin, osteoporosis and may contribute to shortening life expectancy by affecting major organ systems. After 10 years, less than 50 percent of patients can continue to work or function normally on a daily basis. RA affects more than 21 million people worldwide with approximately 1.3 million adults affected in the United States.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health and quality of life. For additional information about the U.S. pharmaceuticals business, visit our website http://www.rocheusa.com. Product and treatment information for U.S. healthcare professionals is available at www.RocheExchange.com.

All trademarks used or mentioned in this release are protected by law.

(1) The Health Assessment Questionnaire Disability Index (HAQ-DI) is a 20-item questionnaire that asks about physical functioning within eight categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip and daily activities). The ability to perform each category is measured on a scale 0 to 3 (0 = no difficulty, 1 = some difficulty, 2 = much difficulty or with assistance, and 3 = unable).

(2) The Disease Activity Score (DAS)28 is a combined index that measures disease activity in patients with RA. It combines information from 28 tender and swollen joints (range: 0-28), erythrocyte sedimentation rate, and a general health assessment on a visual analog scale. The level of disease activity is interpreted as low (DAS28 less than or equal to 3.2), moderate (3.25.1). DAS28<2.6 corresponds to being in remission according to the criteria of the American College of Rheumatology.

(3) The Genant-modified Sharp score focuses on 14 specific sites for evidence of bone erosion and 13 sites for narrowing of the joint space, both key measures of ongoing structural damage to the joints. Erosion scores are assigned to each of the specified sites, with 0 representing "no erosion" and 3.5 representing "destruction of the joint." Joint space narrowing scores are assigned to each of the specified sites, with 0 representing "no narrowing" and 4 representing "total loss of the joint space." Increases in the scores indicate the extent of additional erosion, joint space narrowing or overall structural damage (both scores combined) that have occurred since treatment began.


SOURCE Roche

National Federation of the Blind Congratulates NASA on Successful Mission

Two Louis Braille Coins Return with Atlantis

EDWARDS AIR FORCE BASE, May 24 /PRNewswire-USNewswire/ -- When the space shuttle Atlantis landed today, it also returned from space two Louis Braille Bicentennial Silver Dollars. This unique coin commemorates the birth of the inventor of the reading and writing code for the blind and is the first United States coin to contain tactile, readable Braille. Sales of the coin will be used to support the National Federation of the Blind "Braille Readers are Leaders" campaign. The campaign is a national initiative created to double the number of blind children learning Braille by 2015.

Dr. Marc Maurer, President of the National Federation of the Blind, said: "The National Federation of the Blind wishes to congratulate NASA on a successful mission to enhance our capability to explore the far reaches of space. We are also pleased that this mission promoted Braille literacy by carrying two Louis Braille Bicentennial Silver Dollars into orbit. Blind children in America are facing a crisis--only 10 percent of them are learning Braille, leaving 90 percent illiterate. By dramatically publicizing this coin, whose own mission is to raise critically needed funds to support Braille literacy, NASA has helped to reverse this devastating trend."

To purchase the Louis Braille Bicentennial Silver Dollar, please visit www.usmint.gov or call 1-800-USA-MINT (872-6468). The proof silver dollar is available for $41.95 and the uncirculated silver dollar sells for $33.95. For more information about the National Federation of the Blind and the Braille Readers are Leaders campaign, please visit www.braille.org.


SOURCE National Federation of the Blind

Swine Flu (H1N1) Infectivity to Increase Markedly and Lethality to Remain Low According to Latest Replikin* Peptide Genomic Data

BOSTON, May 23 /PRNewswire/ -- Amid all the speculation over what course the Swine Flu epidemic will take, Boston-based biotech firm Replikins Ltd. (www.replikins.com) last week analyzed the most recent peptide genomic sequence data available and determined that the infectivity of the H1N1 virus will increase markedly, while its lethality will remain relatively low for the immediate future.

The company's quantitative analysis of the most recent sequence data available on PubMed, a standard scientific repository for published papers, showed an increase of 46% in the Replikin Count* over the past five months. This points to a marked increase in infectivity in humans. At the same time, while the total number of replikins has gone up significantly, their composition appears to have changed in a way that makes them more closely resemble their counterparts in earlier pandemics.

The firm, which had predicted a year ago the likelihood of the current H1N1 outbreak, used its proprietary FluForecast(TM) software program to make these determinations. "The dual differentiation of these properties may provide advance warning of the future course of H1N1," noted Samuel Bogoch MD PhD, chairman and founder of Replikins Ltd. "Our understanding of the protein chemistry of rapid replication enables us to develop synthetic vaccines specifically tailored to destroy or restrict replication of the targeted virus strains prior to an outbreak."

Earlier this month, Replikins announced that it had succeeded in synthesizing the first H1N1 influenza vaccine, which is now ready for testing. It used the same approach to produce a peptide H5N1 (avian flu) vaccine that successfully blocked low path H5N1. It has not previously been possible to correlate virus structures with a virus outbreak or cessation of outbreak, let alone to predict six to 12 months ahead of the outbreak or its cessation. In 2001, Drs. Samuel and Elenore Bogoch first demonstrated this correlation retrospectively for whole-organism replikin counts in outbreaks and pandemics of the common influenza strains over the past century.

About Replikins Ltd.

Replikins, Ltd. (www.replikins.com), a Boston-based biotech company, develops and markets novel forecasting tools and synthetic vaccines to fight virulent rapidly replicating diseases including bird flu, malaria, and HIV. The company's predictive products and vaccines in development are based upon the company's discovery of replikins, a new group of peptides related to the rapid replication function in viral and other diseases. The company has designed unique products to predict the emergence of virulent strains of particular diseases (FluForecast(TM)) and is designing synthetic vaccines specifically tailored to combat a given strain and against shared properties of several strains (Syntope(TM) vaccines). The company is partnering with governments and the private sector in providing predictive tools and vaccines in furtherance of the public health initiative to prevent and combat epidemics.

* The company's vaccines and predictive tools are based on the company's discovery of a new group of peptides related to rapid replication called Replikins, whose increase in concentration in virus or other organism proteins (Replikin Count(TM) = number of replikins per 100 amino acids) is associated with rapid replication.

Contact:
John McKenney
Replikins, Ltd.
38 the Fenway
Boston, MA 02215
jmckenney@replikins.com
www.replikins.com
617-536-0220


SOURCE Replikins, Ltd.

USCCB Submits Comments to NIH on Proposed Guidelines for Stem Cell Research

USCCB General Secretary urges respect for human life at all stages

Says science and ethics have been ignored in proposed policy

Cites advances in stem cell research that do not destroy human embryos

WASHINGTON, May 22 /PRNewswire-USNewswire/ -- The National Institutes of Health (NIH) missed "an enormous opportunity to show how sound science and responsible ethics can not only co-exist but support and enrich each other," said Msgr. David Malloy, General Secretary of the U.S. Conference of Catholic Bishops (USCCB), in comments on draft guidelines to authorize federally funded human embryonic stem cell research. The comments were submitted during the official public comment period on the proposed guidelines, which ends May 26. The Conference has also provided a convenient way for other concerned citizens to submit comments to the NIH on this issue, by visiting the Web site www.usccb.org/stemcellcampaign.

Msgr. Malloy cited the dignity of human life at every stage and the innate human right not to be subjected to harmful experimentation without one's express and informed consent. He said laws that fail to recognize this right "do not succeed in nullifying the right in question, but only call into question their own moral legitimacy."

Msgr. Malloy highlighted the "central fact of science" relevant to the issue of embryonic stem cell research, that the embryo that will be destroyed to obtain embryonic stem cells "is a human being at a very early stage of his or her development."

This is not a matter of religious belief, he said, but a fact acknowledged by federal advisory groups on this issue, including the National Bioethics Advisory Commission appointed by President Clinton. This group concluded that because human embryos deserve "respect" as a form of human life, destroying them for stem cells is "justifiable only if no less morally problematic alternatives are available for advancing the research."

Msgr. Malloy added that alternative methods of stem cell research, such as reprogramming ordinary adult cells into "induced pluripotent stem cells" (iPS cells) without harming human life, have made great advances under a federal policy preventing researchers from destroying live human embryos for federally funded research.

"Yet President Obama's executive order of March 9 not only rescinded that policy, but also rescinded the executive order of 2007 instructing the NIH to thoroughly explore new avenues for obtaining pluripotent stem cells without destroying human embryos," Msgr. Malloy said. "Both science and ethics have been ignored in this decision."

Msgr. Malloy said the President's executive order and the draft guidelines fail the Bioethics Commission's test, "by failing to require that morally unproblematic avenues for exploring important medical research goals be thoroughly investigated before the NIH considers any avenues that require destroying embryonic human life."

"Avenues of stem cell research which pose no moral problem are now showing great promise. In fact, human patients suffering from all the conditions cited by President Obama when he signed his executive order -- cancer, juvenile diabetes, Parkinson's disease, spinal cord injury, heart disease -- have been shown in peer-reviewed studies to benefit from clinical trials using human stem cells," he said. "And in every case, the benefit has come not from embryonic stem cells, but from the adult and cord blood stem cells that this organization and others have said should receive priority attention."

Msgr. Malloy expressed relief the proposed guidelines do not seek to fund research in which embryos are created for the purpose of research, but explained how "in key respects the guidelines are nonetheless broader or more permissive than any policy approved in the past by any branch of the federal government.." He also asked the Obama Administration to "make a clear and authoritative statement, as the Clinton Administration did, that it will never fund research that relies on the creation of human embryos for research purposes."

"As the President noted," Msgr. Malloy said, "we must not make 'a false choice between sound science and moral values.' In fact, these sources of guidance both point in the same direction, away from destructive embryonic stem cell research. His executive order and these guidelines nonetheless insist on a course of action that is both morally objectionable and, increasingly, scientifically obsolete."

Noting that prominent stem cell researchers have recently expressed their own moral misgivings about destroying human embryos for research, Msgr. Malloy concluded, "This is not merely a political or ideological problem, or a problem of religious dogma, but a deeply human problem: We are testing the limits of our obligation to treat all fellow human beings, of every age and condition, with basic respect."

The full text of the comments to NIH regarding the draft guidelines can be found online at www.usccb.org/prolife/NIHcomments.pdf.


SOURCE U.S. Conference of Catholic Bishops Secretariat for Pro-Life Activities

Thousands Gather in Downtown Los Angeles to Protest Drastic Cuts to State's Homecare Program

Crowd sends a clear message to the Governor and Legislators that these cuts must be stopped as they will put lives at risk!

LOS ANGELES, May 22 /PRNewswire/ -- More than 5,000 homecare providers, care recipients, disability and senior advocates joined other concerned Californians today in a rally in front of the California State building in Downtown Los Angeles to speak out against the Governor's proposed cuts to the state's homecare program as laid out in his May Revise budget.

Closing down streets, rally participants sent a clear message to Governor Schwarzenegger and Sacramento legislators that cuts to the In-Home Supportive Services (IHSS) program, which delivers care to more than 400,000 seniors and people with disabilities, will not be tolerated.

"Shame on the governor for turning his back on hundreds of thousands of Californians--including the hardworking caregivers who care for our state's most vulnerable people," stated Eliseo Medina, Executive Vice President of Service Employees International Union (SEIU). "The governor's proposed cuts to homecare are cruel and inhumane, forcing workers into poverty and seniors and people with disabilities out of their homes and communities. The governor is wrong and we won't stand for it."

Under Governor Schwarzenegger's recent May Revise budget, homecare worker wages would be slashed to minimum wage ($8.00), essential hours of care would be eliminated, and limitations would be placed on access to the homecare program. Such cuts would place the lives of our parents, grandparents and children with disabilities at risk.

"Cutting a program that saves taxpayers money and brings millions of Federal dollars into the state's economy simply doesn't make 'cents'," said John Ronches, Trustee of SEIU Local 6434. "The Governor says he wants to save $200 million dollars by cutting IHSS, yet by doing so he is saying NO THANK YOU to nearly $700 million in Federal funds that will be left on the table."

The IHSS program delivers quality care to those in need while saving California taxpayers millions of dollars annually as the program is approximately eight times less expensive than institutional care. Additionally, the program draws down Federal funding that covers a majority of program costs.

"Cutting the IHSS program doesn't help California's financial problems, it only makes things worse," stated Rob Robbins, a Los Angeles County Homecare Provider. "These cuts not only place hundreds of thousands of lives at risk, they're fiscally irresponsible and work against the goal of solving our state's budget problems."

Today's rally is the first of many events to take place over the next several weeks to raise awareness of these dangerous cuts and their impact on our most vulnerable residents and those who care for them.

SEIU Local 6434 represent over 174,000 homecare and nursing home workers throughout California.

SOURCE Service Employees International Union Local 6434

H1N1: What You Should Know

DALLAS, May 22 /PRNewswire/ -- Gonzalo Venegas, M.D., has issued the following press release:

As a Dallas-based physician, there has been a recent flurry of panic about the H1N1 (swine influenza). School districts closed down. Intramural sports statewide were cancelled. Some even suggested closing the border with Mexico, where approximately three quarters of a million people routinely cross back and forth every day. The panic certainly was fueled by the media reports. Likewise, the media can serve to educate the public about health issues.

For that reason, I have created this column to respond to frequently asked questions about H1N1 and reassure the public that pork is safe and will continue to be safe to consume.

What is H1N1 (swine flu)?

H1N1 (previously referred to as "swine flu") is a respiratory illness. This new virus was first detected in people in the United States in April 2009. Other countries, including Mexico and Canada, have reported people sick with this new virus. This virus is spreading from person-to-person, probably in much the same way that regular seasonal influenza viruses spread.

Why was the H1N1 virus originally called "swine flu"?

This virus was originally referred to as "swine flu" because laboratory testing showed that some of the genes in this new virus were similar to influenza viruses that have occurred in pigs. But further study has shown that this H1N1 virus is very different from what normally circulates in North American pigs. In fact, this strain is unique and was not previously recognized in either people or pigs.

How is H1N1 spread?

Flu viruses generally spread from person to person, often through the moisture in coughs and sneezes. This can happen when droplets from a cough or sneeze of an infected person are propelled through the air and deposited on the mouth or nose of another individual. Influenza viruses may also be spread when a person touches respiratory droplets on another person or an object and then touches their own or another's mouth or nose. You cannot get H1N1 from handling raw pork or eating cooked pork.

Is the H1N1 virus spread through animals?

It appears that the virus is spreading from humans to humans. No evidence indicates that any of the human illnesses resulted from contact with pigs or other animals.

Isn't it better to be cautious?

According to the most reputable health organizations, including the World Health Organization, U.S. Centers for Disease Control and Prevention, U.S. Departments of Agriculture and U.S. Health and Human Services, the H1N1 flu strain cannot be transmitted by eating pork; it is not a food safety issue. To be cautious, you need to take measures to avoid coming into contact with the virus, such as frequent hand washing. Visit elcerdoesbueno.com for more information.

It doesn't seem clear to me.

The facts are clear. The Centers for Disease Control (CDC) has not found any evidence to indicate that any of the illnesses resulted from contact with pigs. The CDC web site states, "Swine influenza viruses are not spread by food. You cannot get swine influenza from eating pork or pork products. Eating properly handled and cooked pork products is safe."

When should I seek medical care?

Signs that you should seek immediate attention include: difficulty in breathing or chest pain, discoloration of the lips, vomiting and inability to keep liquids down, dizziness, absence of urination or seizures.

Can pork be part of a healthy diet?

Absolutely. Lean cuts such as tenderloin and pork chops rival chicken as an ideal protein source. Pork provides many under-consumed nutrients such as potassium, phosphorous and vitamin B12, a vitamin found only in animal foods.

Editor's Note: Dr. Venegas has been practicing medicine since 1984. He is president of The Venegas Medical Foundation and is active in community organizations including LULAC, The Mexico Institute, Casa Guanajuato and Emmanuel Medical Mission.


SOURCE National Pork Board

What You Need to Know in Your 40s to Have a Healthy Menopause -- Without Hormone Replacement Therapy

BOULDER, Colo., May 22 /PRNewswire/ -- A woman may share genetics with her mother, but she's not necessarily destined to have the same unpleasant menopause filled with hot flashes, insomnia, and mood swings. The June issue of Natural Solutions: Vibrant Health, Balanced Living magazine outlines simple steps women can take during their 40s to lessen the side effects of "the change"--without resorting to hormone replacement therapy (HRT), which increases risk of breast cancer, strokes, and heart disease.

The "Embracing Menopause" issue helps women redefine this rite of passage as an opportunity for self-discovery and renewal. The key to a positive transition: Eat well, exercise regularly, and practice de-stressing in your 40s so you won't be depleted as you move into perimenopause, the years leading up to menopause, when hormones, especially estrogen, fluctuate wildly.

"You're doing yourself a big favor if you're healthy going into menopause," says Mary Jane Minkin, MD, professor of ob-gyn at Yale University. "That isn't to say you're not going to have challenges. But I tell my patients it's best to hit the ground running."

A healthy diet and lifestyle--along with some non-drug alternatives--can reduce menopausal symptoms:

1. Strengthen bones. Dropping estrogen levels means weaker bones. Take calcium supplements and do weight-bearing exercises.

2. Eat more soy. Tofu, soy milk, soy beans and tempeh contain estrogen-mimicking isoflavones. (If you're at risk for breast cancer, eat lentils or chickpeas instead.)

3. Take herbs. Plant-based phytoestrogens--found in black cohosh, red clover, dong quai and chasteberry (vitex)--curb hot flashes and other menopausal complaints.

Surprisingly, women aren't the only ones with hormone swings. Another June Natural Solutions article on male menopause offers alternatives for men with age-related testosterone loss--including taking saw palmetto, pumpkinseed extract, and DHEA to combat libido loss, fatigue, depression, and urinary and erectile dysfunction.

Want more tips on graceful aging in good health? Visit www.naturalsolutionsmag.com.

About Natural Solutions

Natural Solutions: Vibrant Health, Balanced Living, formerly Alternative Medicine magazine, has been the trusted voice in the natural health arena for 15 years. Natural Solutions guides and inspires its readers to make informed decisions about their health and well-being in all aspects of their lives. Visit naturalsolutionsmag.com to view a free digital edition of the magazine.


SOURCE Natural Solutions Magazine

National Medical Interpreter Certification Testing Enters Pilot Phase

BOSTON, May 22 /PRNewswire/ -- The National Board of Certification for Medical Interpreters will begin the pilot phase of the performance exam that will be part of the testing for National Medical Interpreter Certification. Over the next few weeks, 300 interpreters will "test the test" designed to verify the ability of interpreters to apply their knowledge and skills in real-life medical interpreting scenarios. This process will provide additional input to the assessment tool's design, allowing test developers to make final adjustments before its national implementation.

The National Board of Certification for Medical Interpreters program, founded by Language Line(R) University and the International Medical Interpreters Association (IMIA), is a single certification entity that will award individuals with the credential "Certified Medical Interpreter" (CMI) in a specific language. To qualify for the CMI credential, a medical interpreter will have to pass the prerequisites, the National Board Written Exam, and the National Board Performance Exam.

"This new National Board is committed to bringing to fruition a national certification that recognizes the professional achievements necessary to provide quality language assistance in healthcare settings," said Louis Provenzano, President and COO of Language Line Services. "Accurately assessing an interpreter's knowledge and skills is essential and every measure has been taken to ensure that the National Board's written and performance exams accomplish that goal."

A call for subject matter experts and pilot participants was sounded at the Third Annual National Medical Interpreter Certification Forum, May 1, 2009, in Denver, Colorado, where interpreter organizations were also invited to participate in the pilot. Medical interpreters interested in volunteering to take the exams should email info@certifiedmedicalinterpreters.org.

"I would certainly encourage interpreters to become part of this process," advised Orlin Marquez, President of the Medical Interpreter Network of Georgia. "Certification has been a long time coming. We are thrilled that this effort is finally making significant progress, and we eagerly await a recognized national certification for the valuable services provided by medical interpreters on a daily basis."

The National Board Written and Performance Exams were developed under the guidance of PSI Services, an industry-leading provider of professional testing services. Interpreter focus groups, a national job analysis survey, and input from subject-matter experts helped define the test content in this complex statistical and scientific process. Test scoring guidelines were also established. A report on the test development and validation process will be provided following the analysis of the pilot results on the National Board website at http://www.certifiedmedicalinterpreters.org.

"This pilot phase is critical to the test certification process as a key component in ensuring the reliability and validity of the test instruments," said John Weiner, Chief Science Officer with PSI Services.

The test design team included medical interpreters who hold medical degrees, professionals with medical interpreter test design experience, those involved in establishing national interpreter standards, medical interpreting trainers, and testers with experience administering interpreter testing.

About the National Board of Certification for Medical Interpreters

The National Board of Certification for Medical Interpreters will be a non-profit organization, formed from an independent group of industry professionals that represent all stakeholder groups including professional medical interpreters, trainers, employers, and regulators. The Board will be the certifying entity and will be given independent authority over all essential certification decisions. It will not be responsible for accreditation of educational or training programs or courses of study leading to the certification. The formation and structure of the National Board of Certification will adhere to the standards and requirements for certification program governance mandated by the National Organization for Competency Assurance.

Contact:

The National Board of Certification for Medical Interpreters
info@certifiedmedicalinterpreters.org

Press contact:

Abbott Thayer
617-636-1798

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


SOURCE International Medical Interpreters Association

Thousands Rally in Anaheim to Help People With HIV/AIDS

Event raises $480,000 to make vital health and human services available through local nonprofit organizations

IRVINE, Calif., May 22 /PRNewswire-USNewswire/ -- More than 5,000 people converged on Angel Stadium of Anaheim Saturday, May 16 for Orange County's largest annual rally against HIV/AIDS. Donations from OC AIDS Walk 2009 reached $480,000.

"More than 8,000 men, women and children are living with HIV/AIDS in our community. Thanks to our OC AIDS Walk participants, eleven nonprofit organizations will receive the money they need to continue helping people living with the disease," said Phillip Yaeger, executive director/CEO of AIDS Services Foundation Orange County (ASF) that organizes the fundraiser.

"Despite some real concerns about raising money in this economy, Orange Countians showed their generosity for an important cause even in tough times. In fact, we're hopeful that we may yet top $500,000 as additional donations come in," said Yaeger.

OC AIDS Walk included individual walkers and teams from area companies; schools; civic organizations; and churches, synagogues, temples and mosques. Donations were raised through pledges made on behalf of the participants. Rossy Jones, a Laguna Beach resident who walks in memory of her son who died of HIV/AIDS, was recognized for raising $33,000 last year and more than $150,000 in the past 15 years she has walked. This was the 23rd year OC AIDS Walk was held.

Vikki Vargas, Orange County bureau chief for NBC-TV LA, emceed the kick-off program, then asked KROQ radio personality Doc on the Roc to launch the event by cutting the starting-line ribbon.

The 5K course (3.1 miles) included a walk around the stadium before entering the facility and circling the field's warning track. Walkers had the unusual opportunity to watch themselves on the stadium's AngelVision big screen. After completing the walk, participants enjoyed entertainment and a food festival featuring vendors who donated 100 percent of the proceeds from their sales to OC AIDS Walk. Several OC AIDS Walk sponsors set up information and exhibit booths as well.

Organizations benefiting from the money raised at OC AIDS Walk include the following groups, ACTION (AIDS CareTeam in our Neighborhood), AEGIS, AIDS Services Foundation Orange County, The Center Orange County, Mercy House, New Life Serenity House, OC Cornerstone Outreach, Public Law Center, Shanti Orange County, Straight Talk Clinic, Inc. and the University of California, Irvine (UCI) Education Center.

Support for OC AIDS Walk, financial and in-kind, came from a variety of sponsors. Among those aiding the fundraiser were Pacific Life, Disneyland, NBC Channel 4, Nordstrom, Time Warner Cable, ASICS, Wells Fargo, the City of Anaheim, and the PIMCO Foundation.

ASF is a nonprofit organization founded in 1985. Annually, the agency assists more than 1,600 people and their families that are either living with HIV or are impacted by the disease. Among the services ASF provides are food, transportation, housing, emergency financial assistance, mental health counseling, HIV testing, and HIV prevention and education programs. To learn more about ASF go to www.ocasf.org.

MEDIA CONTACTS: Barbara Lohman
AIDS Services Foundation
949-809-5751 or
714 342-7464 (cell phone)

Ty Rose
AIDS Services Foundation
949-809-8762


SOURCE AIDS Services Foundation Orange County

NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two

American Red Cross. (PRNewsFoto/American Red Cross)

WASHINGTON, DC UNITED STATES

WASHINGTON, May 21 /PRNewswire-USNewswire/ -- For the second year in a row, the American Red Cross is encouraging loyal NASCAR fans to donate blood through the Red Cross by joining Red Cross Racing.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO )

Red Cross Racing is a program designed to increase the number of blood donors and the number of times they donate. Participants of this program can get points for a variety of activities including giving blood and/or platelets, and recruiting other blood donors.

"We had nearly 22,500 blood donations through this program in 2008, and hope even more NASCAR fans participate in this lifesaving effort during 2009," said Gail McGovern, American Red Cross President and CEO. "We are grateful to 3M, Roush Fenway Racing and Greg Biffle for their support of Red Cross Racing and look forward to an exciting season ahead."

NASCAR driver Greg Biffle has signed on again as a Red Cross spokesperson this racing season to raise awareness about the ongoing need for blood donations. Biffle, a Red Cross blood donor and member of its National Celebrity Cabinet, will help get the word out to the 75 million passionate NASCAR fans across the country about the importance of blood donation.

"I'm proud to be an American Red Cross blood donor," said Biffle, driver of the No. 16 3M Ford Fusion. "I give blood because it's easy to do and helps support the community. I hope NASCAR fans across the country will join me this racing season by giving lifesaving blood as often as they can."

Thanks to a generous donation from 3M, Biffle will wear the Red Cross fire suit and drive the #16 Ford Fusion with the full Red Cross paint scheme at the Sprint Cup Series races in Charlotte on Memorial Day weekend and in Atlanta on Labor Day weekend.

This year, the program offers participants new and exciting rewards for blood donation activities. Registrants have the chance to get points and exchange them for NASCAR-themed prizes, such as limited edition die-cast cars. Fans can join the program by visiting redcrossracing.com, and can begin accruing points after registering.

About the American Red Cross

The American Red Cross shelters, feeds and counsels victims of disasters; provides nearly half of the nation's blood supply; teaches lifesaving skills; and supports military members and their families. The American Red Cross is a charity, not a government agency, and depends on volunteers and the generosity of the American public to perform its humanitarian mission.

About 3M

A recognized leader in research and development, 3M produces thousands of innovative products for dozens of diverse markets. 3M's core strength is applying its more than 40 distinct technology platforms -- often in combination -- to a wide array of customer needs. With $24 billion in sales, 3M employs 75,000 people worldwide and has operations in more than 60 countries. For more information, visit www.3M.com.

About Roush Fenway Racing

Roush Fenway Racing is NASCAR's largest team operating 13 motorsports teams. Five in the NASCAR Sprint Cup Series with drivers Matt Kenseth, Jamie McMurray, Greg Biffle, Carl Edwards and David Ragan; four in the Nationwide Series with Kenseth, Biffle, Edwards, McMurray, Ragan, Erik Darnell and Colin Braun; and three in the Craftsman Truck Series with Darnell, Braun, Kvapil, John Wes Townley and Bobby East; and one in the ARCA RE/MAX Series with Ricky Stenhouse Jr. For more information on any of the Roush Fenway Racing teams, log onto www.RoushFenway.com. For sponsorship inquiries please contact Robin Johnson at 704.720.4645.


SOURCE American Red Cross

Physical Therapists Advocate for Access to Rehabilitative Services on Capitol Hill

ALEXANDRIA, Va., May 21 /PRNewswire-USNewswire/ -- Two hundred physical therapists, physical therapist assistants, and students of physical therapy marched on Capitol Hill Tuesday to educate lawmakers about the critical need for patients to have improved access to physical therapy services. The group -- members of the American Physical Therapy Association (APTA) -- conducted approximately 350 visits with Representatives and Senators.

During their meetings with congressional representatives, the physical therapy providers emphasized three key issues: the need to remove therapy caps on Medicare part B outpatient rehabilitation services, the benefits of direct access to physical therapy services, and the importance of debt repayment for physical therapy students who choose to practice in underserved areas.

"With the recent release of the Senate Finance Committee's policy options documents and legislation expected to be introduced in the House and Senate in the next several weeks, the timing of these visits is crucial," said APTA President R. Scott Ward, PT, PhD. "To advocate on behalf of physical therapy patients during these decisive days will help raise awareness of the need for health care reform to address the arbitrary limits and burdensome requirements that keep patients from accessing cost-effective physical therapy services in a timely manner and reaching their full potential."

The visits to the lawmakers were the culmination of APTA's 3-day Federal Advocacy Forum that included a variety of speakers and briefings. Members of Congress and health care industry experts spoke about the challenges of reforming the health care system and the role of the physical therapist in reform.

Also on Tuesday, the association presented its 2009 APTA Public Service Award to Representative Lois Capps (D-CA) and Senator Edward Kennedy (D-MA) for their commitment to health care issues and the physical therapy profession.

Physical therapists are highly-educated, licensed health care professionals who can help patients reduce pain and improve or restore mobility -- in many cases without expensive surgery or the side effects of prescription medications. APTA represents more than 72,000 physical therapists, physical therapist assistants, and students of physical therapy nationwide. Its purpose is to improve the health and quality of life of individuals through the advancement of physical therapist practice, education, and research. In most states, patients can make an appointment directly with a physical therapist, without a physician referral. Learn more about conditions physical therapists can treat and find a physical therapist in your area at www.moveforwardpt.com.


SOURCE American Physical Therapy Association

Go Healthy Receives Letter of Endorsement from the Texas Chiropractic Association, District Five State Director - Dr. Thomas Klesmit

SPRING, Texas, May 21 /PRNewswire-FirstCall/ -- Go Healthy, Inc. (Pink Sheets: GOHE) announced today that the company received a letter of endorsement from District Five of the Texas Chiropractic Association. The letter, written by Dr. Thomas Klesmit, State Director of District Five of the T.C.A., mentions positive reviews of both the company's products as well as the customer service rendered to the Association's members. The letter also goes on to recognize the company's attendance at the T.C.A.'s regional meetings and events.

In an excerpt from the letter, Dr. Klesmit states, "On behalf of T.C.A. District Five, I personally want to thank you and your company for introducing the Go Healthy line of Products to thousands of chiropractors, chiropractic students and their patients in the Dallas - Fort Worth area. I visit with many chiropractors in their offices in my position and most of them I visit have the Go Healthy line of products proudly displayed on their office shelves."

Charlie Caudle, CEO of Go Healthy, states, "Our Company has long maintained that a healthy, well nourished body is a major key to overall health. We are proud to work with the members of the Texas Chiropractic Association, giving them a number of products to help supplement their specific areas of treatment and therapy."

About Go Healthy, Inc.

Go Healthy is an innovative nutritional supplement corporation founded on the great tasting products created by the late Dr. J. Robert Cade, the inventor of Gatorade(R). These natural products are at the core of the cholesterol solution, general nutrition, and energy and muscle recovery. Cholesterade(R) and the Go!(R) Energy Recovery Shakes and Bars are widely recommended by experts in the medical community and selected by major university and pro athletic departments.

Forward-Looking Statements Disclosure

This press release may contain "forward-looking statements" within the meaning of the federal securities laws. In this context, forward-looking statements may address the Company's expected future business and financial performance, and often contain words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "seeks," "will," and other terms with similar meaning. These forward-looking statements by their nature address matters that are, to different degrees, uncertain. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can provide no assurances that these assumptions will prove to be correct. All forward-looking statements in this press release are expressly qualified by such cautionary statements, risks, and uncertainties, and by reference to the underlying assumptions.

http://www.goshakes.com

Contact:

Charlie Caudle
CEO - Go Healthy, Inc.
(888) 282-7256
Mobile: (832) 724-9956


SOURCE Go Healthy, Inc.

H1N1 Scare Causes Businesses to Get Serious About Travel Health

State's Biggest Travel Health Firm Sees Uptick in Employer Interest in Their Niche

DENVER, May 21 /PRNewswire/ -- The H1N1 flu scare has caused businesses who regularly send their employees on international business trips to "get proactive" about travel health care, according to the owner of the state's largest travel health provider.

"We are hearing from more employers now about travel health issues, said Jamie Reesman, president of Passport Health Colorado. "I think now both employers and employees are appreciating that a travel health consultation with a travel medicine specialist is an important part of your pre-trip planning," he said.

Reesman reports that the H1N1 situation definitely impacted his clients' travel plans, but that the firm generally witnessed that travelers and companies opted to stick with their travel plans despite the influenza threat.

"As infectious disease experts have been able to better understand the true nature of the virus, we've seen our clients grow more comfortable with the concept of traveling again," Reesman said.

To reduce their risk of disease, Passport Health Colorado is advising their clients to limit their personal risk by:

Maintaining good personal hygiene. Wash your hands frequently. Carry a hand sanitizer for use when soap and water aren't readily available.

Avoid touching your face.

Avoid people who are obviously sick.

Consider your general health prior to travel. Talk to your travel health specialist about whether flu may be a more serious disease for you.

Ensure all routine vaccinations are up-to-date. (This includes pneumocococcal vaccination for some groups of people.)

People who have not had an annual flu vaccination should consider having one to prevent regular seasonal flu.

Passport Health Colorado, with 6 offices on the Colorado Front Range ranging from Colorado Springs in the South to Fort Collins in the North, provides destination-specific travel health information and immunizations for international travelers. The company's clients include corporations, universities and non-governmental organizations operating in the developing world.

Passport Health Travel Medicine Specialists administer and prescribe vaccinations and medications recommended by the CDC, WHO, and other world surveillance organizations that monitor outbreaks.

Passport carries specialty travel health products including kits for malaria, diarrhea, and water purification. Each office has a stock of all vaccines that are recommended or required for international travel.

For more information visit www.passporthealthco.com or call 303.442.8728.


SOURCE Passport Health Colorado

Medicaid Health Plans Provide Cost Savings to States and High Quality and Value to Beneficiaries, New Analysis Shows

Lewin Group Report Finds that Health Plans Contain Costs and Provide Beneficiaries with Improved Access to Health Services

WASHINGTON, May 20 /PRNewswire-USNewswire/ -- Medicaid health plans are producing cost savings for states, increasing access to services for individuals covered by Medicaid, improving quality of care, and earning high satisfaction ratings from enrollees, according to a Lewin Group report released today by America's Health Insurance Plans (AHIP). Twenty-four existing studies were analyzed by the Lewin Group to determine the savings achieved when states have implemented private Medicaid health plans.

"This study provides validation that Medicaid health plans are improving quality and access while also containing costs," said Karen Ignagni, President and CEO of AHIP. "During these difficult economic times, Medicaid health plans provide states with tools that work and on which they can depend."

Since the early 1990s, state Medicaid programs have turned increasingly to private health plans because of their potential to provide high-quality, cost-effective care. According to Lewin, health plans offer an opportunity for Medicaid programs to stretch their dollars and achieve cost savings without cutting eligibility, benefits, or already-low provider payment levels as states look at ways to alleviate the economic pressure faced by their budgets.

Some highlights of the Lewin analysis of 24 studies include:

The studies strongly suggest that Medicaid health plans typically yields cost savings -- savings across the studies range from half of 1 percent to 20 percent.

The studies provide some evidence that Medicaid health plan savings are significant for the Supplemental Security Income (SSI) and SSI-related population while improving quality and value for beneficiaries. For example, Arizona saw that 60 percent of the $102.8 million savings achieved from 1983 to 1991 is from the SSI population.

Various studies demonstrated that states' Medicaid health plan cost savings are largely attributable to changing patterns in unnecessary inpatient utilization such as those in a study of preventable hospitalizations in California, which found that the rates of preventable hospitalization were 38 and 25 percent lower in health plans than in fee-for-service (FFS) programs for the Temporary Assistance for Needy Families (TANF) and SSI populations, respectively.

Pharmacy was also an area where Medicaid health plans yielded noteworthy savings -- a comparison of drug costs under FFS programs vs. Medicaid health plans in multiple states found that the costs per-member per-month (PMPM) were 10 to 15 percent lower for health plans than for FFS programs.

The studies also suggest that health plans with responsibility for certain populations or services are especially likely to generate savings in a health plan delivery system while providing and coordinating comprehensive care for beneficiaries.

The Lewin analysis found that Medicaid health plans were found to have improved Medicaid beneficiaries' access to services and earned high satisfaction ratings from enrollees in addition to containing costs.

"As stewards of public funds, quality accreditation ensures our state administrators that one of America's most financially vulnerable populations is receiving the quality care and service it needs and deserves," said J. Mario Molina, M.D., President and CEO of Molina Healthcare, Inc. "At Molina, we demonstrate this by ensuring all of our eligible health plans are quality accredited by NCQA."

"Medicaid managed care works -- it's that simple," said Daniel J. Hilferty, President and Chief Executive Officer of the AmeriHealth Mercy Family of Companies. "Medicaid recipients are among the most sick and vulnerable people in the United States. Using an integrated, proactive approach to health care, AmeriHealth Mercy has improved outcomes for our members and saved taxpayers millions of dollars. As the nation searches for high-quality, cost-effective health reform options, we offer a model that is proven to increase access to care and control costs."

"This study demonstrates what we see every day: that Medicaid managed care helps our most vulnerable citizens get the healthcare they need and, at the same time, saves money for State governments," said James G. Carlson, Chairman and CEO of AMERIGROUP Corporation. "At AMERIGROUP, our unique programs for people with disabilities and long-term illnesses help our members lead more independent lives by receiving proactive care to prevent unnecessary hospital stays or institutionalization. This approach helps them lead healthier and fuller lives and in the long run lowers the cost of Medicaid."

The study also noted that the FFS setting model makes coordination of care and cost-containment difficult, while health plans create savings opportunities without reducing eligibility and benefits.

For more information, the full Lewin Group report, Medicaid Managed Care Cost Savings - A Synthesis of 24 Studies, can be found here: http://www.ahip.org/content/default.aspx?docid=27090.

An overview of the value that Medicaid health plans provide for beneficiaries and states can be found here: http://www.ahip.org/content/default.aspx?docid=27091.

America's Health Insurance Plans - Providing Health Benefits to More Than 200 Million Americans

About AMERIGROUP Corporation

AMERIGROUP Corporation, headquartered in Virginia Beach, Virginia, improves healthcare access and quality for the financially vulnerable, seniors and people with disabilities by developing innovative managed health services for the public sector. Through its subsidiaries, AMERIGROUP Corporation serves approximately 1.7 million people in Florida, Georgia, Maryland, Nevada, New Jersey, New Mexico, New York, Ohio, Tennessee, Texas and Virginia. For more information, visit www.amerigroupcorp.com.

About the AmeriHealth Mercy Family of Companies

The AmeriHealth Mercy Family of Companies is the industry leader in the delivery of quality health care to low-income populations covered by publicly funded programs, including Medicare, Medicaid, and State Children's Health Insurance Programs. The company's five lines of business -- health plans, management and administrative services, pharmacy management, care management, and behavioral health -- touch the lives of 6.7 million people in 14 states. For more information, go to www.amerihealthmercy.com.

About Molina Healthcare

Molina Healthcare, Inc. is a multi-state managed care organization that arranges for the delivery of health care services to persons eligible for Medicaid, Medicare, and other government-sponsored programs for low-income families and individuals. Altogether, Molina Healthcare's 10 licensed health plan subsidiaries in California, Florida, Michigan, Missouri, Nevada, New Mexico, Ohio, Texas, Utah, and Washington currently serve approximately 1.2 million members. More information about Molina Healthcare, Inc. can be obtained at www.molinahealthcare.com.


SOURCE America's Health Insurance Plans

Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer

- First and only oral targeted therapy to significantly improve overall survival in patients with the disease -

WAYNE, N.J. and EMERYVILLE, Calif., May 20 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Nexavar(R) (sorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC), a type of liver cancer that accounts for 95 percent of all liver cancer cases in Japan(1). Nexavar is also currently available in Japan as an approved treatment for unresectable or metastatic renal cell carcinoma (RCC).

The approval in Japan was based on the international, Phase 3 double-blind, placebo-controlled Sorafenib HCC Assessment Randomized Protocol (SHARP) study that evaluated more than 800 patients who received no prior systemic therapy. The study found that Nexavar improved overall survival in patients with HCC by 44 percent (HR=0.69; p=0.0006) versus placebo. Based on SHARP results, Nexavar is currently approved in more than 70 countries for liver cancer, including the U.S. and countries in Europe.

"Liver cancer is one of the leading causes of cancer-related deaths in Japan, and the incidence is continuing to rise," said Gunnar Riemann, member of the Executive Committee of Bayer HealthCare. "We are pleased with today's approval and what it may mean for liver cancer patients in Japan and their families who now have a therapy like Nexavar that has the potential to extend their lives."

In Japan, approximately 40,000 people are diagnosed with liver cancer each year and approximately 36,000 die from the disease, making primary liver cancer the third leading cause of cancer-related death in Japan.(2)

Hepatitis B viral infection (HBV) and hepatitis C viral infection (HCV) are leading risk factors for developing primary liver cancer worldwide, with HCV being the primary risk factor in Japan. An estimated 80 to 90 percent of Japanese patients diagnosed with liver cancer have HCV.(3)

"This is a significant milestone in the Japanese region where patients, who have high rates of liver cancer, are truly in need of a treatment option that improves survival," said Laura Brege, executive vice president and chief operating officer at Onyx Pharmaceuticals, Inc. "This latest approval provides further evidence that Nexavar is an important therapy for patients with liver cancer as well as kidney cancer, an indication for which Nexavar was first approved in Japan."

Hepatocellular carcinoma is the most common form of liver cancer(4) and is responsible for about 90 percent of the primary malignant liver tumors in adults(5). Liver cancer is the sixth most common cancer in the world(6) and the third leading cause of cancer-related deaths globally(7). More than 600,000 cases of liver cancer are diagnosed worldwide each year (more than 400,000 in China, South Korea, Japan and Taiwan, 54,000 in the European Union, and 15,000 in the United States) and the incidence is increasing(4). In 2002, approximately 600,000 people died of liver cancer including approximately 370,000 in China, South Korea and Japan, 57,000 in the European Union, and 13,000 in the United States(4).

Nexavar's Differentiated Mechanism

Nexavar targets both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to target members of two classes of kinases known to be involved in both cell proliferation (growth) and angiogenesis (blood supply) - two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET. Preclinical models have also demonstrated that Raf/MEK/ERK has a role in HCC; therefore blocking signaling through Raf-1 may offer therapeutic benefits in HCC.

Nexavar is currently approved in more than 70 countries for liver cancer and in more than 80 countries for the treatment of patients with advanced kidney cancer. Nexavar is also being evaluated by the companies, international study groups, government agencies and individual investigators as a single agent or combination treatment in a wide range of cancers, including, lung cancer, breast cancer, colorectal cancer, lung cancer, ovarian cancer, and as an adjuvant therapy for kidney and liver cancer.

Important Safety Considerations For Patients Taking Nexavar

Based on the currently approved U.S. package insert for the treatment of patients with unresectable hepatocellular carcinoma, hypertension may occur early in the course of therapy and blood pressure should be monitored weekly during the first six weeks of therapy and treated as needed. Bleeding with a fatal outcome from any site was reported in 2.4% for Nexavar and 4% in placebo. The incidence of treatment-emergent cardiac ischemia/infarction was 2.7% for Nexavar vs. 1.3% for placebo. Most common adverse events reported with Nexavar in patients with unresectable HCC were diarrhea, fatigue, abdominal pain, weight loss, anorexia, nausea and hand-foot skin reaction. Grade 3/4 adverse events were 45% for Nexavar vs. 32% for placebo. Women of child-bearing potential should be advised to avoid becoming pregnant and advised against breast-feeding. In cases of any severe or persistent side effects, temporary treatment interruption, dose modification or permanent discontinuation should be considered.

For information about Nexavar including U.S. Nexavar prescribing information, visit www.nexavar.com or call 1.866.NEXAVAR (1.866.639.2827).

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals unit of Bayer HealthCare LLC, a division of Bayer AG. One of the world's leading, innovative companies in the healthcare and medical products industry, Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the U.S., Bayer HealthCare Pharmaceuticals comprises the following business units: Women's Healthcare, Diagnostic Imaging, Specialized Therapeutics, Hematology/Cardiology and Oncology. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R) (sorafenib) tablets, a small molecule drug. For more information about Onyx, visit the company's website at: www.onyx-pharm.com.

Forward Looking Statements

This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer Web site at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

This news release also contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the results of the clinical development, safety, regulatory processes, commercialization efforts or commercial potential of Nexavar. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2008, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals, Inc.

(1) British Medical Journal (BMJ), Liver cancer toll high in Japan, Adam Easton; 1999 June 5; 318(7197): 1510.

(2) Ferlay J, et al., GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No.5, Version 2.0. IARCPress, Lyon, 2004. Available at: http://www-dep.iarc.fr. Accessed April 2009.

(3) El-Serag HB, Rudolf KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132(7); 2557-2576.

(4) El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-750

(5) Available at American Society of Clinical Oncology: http://www.asco.org/patient/Cancer+Types/Liver+Cancer.

(6) Ferlay J, et al., GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No.5, Version 2.0. IARCPress, Lyon, 2004. Available at: http://www-dep.iarc.fr. Accessed April 2009.

(7) Forner A, Hessheimer AJ, Isabel Real M, Bruix J. Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol. 2006; 60: 89- 98.


SOURCE Bayer HealthCare Pharmaceuticals; Onyx Pharmaceuticals, Inc.

HIMSS Analytics and NetMotion Wireless Release Study Findings on Key Challenges for Wireless Healthcare Deployments

Approximately one-third of hospitals in the United States now use wireless deployments

Free report examines common obstacles and methods to address them in healthcare settings

SEATTLE, May 20 /PRNewswire/ -- Nearly one-third of hospitals in the United States have deployed a wireless connectivity system in their healthcare organizations, according to the HIMSS Analytics(TM) Database. NetMotion Wireless, a leading provider of mobile productivity and management software, recently sponsored a focus group study in which researchers from HIMSS Analytics set out to identify some of the biggest challenges senior IT executives face when implementing wireless applications and devices in healthcare settings. The results of the study are now published in a free report available for download at www.netmotionwireless.com/resources/whitepapers.

Institutions represented in the focus groups ranged from large (1000+ bed) urban health systems to small (100 bed) rural organizations. All of the participants managed IT for diversified healthcare companies with hospitals, subacute, ambulatory and home health operations. Participants in the focus groups identified the following five key challenges that are detailed in the study:

Physical connectivity issues;
Technology connectivity issues;
Extensive user demand;
Security; and,
Network management.

As indicated in the report, the American Recovery and Reinvestment Act of 2009 includes $20 billion to promote the adoption and use of health information technology (HIT) and especially electronic health records (EHRs). Although there is no specific mention of wireless technology in the legislation, it can be inferred that since the funding is tied directly to migrating to an electronic health record environment, the use of wireless technology to capture and manage patient data electronically at the point of care, and to share this data with other caregivers, will be a key driver in wireless technology adoption for the next five years.

"In theory, secure mobile access to medical records and imaging, prescriptions, and even general administrative databases, should allow doctors, nurses and medics to treat more patients faster, more accurately, and with greater flexibility - from any location in a large hospital, during home visits, or at the scene of an ambulance response," said Jennifer Horowitz, senior director, research, HIMSS Analytics. "However, often the anticipated productivity gains are hampered by a series of fairly common issues related to wireless networks. This report examines some of those key issues and identifies some approaches healthcare agencies are utilizing to address them."

"For hospitals and healthcare agencies across the country, NetMotion Wireless helps mitigate many of the common challenges raised in this new report about wireless deployments," said Pam Cory, vice president of marketing, NetMotion Wireless. "Our Mobile Virtual Private Network, Mobility XE, provides secure connectivity, device and application management, and enhances the productivity of both the end users and IT managers. Our software provides healthcare professionals seamless roaming across wireless networks, and when connections are lost, automatically maintains application sessions freeing clinicians to focus on their patients, and not on their mobile laptop or device."

NetMotion Wireless supports the critical care operations of numerous healthcare providers, from major hospitals and health organizations such as St. Luke's Episcopal Health System, the Marshfield Clinic, and Lee Memorial Health System, to home healthcare organizations such as the Visiting Nurse Service of New York. In addition, the company supports the mobile deployments of a number of emergency medical services and other ambulatory care organizations.

About HIMSS Analytics

HIMSS Analytics is a wholly owned not-for-profit subsidiary of the Healthcare Information and Management Systems Society (HIMSS). The company collects and analyzes healthcare data related to IT processes and environments, products, IS department composition and costs, IS department management metrics, healthcare trends and purchase-related decisions. HIMSS Analytics delivers high quality data and analytical expertise to healthcare delivery organizations, healthcare IT companies, state governments, financial companies, pharmaceutical companies, and consulting firms. Visit www.himssanalytics.org for more information.

About NetMotion Wireless

Based in Seattle, NetMotion Wireless develops software to enable businesses and agencies to maintain and optimize connections to applications as their mobile workers move in and out of wireless coverage areas and across various networks. NetMotion's award-winning Mobile VPN, Mobility XE, enhances mobile worker productivity at more than 1,500 of the world's most respected organizations across multiple industries including utilities, healthcare, communications, public safety, local government, transportation and many others. For more information about NetMotion Wireless or its products, please visit www.netmotionwireless.com or call (206) 691-5500.

NetMotion and NetMotion Mobility are registered trademarks of NetMotion Wireless, Inc. Mobility XE is a trademark of NetMotion Wireless, Inc. All other trade names, trademarks and registered trademarks are the property of their respective owners.


SOURCE NetMotion Wireless

Franklin Memorial Hospital Thrives on the InstaMed Network

FARMINGTON, Maine and PHILADELPHIA, May 19 /PRNewswire/ -- By utilizing InstaMed's solutions, Franklin Memorial Hospital has streamlined its payment collection processes, increased payment card transactions and decreased administrative costs. InstaMed's integrated and flexible platform allows Franklin to collect patient payments over the web, in the back office and at the point of service.

As patient responsibility continues to increase, hospitals like Franklin are proactively seeking solutions to streamline their patient payment process, cut costs and increase patient payments while reducing bad debt. With the added challenge of managing multiple payment locations, hospitals require a simple, reliable solution to process patient payments. By implementing InstaMed's PCI Level One certified solutions, which include the ability to collect in the front and back office, as well as collect from patients via the Web, Franklin has seen a 46% increase in payment card transactions contributing to a significant increase in patient revenue. Additionally, InstaMed's solutions enable Franklin to operate their entire hospital on one platform and network - offering unified real-time reporting, consolidated statements and payment posting, which delivers new actionable information where it's needed in the organization, while saving thousands of dollars in administrative overhead and third party vendor costs. Franklin now has the flexibility to instantly deploy a point of collection to any of Franklin's computers in its front and back offices at no additional cost.

Michael Nile, Business System Specialist of Franklin Memorial Hospital stated, "InstaMed has helped us increase payment card transactions, which has helped our organization thrive even through tough economic times. InstaMed's solutions have proved to be flexible and cost effective for our organization and we are also pleased that their solutions help to facilitate patient satisfaction."

Bill Marvin, President and CEO of InstaMed stated, "Our experience with Franklin Memorial Hospital demonstrates how our flexible solutions can rapidly and cost effectively deploy to meet the dynamic needs of a hospital organization, while maintaining the highest level of compliance in the industry. We are thrilled that Franklin has joined our rapidly growing, nationwide network."

About Franklin Memorial Hospital

Franklin Memorial Hospital in Farmington, Maine, is a progressive, friendly, nonprofit community general hospital whose mission is to provide high-quality, cost-effective, patient-centered health care to west central Maine. The hospital actively works with the community and with other health-care providers to integrate services and ensure the health of people within its service area. Franklin Memorial Hospital offers highest-quality health care and state-of-the-art technological support. At the same time, FMH is one of the lowest cost hospitals in Maine as the result of astute quality assurance and cost containment measures. Care here, as elsewhere in the country, has shifted rapidly from a primarily inpatient medical model to one that emphasizes education, prevention, and outpatient services. Visit Franklin Memorial Hospital on the web at www.fchn.org.

About InstaMed

InstaMed is the industry leading healthcare payments network and platform. InstaMed's mission is to transform the healthcare payment process for healthcare Providers, Payers, Banks and Patients so their payment experience is simple, convenient, reliable and secure. InstaMed processes all of the healthcare and payment transactions in the healthcare revenue cycle and offers patent pending, integrated healthcare and payment transactions that accelerate the healthcare payment process and reduce the administrative costs to all parties. InstaMed currently supports the healthcare payment processing needs of over 900 hospital and clinic locations; practice management vendors and billing services representing over 50,000 providers; and hundreds of healthcare payers of all sizes. InstaMed is registered with Visa and MasterCard and is certified as a Payment Card Industry Data Security Standards (PCI-DSS) Level One Service Provider. InstaMed is also fully accredited by the Electronic Healthcare Network Accreditation Commission (EHNAC) as a healthcare clearinghouse. InstaMed is an AHIP Solutions Partner (America's Health Insurance Plans), a member of the C.O.R.E. Initiative (Committee on Operating Rules for Information Exchange), the Medical Banking Project, ASC X12, HBMA (Healthcare Billing & Management Association), Electronic Payments Network ACH Association Services, MGMA's Project SwipeIT (Medical Group Management Association) and WEDI (Workgroup for Electronic Data Interchange). Visit InstaMed on the web at www.instamed.com.


SOURCE InstaMed

IntraHealth International Addresses Capacity Building and Open Source Technologies at Tech-Themed Global Health Conference

CHAPEL HILL, N.C., May 19 /PRNewswire-USNewswire/ -- IntraHealth International will highlight its commitment to leveraging technology to benefit the people of the developing world during the 36th annual International Conference on Global Health in Washington D.C., May 26-30. Hosted by the Global Health Council, this year's conference, "New Technologies + Proven Strategies = Healthy Communities," focuses on the ways in which technologies in combination with best practices and evidence-based policies improve health around the world.

"IntraHealth wants to help strengthen local health workers' ability to identify, develop and implement appropriate technologies that support improved global health outcomes," says President and CEO Pape Gaye, who will speak as part of a special session, "The Big Choice: The Successes and Challenges of Open Source Technology."

The global nonprofit will host an evening ceremony at the conference celebrating its recently launched IntraHealth OPEN Initiative benefiting Africa's health workers. IntraHealth has partnered with Youssou N'Dour, Nas, Peter Buck of R.E.M. and global leaders in music, technology and public health, to create and release a series of free MP3s in support of the campaign. Participating bands will be performing at the event including Afrissippi, Toubab Krewe, DJ Equal and Umar Bin Hassan. IntraHealth and Indaba Music will announce the winner of the IntraHealth Global Music Remix Contest at the event, and premiere a clip from the new Youssou N'Dour biopic "I Bring What I Love."

An interactive expo hosted by the IntraHealth-led USAID Capacity Project will demonstrate resources and open source software designed to build local equity and expertise and help decision makers use data to lead and manage successfully.

IntraHealth's work is also featured in workshops and sessions on human resource and health management information systems, new technologies for supervision and Geographic Information Systems. Staff and partners from Ethiopia, India, Kenya, Mali, Senegal, South Africa, South Sudan, Rwanda and Uganda will be attending.

Concurrent with the conference, IntraHealth is holding the inaugural meeting of the IntraHealth OPEN Council, bringing global leaders and local innovators in technology and public health together to discuss eHealth strategies in the developing world.

ABOUT INTRAHEALTH INTERNATIONAL

IntraHealth International mobilizes local talent to create sustainable and accessible health care in developing countries. A not-for-profit organization, IntraHealth has worked in more than 50 countries over the last three decades. www.intrahealth.org


SOURCE IntraHealth International

Pharma and Biotech Companies Plug into Singapore's Integrated Research Network

Singapore provides a home for innovation in Asia

ATLANTA, May 19 /PRNewswire-Asia/ -- Leading pharmaceutical and biotech companies are drawing on Singapore's integrated network of public-sector and academic institutes to enhance their R&D productivity, leverage academic insights and diversify risks. Located at the heart of Asia with a population base that is representative of key Asian ethnic groups, Singapore provides a home-base of innovation for companies to test and develop new solutions for Asia and beyond.

Recent announcements of public-private partnerships (PPP) include GlaxoSmithKline Biologicals committing US$1.3 million in vaccine and process development with Singapore's Bioprocessing Technology Institute (BTI); Lilly Singapore Centre for Drug Discovery (LSCDD) teaming up with Singapore's National Neuroscience Institute (NNI), and the Singapore Institute for Clinical Sciences (SICS) to advance drug discovery using adult brain tumor stem cells.

AstraZeneca announced its collaboration with the National Cancer Centre Singapore (NCCS) and the National University Hospital (NUH) in pre-clinical and clinical development activities of anti-cancer compounds to build up AstraZeneca's drug development capabilities in Asia; Singapore Immunology Network (SIgN) partnered European biotechs - Humalys SAS and Cytos Biotechnology Ltd - to develop antibodies for combating and managing viruses prevalent in Asia including hand, foot and mouth disease.

Massachusetts-based biotech, FORMA Therapeutics, has also set up its first overseas lab in Singapore's Nanyang Technological University (NTU). An emerging biotech company, Forma seeks to integrate important new advances in biology and chemistry to unlock the best targets and pathways that genomic medicine has revealed. FORMA will be collaborating with the Experimental Therapeutics Centre of Singapore (ETC) to co-discover novel therapeutics.

"There is no doubt Asia will soon be the next centre of gravity for the global pharma industry. While the diverse Asian market presents tremendous opportunities, it remains challenging to navigate the region's complexities and harness its opportunities. Singapore provides one of the best locations in Asia, which would enable us to conduct our targeted research, collaborate with public institutions and tap into regional capabilities to supplement our activities," said Dr Steven Tregay, Chief Executive Officer, FORMA Therapeutics.

Public-Sector Resources Allow for End-to-End Research Activities

As companies worldwide seek to develop new therapies and diagnostics to expand their pipeline of innovative products, PPPs represent an effective way for companies to enhance their R&D productivity and accelerate commercialisation efforts.

Singapore's advanced research infrastructure, base of more than 2,800 public sector researchers and business-friendly economic policies are fuelling the rapid growth of PPPs in biomedical sciences. Companies may leverage on Singapore's extensive resources and cross-institutional capabilities to handle complex bench-to-bed and bed-to-bench translational projects. These resources include dedicated clinical bio-imaging research, bio-safety, and early-phase trial facilities. Companies can also tap into the preclinical predictive disease models and platform technologies in genomics and bio-imaging available in Singapore.

Mr. Yeoh Keat Chuan, Executive Director, Biomedical Sciences, Singapore Economic Development Board (EDB) said: "The EDB provides a one-stop shop to link companies to our integrated network of public-sector research and medical institutes. Singapore is also strategically located at the heart of Asia, which makes us an ideal control tower to oversee R&D activities across the heterogeneous landscape in Asia, especially in translational medicine and Asian diseases. Coupled with our pro-business policies and focused efforts to be future-ready, Singapore is well-positioned to be a strategic research partner for the industry and a home-base for innovation in Asia."

Singapore's Biopolis: Asian Home-Base for R&D

The Biopolis, a 2.4 million square-foot research campus, is the icon of Singapore's success in biomedical sciences. Co-locating global companies' research operations with publicly funded research institutes, the Biopolis is imbued with a campus spirit to advance science and human healthcare via cross- disciplinary, public-private collaborations.

In recognition of this significant advantage, numerous companies have chosen to set up their Asian R&D operations at the Biopolis. Emerging biotech companies such as PharmaLogicals and SGAUSTRIA (formerly Austrianova) are located alongside leading pharmaceutical companies. A 400,000 square-foot Phase 2 expansion of the Biopolis launched in 2006 is already fully subscribed. Another 440,000 square feet of research space is being added and will be ready by 2010.

Recent announcements at the Biopolis include:

-- Lilly opened its Singapore Centre for Drug Discovery (LSCDD) that will
coordinate its activities throughout Asia via the new FIPNet (Fully
Integrated Pharmaceutical Network) model. Staffed by 150 researchers,
LSCDD is also one of the world's first R&D centres to conduct drug
discovery through an integrated approach of biomarker discovery
research, integrated informatics and bioinformatics.
"At a strategic level, LSCDD is about expanding into Asia to leverage
talent and to establish collaborations with others to support our drug
discovery efforts. Our expanded location now at the Biopolis, where
other industry peers and academic institutions reside will help us to
achieve this goal," said Jonathon Sedgwick, Managing Director and Chief
Scientific Officer, LSCDD.
-- Schering-Plough opened its first Translational Medicine Research Centre
(TMRC) that will carry out biomarker discovery and development. The
TMRC will also coordinate the company's participation in biomarker
consortia and collaboration with research institutes in Singapore. The
facility will be staffed by over 50 scientists.
-- Abbott opened its US$5 million pharmaceutical analytical research
laboratory, the first in Southeast Asia. This lab will initially employ
17 researchers. In addition, Abbott announced its Asia-Pacific Research
and Development Center for Nutrition Science which will also be located
at the Biopolis. This centre will focus on clinical trials and
development of nutritional products that are tailored to Asian dietary
needs.

About Singapore Economic Development Board (EDB)

EDB is the lead government agency for planning and executing strategies to enhance Singapore's position as a global business centre and grow the Singapore economy. We dream, design and deliver solutions that create value for investors and companies in Singapore. In so doing, we attract economic opportunities and jobs for the people of Singapore, and help shape our country's economic future.

For more information on how EDB can help in biomedical sciences business and investment, please visit http://www.biomed-singapore.com .

For media enquiries, please contact Ruder Finn.

Kaele Stock
Senior Account Executive
Ruder Finn (New York)
Tel: +1-202-276-2471
Email: stockk@ruderfinn.com

Parveen Kaur
Senior Consultant
Ruder Finn Asia (Singapore)
Tel: +65-9327-8175
Email: kaurp@ruderfinnasia.com


SOURCE Singapore Economic Development Board (EDB)

IBD Patient Launches iPhone Application to Help Doctors Treat Crohn's and Ulcerative Colitis

Developed by a Crohn's patient with help from GI specialists, GI Monitor, an iPhone App launched by WellApps, Inc., allows patients with (IBD) Crohn's and Ulcerative Colitis to track their symptoms and deliver accurate data to their doctors.

UPPER SADDLE RIVER, N.J., May 19 /PRNewswire/ -- WellApps, Inc. launched an iPhone application to help people with (IBD) Crohn's and Ulcerative Colitis provide accurate symptom data to their doctors for optimal treatment. The application, called GI Monitor , was developed by an 18-year Crohn's patient after a recent flare up of his condition.

Inspired by a long battle with Crohn's disease, 34-year old Brett Shamosh, a Digital Media Executive from Bergen County, NJ, decided to use technology to help fellow IBD patients. After a recent Crohn's flare up, Mr. Shamosh visited New York digestive disease specialist, Bruce Yaffe, M. D., for treatment. During his visits, Mr. Shamosh worked with Dr. Yaffe to understand what information helped him make treatment decisions. Says Mr. Shamosh, "The idea is not to replace a doctor's diagnosis, but rather to help the doctor make better informed decisions. With so much going on in my life, it is difficult to recall exactly how I was feeling at a particular time and provide my doctor with accurate data about my symptoms. This is the problem I was trying to solve."

GI Monitor allows a patient to easily log the frequency of bowel movements, consistency and blood level of stool, and pain/stress levels. In addition, the patient can keep a record of medications and dosages prescribed. All of this information is kept in detailed logs on the patient's iPhone and is calculated into "My Status," which reveals how the patient is feeling on a simple scale of 1-10. Reports from any date range can be emailed directly to a doctor, or any concerned mother, right from the patient's iPhone with the click of a button. The application is currently available in iTunes for $4.99 and will be released for BlackBerry devices soon.

About WellApps, Inc.

WellApps, Inc. is a mobile health applications development company. Our condition-specific applications allow users to easily track their symptoms and report their status to their doctors, resulting in optimal diagnosis, treatment and recovery. For more information, contact Brett Shamosh at 201-446-7224 or email brett@wellapps.com

Visit WellApps, Inc. at http://www.wellapps.com

This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.


SOURCE WellApps, Inc.

Be Smart About Tooth Whitening

HARRISBURG, Pa., May 18 /PRNewswire-USNewswire/ -- Everyone wants a whiter, brighter smile. These days, there are many ways people seek to achieve this goal, from a whitening procedure in the dental office to strips sold over-the-counter to whitening toothpaste. Recently, tooth whitening kiosks have been popping up in places such as local malls. This trend raises the question, is it safe?

The Pennsylvania Dental Association (PDA) encourages the public to consult with and have a thorough examination performed by a licensed and registered dentist prior to having any tooth whitening procedure.

PDA reminds the public that tooth whitening procedures, outside of those readily available for over-the-counter purchase by the consumer for self-use, should be performed only by a licensed dentist within a registered dental office or branch thereof. The Pennsylvania State Board of Dentistry also is developing a policy statement that will help provide more guidance by clearly defining tooth whitening as the practice of dentistry. This approach will ensure that the patient's specific dental needs are being properly addressed by an individual who is trained and licensed to diagnose and identify possible complications that could occur due to inadequately performed procedures.

Since not all tooth discoloration is the same, patients should first be examined by a licensed dentist to see what type of bleaching is best. After an examination and cleaning to remove simple stains, your dentist may recommend one of the following treatment options:

Over-the-counter whitening products, such as whitening strips. These typically yield a very subtle lightening of the teeth. The American Dental Association only approves dentist-dispensed home-use whitening products, to ensure appropriate application and follow-up.
Prescription bleaching kits, dispensed by a licensed dentist, contain peroxide(s) that will bleach the tooth enamel. Prescription bleaching kits contain higher levels of carbamide or hydrogen peroxide than their non-prescription counterparts. Peroxide whiteners typically come in a gel and are placed in a tray similar to a mouthguard. By obtaining the bleaching solution from your dentist, he or she can make a custom-fitted tray specifically designed to fit your teeth. Poorly fitting trays can cause gingival irritation and tissue burning.
Zoom whitening (power whitening) is a high concentration of hydrogen peroxide gel coupled with a high intensity light used to whiten the teeth. This in-office procedure takes approximately one hour. Costing around $600, the results typically last about three years.
Whitening toothpaste. While these will not change the natural color of teeth, some contain a special chemical or polishing agent to help more effectively remove stains from the tooth's surface.

Keep in mind that bonded teeth, tooth-colored fillings, crowns and veneers cannot be whitened. Discolored teeth that have a brown, yellow or grayish hue may not yield a full whitening effect.

"Since patients should be cautious when seeking tooth whitening procedures, the first stop should be with their licensed family dentist," said Dr. Joseph Ross, a PDA member and general dentist from New Castle. "Their dentist can inform them of the appropriate options available. Tooth whitening kiosks in malls and shopping centers may not be operated by licensed dentists. Although tooth whitening is cosmetic in nature, there are biological effects. Only a trained licensed dentist can properly diagnose and treat tooth discolorations."

For more information on other oral health topics, visit PDA's Web site at www.padental.org.


SOURCE Pennsylvania Dental Association

Drug That Targets Vasculature Growth Attacks Aggressive Thyroid Cancer, Mayo Clinic Researchers Report

ORLANDO, May 18 /PRNewswire-USNewswire/ -- A medication that helps stop the growth of new blood vessels has produced dramatic benefits for some patients with aggressive thyroid cancer, research from Mayo Clinic indicates.

At the annual meeting of the American Society of Clinical Oncology (ASCO), Mayo investigators report that cancer in about two-thirds of 37 patients with aggressive differentiated thyroid cancer treated with the drug pazopanib either stopped growing, or quickly shrank.

The patient responses seen to date are promising, the researchers say, because all patients had fast-growing cancers that had spread to their lungs, with half involving lymph nodes and 39 percent also involving bones.

"The benefits were striking in many patients to a degree we have not previously seen in thyroid cancer in response to other therapies, including the standard treatment of radioiodine," says Keith Bible, M.D., Ph.D., a medical oncologist and researcher who led the multicenter clinical trial funded by the National Cancer Institute. Most of the patients treated were enrolled at the Mayo Clinic campuses in Minnesota and Florida.

Approximately one-third of patients achieved sustained and dramatic benefit from pazopanib, while another one-third experienced stabilization of their cancer or some tumor shrinkage. The remaining one-third of patients did not benefit from the drug. The agent was also well tolerated by the majority of patients, Dr. Bible adds.

What is not yet known, however, is the drug's effect on overall survival. "We need more time to establish that definitively," says Dr. Bible. "The trial has been going on for just over a year, and some of our patients are still maintaining a response, while others have not been in the study long enough for us to confirm duration of response." He notes that of the 37 original trial participants, two have died -- one from cancer progression and another from other causes.

The National Cancer Institute estimated that 37,340 new cases of thyroid cancer would be diagnosed in 2008, with 1,590 deaths from the cancer. The cancer is much more common in women; it is the seventh most common cancer in women in the U.S. The occurrence of thyroid cancer has recently been rising.

Most thyroid cancers are of two major "differentiated" types -- papillary thyroid cancer (the most common, accounting for 75 percent of cases) and follicular thyroid cancer (15 percent).

Fortunately, most patients with thyroid cancer respond well to surgery and to follow-up treatment with radioiodine; even if the cancer recurs and spreads, the disease progresses slowly in most patients, Dr. Bible says. "Many patients do well for a long time without the need of additional therapy," he says. However, about 5 percent of these patients experience rapidly progressing life-threatening disease that is insensitive to radioiodine and other treatment approaches. "Until only recently, we have not had any effective therapies for such patients."

Pazopanib is an experimental agent that is also being studied in advanced kidney, ovarian and other cancers. The drug, administered in pill form, targets proteins involved in angiogenesis, the growth of new blood vessels that has a critical role in the growth and spread of tumors. The proteins that pazopanib targets include vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), c-kit and Ret.

Mayo investigators are also leading clinical trials to test pazopanib in two other thyroid cancer subtypes -- medullary, which does not respond to radioiodine, and anaplastic, the most aggressive subtype.

Dr. Bible says plans are also under way to test pazopanib in a larger, controlled and randomized clinical trial of patients with advanced differentiated thyroid cancer. Researchers want to more accurately assess benefits and risks.

About Mayo Clinic

Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. Doctors from every medical specialty work together to care for patients, joined by common systems and a philosophy of "the needs of the patient come first." More than 3,300 physicians, scientists and researchers and 46,000 allied health staff work at Mayo Clinic, which has sites in Rochester, Minn., Jacksonville, Fla., and Scottsdale/Phoenix, Ariz. Collectively, the three locations treat more than half a million people each year. To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. For information about research and education, visit www.mayo.edu. MayoClinic.com (www.mayoclinic.com) is available as a resource for your health stories.

VIDEO ALERT: Additional audio and video resources, including excerpts from an interview with Dr. Keith Bible describing the research, are available on the Mayo Clinic News Blog.


SOURCE Mayo Clinic

Itasca Medical Care Implements DST Health Solutions' CareAnalyzer Solution to Improve Care Management, Quality

Solution Analyzes Patient Risk, Care Opportunities and Provider Performance to Increase Effectiveness of Health Plan's Care Management Program

BIRMINGHAM, Ala., May 18 /PRNewswire/ -- DST Health Solutions(R) today announced that Itasca Medical Care, a Minnesota health plan, has successfully implemented CareAnalyzer(TM), its analytic solution suite that combines elements of patient risk, care opportunities and provider performance. CareAnalyzer helps health plans meet reporting requirements for the Healthcare Effectiveness Data and Information Set (HEDIS(R)) and effectively identify high-risk members for care management.

Itasca Medical Care, headquartered in Grand Rapids, Minn., is a Medicaid/Medicare Advantage health plan administered by Itasca County Health & Human Services. Its members include Minnesota residents of Itasca, Koochiching and Aitkin counties.

"We chose CareAnalyzer to help us efficiently meet HEDIS reporting requirements," said Brett Skyles, program director, Itasca Medical Care. "The system presents data in a very logical and easy to use manner, which saves us time and increases accuracy in reporting."

In addition to meeting HEDIS reporting requirements, CareAnalyzer incorporates predictive modeling to help health plans identify high-risk members with chronic conditions such as diabetes, asthma or lower back pain. High-risk members then may be enrolled in care management programs that include preventive health screenings and treatment plans tailored to their condition.

CareAnalyzer incorporates the Johns Hopkins ACG(R) (Adjusted Clinical Grouper) Case System, a peer reviewed software tool for provider profiling, predictive modeling, resource management, and reimbursement rate adjustment. The ACG System was developed by The Johns Hopkins University Bloomberg School of Public Health, and is distributed exclusively by DST Health Solutions.

"CareAnalyzer supports ongoing performance improvement by allowing end users to readily access summary level quality reports supported by comprehensive member profiles," said Amy Salls, business solutions director for decision support, DST Health Solutions. "Health plans, such as Itasca, report that CareAnalyzer supports a more complete member assessment with intuitive navigation, a consolidated view of disparate data sources and a reduced reliance on IT resources to build queries."

About DST Health Solutions

DST Health Solutions, LLC delivers systems and services that help improve efficiency, reduce operational costs, increase speed to market, facilitate medical cost management and price containment - improving both member experience and service for commercial health plans, consumer-directed plans, government plans (Medicare Advantage, Medicare Part D and Medicaid) and physician practices. DST Health Solutions' enterprise applications and ASP and BPO services include claims processing, member and provider management, benefit plan management, new product development, care management and medical management, and decision support/analytics supporting nearly 400 clients representing 40 million lives. For more information about DST Health Solutions, contact 800.272.4799, e-mail inforequests@dsthealthsolutions.com or visit www.dsthealthsolutions.com.


SOURCE DST Health Solutions, LLC

18 More Anti-Abortion Activists Arrested at Notre Dame on Saturday; More Arrests Planned for Sunday

Notre Dame warns TV networks that they will "cut the feed" of any network that covers disruption of Obama Speech on Sunday.

Dr. Alan Keyes to be available soon for interview -- judge grants hearing and posts $1,000 bond each for 5 pro-lifers that have been held in jail without bond. They will be released soon.

SOUTH BEND, Ind., May 16 /PRNewswire-USNewswire/ -- The Following is Being Issued by Randall Terry, Founder of Operation Rescue:

At approximately 12:00 Noon, over 40 pro-life activists walked on Notre Dame's campus, praying the Rosary.

They were led by pro-life icons Norma McCorvey, Joan Andrews Bell, and Father Norman Weslin.

Five women and thirteen men were arrested while they carried images of Our Lady of Guadalupe and prayed the Rosary. Those arrested included Fr. Weslin and Joan Andrews Bell. Norma McCorvey was not arrested.

Over one hundred pro-lifers gathered on all 4 corners of the main entrance block of Notre Dame, holding signs and praying.

Other news: A Local attorney requested an emergency hearing, in order to request bond for the five pro-lifers who were being held without bond. The judge granted the request, but placed a high bond on those in custody. Pro-lifers are currently seeking people to bond them out.

Other news: A journalist told a StopObamaNotreDame official that the University threatened to "cut the feed" of any network that covers disruptions during Obama's address.

Randall Terry states: "Notre Dame is so desperate to hide the fruit of their sin, that they will cover up the truth of what happens inside the auditorium. We pray for the success of those who are committed to bearing witness during Obama's address."

To Schedule an interview with Dr. Alan Keyes after his release from jail, contact Kathy Veritas at 904-687-9804.

www.StopObamaNotreDame.com


SOURCE Randall Terry, Founder, Operation Rescue

Americans Skimp on Healthy Activities in Bad Economy

Survey says corporate wellness programs, walking offer ways to keep health on track

DALLAS, May 17 /PRNewswire-USNewswire/ -- Yet another negative result of the bad economy: Americans are cutting back on healthy activities such as eating fresh foods and exercising regularly.

In a national omnibus survey of 1,000 people conducted in March 2009 by the American Heart Association:

57 percent said the economy has affected their ability to take care of their health.
32 percent have made a change in the last six months to save money, such as delaying preventive care appointments, not taking medications or skipping the dentist.
25 percent of those with gym memberships have cancelled in the previous six months.
42 percent plan to make changes in the next six months that may impact their health, such as buying fewer fruits and vegetables.

Results of the study spell trouble for Americans' overall well-being and heart health in particular, said Timothy Gardner, M.D., President of the American Heart Association.

"We've made dramatic gains in recent years in our fight against heart disease and stroke, but trends like these threaten to reverse these gains. We need to remind people that even in hard times their health is important. Physical activity, in particular, is an easy, inexpensive way for people to prevent heart disease and manage their stress -- another byproduct of a tough economy."

The American Heart Association encourages walking because it's the most accessible form of physical activity and it has the lowest drop out rate among Americans. The association supports the federal government's recently revised guidelines for physical activity, which focus more on a cumulative amount of activity over a week, rather than a specific amount each day.

"The message now is that physical activity can be worked in any time, anywhere," said Gardner. "The important thing is to make sure you are getting at least 150 minutes of moderate-intensity physical activity each week. We encourage people to incorporate regular walking into their normal routines, such as during the work day."

In the last two years, the association has recognized nearly 1,000 companies as "Fit-Friendly", meaning they champion the health of their employees and offer opportunities for wellness at work.

Employers can save $16 for every $1 they invest on health and wellness. Fitness programs have reduced employer healthcare costs by 20 percent to 55 percent, and reducing one health risk increases productivity by 9 percent and absenteeism by 2 percent.

The Centers for Disease Control and Prevention estimate that physically active people save $330 per year in direct medical expenditures.

Cardiovascular disease continues to be the nation's leading cause of death, with direct and indirect costs estimated to be $475.3 billion. The savings that individuals can attribute to regular exercise not only impact their own wallets, but also those of the nation and their workplace.

About the American Heart Association:

Founded in 1924, the American Heart Association is the nation's oldest and largest voluntary health organization dedicated to reducing disability and death from cardiovascular diseases and stroke. These diseases, America's No. 1 and No. 3 killers, claim over 864,000 lives a year. In fiscal year 2005-06 the association invested more than $473 million in research, professional and public education, advocacy and community service programs to help all Americans live longer, healthier lives. To learn more, call 1-800-AHA-USA1 or visit www.americanheart.org.

About Start!

Start! is the American Heart Association's national initiative that calls on Americans and their employers to create a culture of physical activity and health through walking. Start! is sponsored nationally by SUBWAY(R)Restaurants, Healthy Choice(R) and AstraZeneca. Visit www.startwalkingnow.org to download a free personal walking plan, track your physical activity online or find a walking buddy in your area.


SOURCE American Heart Association

Creighton Medical Laboratories First to Offer New Cancer Test

OMAHA, Neb., May 15 /PRNewswire/ -- Creighton Medical Laboratories, based at Creighton University School of Medicine in Omaha, announced today that it has become the first clinical laboratory worldwide to offer a new and more effective testing method for cancer.

The method, called SNP array karyotyping, has been successfully used in

research laboratories to study cancer for several years. However, Creighton Medical Laboratories, using AffymetrixTM SNP arrays, is the first laboratory to validate the test in a clinical setting and make it available for routine clinical use.

The method can help doctors make more accurate cancer diagnoses and tailor patient management based on the DNA profiles of each person's cancer.

Array-based karyotyping is a 21st century spin on older genetic testing methods that have helped guide patient care for decades. DNA is bundled inside cells as chromosomes; a karyotype is a representation of all of the chromosomes in a cell. Normal human cells have two copies of each

chromosome. Cancer cells will often duplicate or lose pieces of chromosomes, and these chromosomal changes can help physicians categorize a tumor, determine its aggressiveness, and/or determine which tumors will respond to specific drugs.

With the new method being used at Creighton Medical Laboratories, DNA from
tumor cells is applied to the arrays and scanned into a computer. The chromosomes are reconstructed by the computer to provide a genome-wide view of the cancer cells at unprecedented resolution; physicians then 'surf' the cancer genome using web-based genome browsers.

"SNP array karyotyping is a powerful new tool in our molecular tool box," said Jill Hagenkord, M.D., a pathologist and director of molecular pathology and clinical genomics at Creighton Medical Laboratories. "We can detect genetic abnormalities that previously would have been missed."

The SNP (single nucleotide polymorphism) array used by Creighton allows the detection of a very common genetic abnormality or lesion in cancer cells - called copy neutral loss of heterozygosity (LOH) - that often goes undetected with conventional diagnostic methods as well as standard array-based karyotyping.

"As an example, with SNP-array virtual karyotypes, we have detected copy neutral LOH at important regions of the cancer genome, like the p53 gene in chronic lymphocytic leukemia. If the tumor has no functional copies of this important gene, it tends to behave aggressively, and the treating physician may want to treat it more aggressively," Hagenkord said. "This genetic lesion would not have been detectable with the current testing methods, which really underscores the importance of having this new testing method available clinically."

Roger Brumback, M.D., chair of the Department of Pathology at Creighton University School of Medicine, said, "We feel that SNP array karyotyping will become the standard of care for the diagnosis and management of many cancers. Creighton Medical Laboratories is excited to be at the forefront of this technology and proud to provide progressive medical care for our patients."

"We are very fortunate to have Dr. Hagenkord at the helm in clinical genomics, since she is currently the only pathologist worldwide with fellowship training in both molecular genetic pathology and pathology/oncology informatics. She has been performing SNP array karyotyping of tumors since the technology emerged and she is truly an expert in the field."

For more information about the clinic, Hagenkord and SNP array karyotyping, visit http://cml.md.

About Creighton Medical Laboratories: (CML) is a leading provider of diagnostic medical testing and consultative services. Through its affiliation with Creighton University School of Medicine, an institution with an international reputation for medical research, CML helps physicians, clinics, nursing facilities and hospitals it serves deliver advanced and more effective patient-care.

About Creighton University: Creighton University, a Catholic, Jesuit institution located in Omaha, Neb., enrolls more than 4,000 undergraduate and 2,900 professional school and graduate students. Nationally recognized for providing a balanced educational experience, the University offers a rigorous academic agenda with a broad range of disciplines, providing undergraduate, graduate and professional degree programs that emphasize educating the whole person: academically, socially and spiritually. Creighton has been a top-ranked Midwestern university in the college edition of U.S. News & World Report magazine's for more than 20 years. For more information, visit our website at: www.creighton.edu.

This news release was issued on behalf of Newswise(TM). For more information, visit http://www.newswise.com.


SOURCE Creighton University

Disability Activist Urges Obama to Escalate Stem Cell Research to End Paralysis For Millions of Americans

Cody Unser Comments on President Obama's Town Hall Acknowledgement of Economy's Toll on Disabled

ALBUQUERQUE, N.M., May 15 /PRNewswire-USNewswire/ -- Cody Unser, a 22-year-old student at University of Redlands and head of the Cody Unser First Step Foundation, commends President Obama for acknowledging in yesterday's town hall meeting the financial hardships of Americans living with disabilities and now strongly urges for rapid acceleration of stem cell research so that a cure can be found for paralysis. Ending the condition could potentially return millions of Americans to the workforce.

According to an April 2009 survey from the Christopher and Dana Reeve Foundation, more than 5.6 million Americans currently live with paralysis -- five times more than originally estimated. Given that nearly a quarter of these paralyzed Americans only have annual household incomes of $10,000 or less, it is especially important to the Cody Unser First Step Foundation that a cure for paralysis is found soon. Lofty medical expenses would diminish, employment opportunities would expand, and financial independence would boost.

Unser, who attended the town hall by invitation of Kareem Dale, Special Assistant to the President on Disability Policy, has been paralyzed since 12, and has worked closely with the Christopher and Dana Reeve Foundation to ensure that stem cell advocacy continues.

"I am determined to work with President Obama and his administration to bring stem cell capabilities to fruition," said Unser. "Too many Americans are living in unacceptable conditions that could be reversed with the help of this medical technology."

Set to graduate next week from the University of Redlands in Southern California, Unser will receive the nation's first undergraduate degree in biopolitics. She will use the degree to lobby the federal government for expanded awareness of -- and a cure for -- paralysis. Meanwhile, her foundation efforts will continue to focus on quality of life programs for paralyzed people, such as 'Operation Deep Down,' that uses SCUBA diving for therapeutic and psychological healing of wounded veterans. Unser is simultaneously elevating public awareness as the center of a recently released documentary entitled "Cody," which will air on PBS in July.

The Cody Unser First Step Foundation is a global not-for-profit organization dedicated to raising research funds, public awareness and quality of life for those afflicted with all forms of spinal cord-related paralysis. The Foundation will also address the cause, rehabilitation, prevention, and cure for Transverse Myelitis, and freely affiliate with other medical, charitable and corporate entities to achieve these goals. For more information, please visit www.codysfirststep.org.


SOURCE Cody Unser First Step Foundation; University of Redlands

Healthcare Leader Dr. Gary Gottlieb Keynotes Commencement

BOSTON, May 15 /PRNewswire-USNewswire/ -- Dr. Gary L. Gottlieb, President of Brigham and Women's Hospital, will be the keynote speaker at Bunker Hill Community College's 35th commencement exercises, on Saturday, May 30, at 11:00 a.m. Dr. Gottlieb, a strong proponent of alleviating mental health care disparities, will receive the President's Distinguished Service Award in recognition of his outstanding commitment and service to the College.

"Dr. Gottlieb is a visionary leader with a lifelong commitment to healthcare based on equity and affordability," said Mary L. Fifield, Ph.D., President of the College. "His dedication to our College has been shown time and again. He was instrumental in the design of our College's strategic goals. Further, he has spearheaded partnerships between BHCC and Brigham and Women's Hospital to help hospital employees upgrade job skills and to enable our students to obtain clinical experience."

Gottlieb became president of Brigham and Women's Hospital in 2002. In January of 2010, he will become president of Partners HealthCare, the largest healthcare provider in Massachusetts.

In 2005, Boston's Mayor Thomas Menino appointed Dr. Gottlieb chair of the Private Industry Council, the city's workforce development board. The Council works with education, labor, government and the community to oversee public and private workforce development programs.

From 1998-2002, Dr. Gottlieb served as Chairman of Partners Psychiatry and Mental Health System in Boston. Prior to his arrival in Boston, he served as Director and Chief Executive Officer of Friends Hospital in Philadelphia, the nation's oldest, independent, psychiatric hospital. He was appointed to that position in 1994.

Gottlieb received his M.D. from Albany Medical College of Union University, in New York State. He received a master's degree in Business Administration at the University of Pennsylvania, and a B.S. cum laude from Rensselaer Polytechnic Institute in New York State.

Bunker Hill Community College is the largest community college in Massachusetts. The College enrolls almost 9,800 students on two campuses and at five satellite locations each semester. Some 2,000 students take classes online. BHCC is one of the most diverse institutions of higher education in the Commonwealth. Six in ten students are people of color and more than half of BHCC's students are women. The College also enrolls more than 690 international students who come from more than 103 countries and speak 75 different languages.


SOURCE Bunker Hill Community College

Trust for America's Health Supports Appointment of Thomas Frieden to Lead CDC

WASHINGTON, May 15 /PRNewswire-USNewswire/ -- The following is a statement by Jeff Levi, Ph.D., Executive Director of Trust for America's Health (TFAH) on the appointment of Thomas R. Frieden to serve as Director of the U.S. Centers for Disease Control and Prevention (CDC):

"Dr. Frieden is a bold leader who has the courage to shake up the status quo if science and evidence show that change needs to happen. He doesn't shy away from the tough problems. His innovative strategies have led to real reductions in smoking rates, diabetes, HIV/AIDS, tuberculosis, and food-borne illness in New York City.

"During the campaign, President Obama made a commitment to make policy decisions based on the integrity of science. With this appointment, the President has taken an important step to fulfill this promise.

"Dr. Frieden will have the serious challenge of reinvigorating the CDC to help turn around our nation's health. The agency must be modernized to face today's health threats. The CDC should be commended for its rapid, coordinated response to the recent H1N1 outbreak, but it also highlighted the gaps in our public health system where more investment is desperately needed.

"As the country considers ways to reform the health system, Dr. Frieden's leadership will be critical to ensure that public health is front and center -- so that we transform our sick care system to a health care system that focuses on preventing disease and keeping Americans healthier in the first place.

"Dr. Frieden brings the expertise and experience needed to confront the wide range of serious public health challenges we face. He brings the perspective and energy needed to galvanize the federal, state, and local agencies and lead America's public health system into the 21st century."

Trust for America's Health is a non-profit, non-partisan organization dedicated to saving lives by protecting the health of every community and working to make disease prevention a national priority.


SOURCE Trust for America's Health

APHA Applauds Choice of Frieden to Lead CDC

WASHINGTON, May 15 /PRNewswire-USNewswire/ -- The following is a statement from Georges C. Benjamin, MD, FACP, FACEP (E), Executive Director of the American Public Health Association:

"The American Public Health Association (APHA) welcomes today's selection of Association member Dr. Thomas Frieden as the new director of the Centers for Disease Control and Prevention (CDC).

"During his tenure as New York City's health commissioner, Frieden has demonstrated an unwavering commitment to protecting the public's health through his tireless work on issues ranging from implementing a ban on smoking in restaurants and bars to increasing HIV testing rates. He has not backed away from the tough public health challenges and in doing so has helped the people he served lead healthier, longer lives.

"Frieden's experience and dedication to public health make him an excellent choice to lead the CDC. As a strong public health system is the foundation for a healthy America, APHA looks forward to working with Dr. Frieden in the months ahead as we think broadly about how to improve health in our nation."

Learn more about the American Public Health Association at http://www.apha.org/about/news/presskit/boilerplate.htm.

Contact: Bithiah Lafontant
(202) 777-2509
bithiah.lafontant@apha.org


SOURCE American Public Health Association

UPMC Health Plan Sponsors 'School of Swing' with MCG Jazz

PITTSBURGH, May 15 /PRNewswire/ -- Manchester Craftsmen's Guild will present its annual series of School of Swing concerts for elementary schoolchildren on Monday, Tuesday, and Wednesday, May 18, 19 & 20, 2009. This three-day program (May 18 & 19 at 9:30 a.m., 11:00 a.m. and 12:30 p.m. each day, and May 20 at 9:30 a.m. and 11:00 a.m.) will serve approximately 2,600 students overall. Outreach sessions serving an additional 840 students will be presented on May 21 at 1:00 p.m. at Jefferson Morgan Elementary, and on May 22 at 10:00 a.m. at Blackhawk Elementary and 1:30 p.m. at St. Athanasius. The music-based youth education program will also promote UPMC for Kids and health and nutrition awareness programs being presented by School of Swing sponsor UPMC Health Plan.

School of Swing is an interactive jazz education event, which occurs at Manchester Craftsmen's Guild and primarily serves Pittsburgh Public School third grade students. Short performances by local jazz educators, with audience participation components and a child-focused structure, provide a unique and successful formula for a memorable and meaningful introductory jazz music experience.

"The School of Swing concerts explore some of the key origins and techniques of jazz music and also present world-class musicians as role models for young audiences," said Marty Ashby, Executive Producer of MCG Jazz. "These players convey a passion for jazz that lets young people really connect with this music." Taking the stage will be ensemble musicians Roger Humphries (drums), Mike Tomaro (woodwinds), Jay Ashby (trombone and percussion), Max Leake (piano), Dwayne Dolphin (bass), and newcomers Kim Nazarian (vocals) and James Moore (trumpet). All of these individuals are professional musicians and educators who have shared their talents with audiences all over the world and welcome the opportunity to perform for students and express their love of jazz.

UPMC Health Plan is pleased to sponsor School of Swing as a leading model for programming that makes a positive contribution to youth education. UPMC Health Plan's involvement with these programs reaffirms their commitment to the health and well-being of children and their families in the community.

School of Swing is a prime example of how educational outreach programs can work in unity to create opportunities for children and families. Components of the message to "take steps to better health" will be incorporated into each jazz education performance.

Manchester Bidwell at a Glance:

Manchester Craftsmen's Guild and Bidwell Training Center, Inc. are non-profit, multi-discipline arts and training centers housed at 1815 Metropolitan Street on Pittsburgh's North Shore. Both organizations share a dedication to helping urban residents of the Pittsburgh area by offering them exceptional quality educational and cultural opportunities.

About UPMC Health Plan

UPMC Health Plan, the second-largest health insurer in western Pennsylvania, is owned by the University of Pittsburgh Medical Center (UPMC), one of the nation's top-ranked health systems. The integrated partner companies of the UPMC Insurance Services Division -- which includes UPMC Health Plan, UPMC Work Partners, LifeSolutions (EAP), UPMC for You (Medical Assistance), and Community Care Behavioral Health -- offer a full range of group health insurance, Medicare, Special Needs, CHIP, Medical Assistance, behavioral health, employee assistance, and workers' compensation products and services to nearly 1.3 million members. Our local provider network includes UPMC as well as community providers, totaling more than 80 hospitals and more than 7,600 physicians in a 29-county region. For more information, visit www.upmchealthplan.com.


SOURCE UPMC Health Plan

400 People Join Panther Racing CEO and Physician to Celebrate Improved Health and Quality of Life

John Barnes and Dr. Samer Mattar team to improve nation's health

CARMEL, Ind., May 15 /PRNewswire/ -- CEO and co-owner of Panther Racing, John Barnes, will discuss his weight loss journey with over 400 current and former patients of Clarian Bariatrics at a special recognition event in the East Chalet at the Indianapolis Motor Speedway on Friday, May 15.

Barnes fueled his competitive spirit on the race track, but was struggling to keep up in his personal life. A severe diabetic weighing 350 pounds, he was frustrated by his limited mobility and how easily he was exhausted.

On numerous medications to regulate high blood pressure and taking insulin shots six times a day, Barnes was fatigued getting out of bed and walking small distances. Worst of all, his lack of energy was preventing him from spending time with his three-year-old grandson and made it difficult to keep up in the fast-paced world of IndyCar racing.

"I'm the kind of person, when I make up my mind to do something, I don't second guess it," he said. "When I saw what was happening to me physically and emotionally, and I saw the capabilities of myself dwindling, I knew something needed to be done."

After many discussions with friends and family, Barnes met with the staff at Clarian Bariatrics and underwent weight loss surgery in early 2008. Now he is enjoying life and feels "15 to 20 years younger."

"I always tell people that you can turn your eyes to look at something," he said. "But you have to turn your feet to make it happen."

Initially Barnes was impressed with the warm welcome from the Clarian Bariatrics staff and the comprehensive nature of the program, which includes cooking classes, support groups and long-term follow up.

The event, "Victories at the Track," is one example of the many ways Clarian Bariatrics keeps patients connected. Attendees will have the opportunity to hear Barnes discuss his journey and the impact it has had on his racing career as well as tour the garages and watch time trails.

Members of the media are invited to attend the event and listen to Barnes' story.

"Victories at the Track"
Friday, May 15, 3-4PM EDT 2009
Indianapolis Motor Speedway, East Chalet


About Clarian Bariatrics

Offering a comprehensive and unique program that goes beyond the initial weight loss that patients experience, Clarian Bariatrics uses cooking classes that promote healthy meal preparation and puts significant focus on patient education and long-term follow up. Clarian Bariatrics works with each patient individually while also providing comprehensive physiologic, mental and nutritional evaluation and support. The program has been named an American Society for Metabolic and Bariatric Surgery (ASMBS) Bariatric Surgery Center of Excellence. The ASMBS Center of Excellence designation recognizes surgical programs with a demonstrated track record of favorable outcomes in bariatric surgery. To learn more about Clarian Bariatrics, please visit www.ACallToChange.org.

About Panther Racing

Panther Racing is a championship-winning motorsports franchise in the Indy Racing League's premier IndyCar Series, and its developmental league, Firestone Indy Lights. In its history, Panther has collected a total of 28 race victories and three championships during its 11 seasons of competition. Panther is the winningest team in the history of Texas Motor Speedway and has won Indy Lights races on both the historic oval and road course of the Indianapolis Motor Speedway.

Headquartered in Indianapolis, Indiana, Panther is owned by founding partners John Barnes and Mike Griffin as well as Joe Cain, Chris Bowers, Courtney Jones, Mark Driscoll, former boxing world champion George Foreman and current Stanford University head football coach Jim Harbaugh.

For more information on Panther Racing, its drivers and sponsors, visit: www.pantherracing.com


SOURCE Clarian Bariatrics

Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital

LA JOLLA, Calif., May 15 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that it has acquired exclusive intellectual property rights jointly owned by Children's Hospital Boston and Massachusetts General Hospital. This intellectual property covers compositions and methods for supporting hematopoietic stem cells. These proprietary technologies developed by Leonard Zon, M.D., director of the Stem Cell Program at Children's Hospital Boston and a scientific founder of Fate Therapeutics, expand the Company's broad intellectual property portfolio for modulating the activity and state of stem cells. Fate Therapeutics is utilizing its adult stem cell biology engine and induced pluripotent stem (iPS) cell technology platform to develop Stem Cell Modulators (SCMs) - small molecules and biologics that guide cell fate for therapeutic purposes.

"Over the past two years, Fate Therapeutics has amassed extensive intellectual property assets as a foundation for our adult stem cell biology engine," said Paul Grayson, president and CEO of Fate Therapeutics. "The agreement we signed today with Children's Hospital and the technologies associated with it continue to expand our engine and accelerate the Company's core mission to develop small molecules and biologics that modulate adult stem cells for regenerative medicine."

The exclusive rights acquired today will be incorporated into Fate Therapeutics' growing adult stem cell biology engine, which also includes exclusive rights to the pioneering work of the Company's scientific founders and other leaders in the field. Adult stem cells are naturally-occurring cells found in almost all tissues or organs in the body and are primarily responsible for maintaining and repairing their native tissue. An adult stem cell has unique properties, in that it can renew itself and differentiate to become some or all of the major specialized cell types of the particular tissue or organ in which it is found. The discovery of a number of conserved mechanisms from developmental biology and tissue repair has led to the identification of small molecules and biologics that can direct stem cell proliferation and function. Fate Therapeutics is developing these small molecule and biologic SCMs to modulate the activity of adult stem cells to stimulate healing or block cancer growth.

About Fate Therapeutics, Inc.

Fate Therapeutics is interrogating adult stem cell biology and applying induced pluripotent stem (iPS) cell technology to develop Stem Cell Modulators (SCMs), small molecule or biologic compounds that guide cell fate for therapeutic purposes. Fate's approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases. The Company's first therapeutic candidate is scheduled to enter clinical trials in early 2009 in hematopoietic stem cell support. In addition, Fate Therapeutics and Stemgent have formed an alliance - Catalyst - a collaborative program to provide its partners with first access to the most advanced induced pluripotent stem (iPS) cell technologies for drug discovery and development. Fate Therapeutics is headquartered in La Jolla, CA. For more information, please visit http://www.fatetherapeutics.com.

*****************
Fate Therapeutics along with Stemgent, Genzyme, Burrill & Company and WIRED Magazine, will be featured in a panel presentation entitled "Mastering Your (Cell) Fate: Stem Cells, iPSCs and the Future of Medicine" on May 18, 2009 at 2 p.m. at the 2009 BIO International Convention in Atlanta, GA.


SOURCE Fate Therapeutics, Inc.

Poniard Pharmaceuticals Files Shelf Registration

SOUTH SAN FRANCISCO, Calif., May 15 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC) that, when declared effective by the SEC, will allow Poniard from time to time to offer and sell up to $60 million aggregate amount of its common stock, common stock warrants or a combination thereof.

The shelf registration, once effective, is intended to provide the Company with flexibility to facilitate the periodic sale of its securities, subject to market conditions and the Company's future financing needs. Poniard intends to use the proceeds from the sale of any securities to advance its picoplatin clinical program, pursue potential new product opportunities and for other general corporate purposes.

The shelf registration statement filed with the SEC has not yet become effective. No securities may be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy the securities, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Any offer of the securities will be solely by means of the prospectus included in the registration statement and one or more prospectus supplements that will be issued at the time of the offering.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's financial prospects, business objectives and strategic goals. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the current distressed economic and financial market; the Company's research and development activities; the results of preclinical and clinical testing; the receipt and timing of FDA and other required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and its Quarterly Report on Form 10-Q for the period ended March 31, 2009. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


SOURCE Poniard Pharmaceuticals, Inc.

Mobile Massage Team to be a Sponsor at 7th Annual Yoga Unites(R) for Living Beyond Breast Cancer

PHILADELPHIA, May 15 /PRNewswire/ -- The Mobile Massage Team (www.mobilemassageteam.com), a leading provider of on-site seated massage services for corporate wellness programs, promotional events, and special affairs, today announced that the company will be a sponsor at the 7th Annual Yoga Unites(R) for Living Beyond Breast Cancer (http://www.lbbc.org/) held on Sunday, May 17, from 8:00 a.m. to 12:00 p.m. on the steps of the Philadelphia Museum of Art. Team members will be set up on site to give chair massages to participants throughout the event with proceeds going towards the organizations fund raising initiatives for breast cancer education and support.

From the reduction of stress and anxiety, to the improvement of blood circulation and pain reduction, the benefits of massage therapy are widely documented.

However, in today's fast paced, high tension world, the majority of individuals do not have the time or resources available for intensive and expensive captive spa services.

The Mobile Massage Team on-site seated massage service platform offers a new and unique paradigm in bringing these benefits to all individuals in an efficient and cost-effective manner, inside or outside of the workplace.

About Mobile Massage Team

The Mobile Massage Team (www.mobilemassageteam.com) and its parent company, MMT Holdings LLC, are based out of Philadelphia, PA. The Mobile Massage Team is a leading service provider of on-site seated massage services for corporate wellness programs, promotional events, and special affairs.


SOURCE Mobile Massage Team

Continental Who's Who Executive Press Release: Dr. Bruno E. Gerber - Medical Professional

NEW YORK, May 15 /PRNewswire/ -- Dr. Bruno E. Gerber is recognized in Continental Who's Who among Medical Professionals. Doctor Gerber is a Consultant Orthopedic Surgeon with a special interest in biologic surgical treatments of musculoskeletal conditions of the lower limbs. He also is employed as medical advisor of a European research and development project regarding innovative orthopedic laser treatment.

Dr. Gerber undertook his comprehensive orthopedic surgical specialist training at the Orthopedic Department of the Basel University Teaching Hospitals in Switzerland, where he was made responsible for the elective arthroscopic surgery service. He completed a fellowship at Arthritic Orthopedic Hospital in Toronto, Canada before taking over the post of surgeon in chief of the orthopedic department in the City General Hospital of Neuchatel, Switzerland.

Since 2002 he has been a Senior Consultant Orthopedic Surgeon at the University Hospital Lewisham in London where he has set up a reference centre for computer navigated orthopedic surgery, of which he is a longstanding expert and developer.

In addition to his work as a surgeon, Dr. Gerber has also conducted various basic and clinical research projects and has been teaching students and surgeons in training since his activity at the Basel University Teaching Hospitals. He has also lectured at many local and international meetings and is the author of numerous publications.

In the future, Dr. Gerber looks forward to further working on the development of expanded computer navigated surgery applications and is conducting ongoing research about biological repairs of cartilage and ligaments.

For further information, please contact: Dianne Webster pr@continentalwhoswho.com or visit our Continental Who's Who web site.


SOURCE Continental Who's Who

New Clinical Recommendations for Treating America's Largest Healthcare Epidemic

American Association of Clinical Endocrinologists logo. (PRNewsFoto/American Association of Clinical Endocrinologists)

JACKSONVILLE, FL UNITED STATES

HOUSTON, May 14 /PRNewswire-USNewswire/ -- Diabetes experts today issued new recommendations for the treatment of prediabetes, a condition affecting 57 million Americans, at the American Association of Clinical Endocrinologists (AACE) 18th Annual Meeting & Clinical Congress. These clinical recommendations include specific instructions for lifestyle intervention and medication.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090324/DC88061LOGO-b)

They come as a result of the first-ever prediabetes consensus conference, which was held last July in Washington, D.C. At the conference, 23 international experts in diabetes and metabolic disorders reviewed all existing scientific data to examine the status of the disease, facts about related complications, what happens to people who progress to diabetes, economic implications of early intervention, and what further studies were needed. After analyzing all available data, their recommendations called for specific guidelines on both lifestyle and pharmaceutical intervention where appropriate.

Some suggested lifestyle modifications for people with prediabetes include:

Weight Reduction - Prediabetes patients should attempt to reduce their weight by five to ten percent, with long-term maintenance at this level. This modest degree of weight loss may result in decreased fat mass, blood pressure and glucose.

A program of moderate to intense physical activity for 30 to 60 minutes daily, at least 5 days a week.

A diet that includes calorie restriction, increased fiber intake, and possible limitations in carbohydrate intake. Dietary recommendations specifically for blood pressure include lower sodium intake and avoiding excess alcohol.

AACE Vice President Daniel Einhorn, MD, FACP, FACE, also suggested a more aggressive approach to treating patients in high risk groups with medications, including Metformin, TZD's, DDP4 and GLP1.

"These medications illustrate a specific 'plan of attack' for treating prediabetes," Dr. Einhorn said. "But it's important that caution is exercised."

Prediabetes is a condition that leaves patients at risk for developing type 2 diabetes and cardiovascular complications. It is defined by elevated fasting glucose levels or impaired glucose tolerance, although Dr. Einhorn suggested A1c levels should be considered as a diagnostic tool.

"An A1c level of 6.0 to 6.5 indicates treatment for prediabetes with certain caveats," he said.

As with diabetes management, the new AACE recommendations focus on early detection and smart lifestyle choices.

"Lifestyle intervention should be the cornerstone of treatment for all patients," Einhorn said. "And it should be reinforced with each visit to the doctor."

A complete copy of the ACE/AACE Consensus Statement titled, "Diagnosis and Management of Prediabetes in the Continuum of Hyperglycemia - When do the Risks of Diabetes Begin?" is available for download on the AACE Web site here.

For more information about diabetes, download the American College of Endocrinology's (ACE) "Power of Prevention(R)" Magazine here. The magazine features medical information on prediabetes, type 1 and type 2 diabetes, diabetes complications, and tips on how diabetes patients can best prepare for disaster.

A short, one page bio and high resolution photo of AACE Vice President Daniel Einhorn, MD, FACP, FACE, are available here.

About AACE

AACE is a professional medical organization with more than 6,200 members in the United States and 92 other countries. Founded in 1991, AACE is dedicated to the optimal care of patients with endocrine problems. AACE initiatives inform the public about endocrine disorders. AACE also conducts continuing education programs for clinical endocrinologists, physicians whose advanced, specialized training enables them to be experts in the care of endocrine diseases such as diabetes, thyroid disorders, growth hormone deficiency, osteoporosis, cholesterol disorders, hypertension and obesity.


SOURCE American Association of Clinical Endocrinologists

Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Roxicodone(R) Tablets

DETROIT, May 14 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has recently launched oxycodone hydrochloride tablets on behalf of Sun Pharmaceutical Industries Inc., a subsidiary of Sun Pharmaceutical Industries Ltd. (Sun Pharma), following Sun Pharma's recently received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for generic Roxicodone(R) tablets.

Oxycodone hydrochloride tablets are an immediate-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain where the use of an opioid analgesic is appropriate. These generic versions of oxycodone 5 mg, 15 mg, and 30 mg tablets are therapeutically equivalent to Roxicodone(R) tablets from Xanodyne Pharmaceuticals Inc. According to IMS Data, these strengths of oxycodone tablets had US sales of approximately $160 million for the calendar year of 2008.

Daniel H. Movens, Caraco's Chief Executive Officer, said, "We are pleased to add this product to our portfolio and help address the current shortage in the marketplace by launching oxycodone tablets. We continue to focus on working towards expanding our product offerings both as a marketing partner and through our own development pipeline of products as quickly and effectively as possible."

Roxicodone(R) is a registered trademark of Xanodyne Pharmaceuticals Inc.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission and include, but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or cheaper products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


SOURCE Caraco Pharmaceutical Laboratories, Ltd.

Leading Healthcare Technology Companies Launch National Physician Education Program on Stimulus and Electronic Health Records

"EHR Stimulus Alliance" Includes Allscripts, Cisco, Citrix, Dell, Intel, Intuit, Microsoft Corp., and Nuance; Will Deliver Education Programs Across the U.S.

CHICAGO, May 14 /PRNewswire-FirstCall/ -- Allscripts today announced the formation of a coalition of technology innovation leaders who are partnering to educate 500,000 U.S. physicians about opportunities aligned with the American Recovery and Reinvestment Act (ARRA) of 2009. The Act details President Obama's plan to improve healthcare quality, safety and efficiency through the secure exchange of electronic health information and the adoption of Electronic Health Records (EHR) and associated technologies. By connecting physicians, hospitals, pharmacies, payers, public health organizations and other stakeholders across healthcare, information technologies such as the EHR can improve the management of chronic health conditions that account for about 75 percent of U.S. healthcare costs, and enhance the efficiency and effectiveness of U.S. healthcare.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO)

The EHR Stimulus Alliance(TM) - which includes Allscripts, Cisco, Citrix, Dell, Intel, Intuit, Microsoft Corp., and Nuance - marks the first nationwide campaign by a broad coalition of healthcare and technology companies to help physicians explore opportunities associated with the ARRA. Alliance members are sponsoring The EHR Stimulus Tour(TM), a significant education program with hundreds of planned virtual and physical events for physicians in cities across the U.S.

"Encouraging every physician to use electronic health records is essential to achieving President Obama's goal of a safer, higher quality healthcare system at a price we can afford," said Glen Tullman, Chief Executive Officer of Allscripts, which is leading the Alliance. "The EHR Stimulus Alliance marks a major step forward in helping more physicians to understand their options for entering the electronic healthcare highway."

Surveys indicate that, while large numbers of physicians are familiar with the basic tenets of the federal incentive program, many do not know the details, including how much money they are eligible to receive, when it will be allocated, how they can qualify, how to meet ARRA's requirements for information exchange, or the cost of implementing an Electronic Health Records. The EHR Stimulus Tour will provide the answers via executive briefings, roundtables, trade show presentations, webcasts, and local meetings bringing physicians together with Alliance experts and medical groups that have already successfully adopted Electronic Health Records.

Signed into law on February 17, 2009, the ARRA provides physicians a maximum of between $44,000 and $64,000 in incentives for adopting and demonstrating "meaningful use" of an Electronic Health Record beginning in fiscal 2011. Recent studies have demonstrated that physicians who use a connected Electronic Health Record believe the technology dramatically improves the practice of medicine. One such survey of 2,758 physicians, published in the June 18, 2008 issue of the New England Journal of Medicine, found that physicians who use a fully functional Electronic Health Record reported the system positively affects the quality of their clinical decisions (82 percent), their ability to avoid medication errors (86 percent), their communication with other providers (97 percent) and patients (72 percent), timely access to medical records (97 percent), and the delivery of long-term and preventive care that meets clinical guidelines (82-85 percent).

Under the ARRA, the Centers for Medicare and Medicaid Services (CMS) will pay the incentives to physicians over five years, beginning in fiscal 2011. Physicians who have not adopted certified Electronic Health Record systems by 2014 will have their Medicare reimbursements reduced by 1 percent beginning in 2015; 2 percent in 2016; and by up to 3 percent in 2017 and thereafter. According to a Congressional Budget Office review of the law, the incentives will drive up to 90 percent of U.S. physicians to adopt Electronic Health Records in the next decade.

Alliance Members

The broad cross-section of EHR Stimulus Alliance members have unique experiences, insights and solutions that are vitally important in helping physicians adopt Electronic Health Records and connect with their patients and all stakeholders to improve the clinical or financial aspects of care.

Allscripts, the nation's largest publicly-traded Electronic Health Record provider, uses innovation technology to help physicians and their patients Connect to Health(TM) - improving quality, eliminating errors and lowering costs.

Cisco prepares physician offices for EHR technology with reliable secure connectivity, network assessments and help in unlocking the value of an EHR with integrated communication and collaboration capabilities.

"We are pleased to take part in this alliance, which is an important step in the effort to make information technology an integral part of the healthcare experience," said Kaveh Safavi, Vice President, Global Healthcare Practice, Cisco Internet Business Solutions Group. "We are entering a healthcare industry transformation. New Internet-based technology solutions address a significant barrier to EHR adoption. Patients need to trust that the information they make available to physicians will be private and highly secure."

Citrix simplifies the ability to deliver information and applications remotely with the same look, feel, performance and security regardless of the physician's location or end device. With Citrix, healthcare professionals can always have electronic health records close at hand.

"Citrix provides secure and mobile access to electronic data, which is critical for electronic health records and to healthcare professionals in any setting," said Carlos Ramos, director of health and human services for Citrix Government, Education & Health. "This alliance gives us an unprecedented opportunity to share this data security with hospitals, physicians and mobile caregivers across the country."

Dell provides healthcare IT solutions that improve quality and efficiency and reduce cost.

"In a recent survey about stimulus funds, our healthcare customers told us they need clearer and more customized information about ARRA funds and how to address their IT challenges," said Dr. James Coffin, vice president and general manager, Dell Healthcare and Life Sciences. "Dell is developing solutions that will make the adoption and integration of healthcare IT as simple and cost-effective as possible to improve the quality of care and help clinical practices meet requirements for ARRA funding."

Intel highlights the importance of high performance computing and mobility at the point of care for an EHR solution.

"We have long believed that deployment of standards-based IT technologies can streamline processes and create efficiencies in healthcare, ultimately providing the highest quality of care at the lowest cost," said Louis Burns, general manager of Intel's Digital Health Group. "The Allscripts Stimulus Alliance provides an opportunity for our industry to work with physicians, understand their unique needs and provide them the information they need to deploy electronic health records and e-prescribing technologies today."

Intuit's Quicken Health Group is working with health plans, employers and physicians on solutions to make the financial side of healthcare easier and is working with Allscripts on a new solution, scheduled to be available in the summer of 2009 that will benefit practices and patients. Today, thousands of practices use Intuit solutions like QuickBooks(R) financial software, payroll solutions, Web site solutions, payment processing and QuickBase(R) to make their business more efficient.

"At Intuit, simplifying complex tasks for people is what we do best, and we know that managing healthcare finances is especially difficult for both patients and providers," said Peter Karpas, senior vice president and general manager for the Quicken Health Group. "As part of this alliance, we have an opportunity to share our unique patient insights with physicians in an effort to help them get paid faster and increase patient satisfaction, enabling them to spend more time focusing on providing the best care."

Microsoft is committed to improving health around the world through software innovation. In addition to the Amalga Unified Intelligence System and HealthVault consumer web platform, Microsoft collaborates with industry partners such as Allscripts to help unify health information and make it more readily available, ensuring quality of life and affordable care for everyone.

"The time is now for all providers, especially physicians, to begin adopting EHRs and liberating data trapped in paper records or isolated in siloed systems," said Steve Aylward, general manager of U.S. Health & Life Sciences, Microsoft Corp. "Working with Allscripts, Microsoft is committed to helping providers reduce the need for redundant paperwork and testing, making it easier to retrieve digital radiology images, patient history, prescription information and more. By unlocking data and delivering it to patients through a consumer-controlled personal health record, we can enable improved decision-making and enhance the continuity of care."

Nuance enables EHRs to seamlessly convert voice into text. From free-form clinician dictation to customized voice shortcuts, Nuance's speech recognition technology helps capture physician narrative as part of the EHR to promote meaningful use and ongoing higher quality care while eliminating clinician reliance on typing or manual transcription.

"The EHR Stimulus Alliance is a unified movement toward turning the national dialogue surrounding the EHR transition into action," said John Shagoury, president, Nuance Healthcare. "Each of the partners involved has unique solutions that are crucial to EHR implementation. In our case, speech recognition technology helps increase the meaningful use and efficiency of EHRs by decreasing physician reliance on the keyboard and mouse. By providing speech recognition as an EHR documentation option, medical records are more complete with a detailed clinical history and care plan specific information and are not reduced to point-and-click templates alone. Because most doctors speak at least three times faster than they type, speech recognition makes it possible to get things done more quickly by voice in the EHR than by relying on keyboards and mice alone."

Interested physicians and office administrators can register to take part in The EHR Stimulus Tour by visiting the tour website www.EHRStimulusTour.com or by calling the EHR Stimulus Education hotline: 877-EHRNOW1. Additionally, the tour website provides valuable information such as legislative updates, FAQs, resources from Alliance members, and summaries of all of the summer Tour stops.

About Allscripts

Allscripts (NASDAQ: MDRX) uses innovation technology to bring health to healthcare. More than 150,000 physicians, 700 hospitals and nearly 7,000 post-acute and homecare organizations utilize Allscripts to improve the health of their patients and their bottom line. The company's award-winning solutions include electronic health records, electronic prescribing, revenue cycle management, practice management, document management, medication services, hospital care management, emergency department information systems and homecare automation. Allscripts is the brand name of Allscripts-Misys Healthcare Solutions, Inc. To learn more, visit www.allscripts.com.

About Cisco Systems

Cisco, (NASDAQ: CSCO), is the worldwide leader in networking that transforms how people connect, communicate and collaborate. Information about Cisco can be found at http://www.cisco.com. For ongoing news, please go to http://newsroom.cisco.com.

About Dell

Dell listens to customers and delivers innovative technology and services they trust and value. Dell serves those who serve with next generation infrastructure for healthcare.

About Intel's Digital Health Group

Intel's Digital Health Group is committed to delivering research-based innovation for healthcare. Informed by more than a decade of ethnographic studies, we share a vision with healthcare leaders of using innovative technologies to transform healthcare, improve chronic disease management, and enhance wellness and independence. We develop new health technologies for individuals in the home or on the go, and collaborate with healthcare professionals to enable seamless interaction and information exchange. We help to connect people and information in new ways that increase patient care and safety, reduce healthcare costs, and improve quality of life across the continuum of care

About Intuit, Inc.

Intuit Inc. (NASDAQ: INTU) is a leading provider of business and financial management solutions for small and mid-sized businesses; financial institutions, including banks and credit unions; consumers and accounting professionals. Its flagship products and services, including QuickBooks(R), Quicken(R) and TurboTax(R), simplify small business management and payroll processing, personal finance, and tax preparation and filing. ProSeries(R) and Lacerte(R) are Intuit's leading tax preparation offerings for professional accountants. The company's financial institutions division, anchored by Digital Insight, provides on-demand banking services to help banks and credit unions serve businesses and consumers with innovative solutions.

Founded in 1983, Intuit had annual revenue of $3.1 billion in its fiscal year 2008. The company has approximately 8,000 employees with major offices in the United States, Canada, the United Kingdom and other locations. More information can be found at www.intuit.com.

About Nuance Communications, Inc.

Nuance is a leading provider of speech and imaging solutions for businesses and consumers around the world. Its technologies, applications and services make the user experience more compelling by transforming the way people interact with information and how they create, share and use documents. Every day, millions of users and thousands of businesses experience Nuance's proven applications and professional services. For more information, please visit www.nuance.com.

This news release may contain forward-looking statements within the meaning of the federal securities laws. Statements regarding future events, developments, the Company's future performance, as well as management's expectations, beliefs, intentions, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. These forward-looking statements are subject to a number of risks and uncertainties, some of which are outlined below. As a result, actual results may vary materially from those anticipated by the forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: the volume and timing of systems sales and installations; length of sales cycles and the installation process; the possibility that products will not achieve or sustain market acceptance; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; competitive pressures including product offerings, pricing and promotional activities; our ability to establish and maintain strategic relationships; undetected errors or similar problems in our software products; compliance with existing laws, regulations and industry initiatives and future changes in laws or regulations in the healthcare industry; possible regulation of the Company's software by the U.S. Food and Drug Administration; the possibility of product-related liabilities; our ability to attract and retain qualified personnel; our ability to identify and complete acquisitions, manage our growth and integrate acquisitions; the ability to recognize the benefits of the merger with Misys Healthcare Systems, LLC ("MHS"); the integration of MHS with the Company and the possible disruption of current plans and operations as a result thereof; maintaining our intellectual property rights and litigation involving intellectual property rights; risks related to third-party suppliers; our ability to obtain, use or successfully integrate third-party licensed technology; breach of our security by third parties; and the risk factors detailed from time to time in our reports filed with the Securities and Exchange Commission, including our 2007 Annual Report on Form 10-K available through the Web site maintained by the Securities and Exchange Commission at www.sec.gov. The Company undertakes no obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise.


SOURCE Allscripts

Health Insurance: Stay Protected Amid Layoffs, Budget Cuts

Insurance Regulators Offer Tips, Information for Consumers

KANSAS CITY, Mo., May 14 /PRNewswire/ -- With the national unemployment rate at 8.5 percent,(1) families are living on tighter budgets, and many are struggling to maintain their health insurance coverage. Despite these challenges, there are still ways for consumers to remain protected and save on insurance costs, according to the National Association of Insurance Commissioners (NAIC).

"These uncertain times require us all to be vigilant about our insurance to make sure we are protected," said NAIC President and New Hampshire Insurance Commissioner Roger Sevigny. "Consumers can safeguard themselves and their families regardless of their employment situation by making sure they understand their coverage and researching less expensive alternatives."

Options for the Newly Unemployed

It is important for the newly unemployed to examine their options early, because some choices expire within weeks of job termination. The NAIC offers the following tips about health insurance for those who have recently lost their jobs or believe they might need to plan for the possibility:

* If married, consider joining your spouse's plan: Transitioning to a
spouse's plan is typically the most affordable option, but you have
to act quickly. There is a 30-day special enrollment period during
which an employee can add a dependent who has lost coverage. If that
30-day window expires, then your spouse would need to wait to add you
to his/her plan until the open enrollment period occurs.

* Consider COBRA: The federal Consolidated Omnibus Budget
Reconciliation Act (COBRA) allows individuals who leave their jobs at
companies with 20 or more employees to continue their health
insurance coverage for 18 months. Many states extend similar access
for those who worked for small companies through "mini-COBRA" laws.
In most cases, you have 60 days to elect coverage. COBRA coverage can
be expensive, because you are required to pay the full premium, plus
an administrative fee. However, it is also retroactive once you elect
it, so use those two months to evaluate other options. Those who lose
their jobs because a company goes out of business might not be
eligible for COBRA if the company stops its group insurance plan.

As part of the newly enacted economic stimulus package, the federal
government will pay 65 percent of COBRA extended coverage premiums
for workers laid off between Sept. 1, 2008, and Dec. 31, 2009.
Employers had until April 18 to notify former staff eligible for this
option. There are income limits for subsidy eligibility, however:
$125,000 for single adults or $250,000 for couples who file taxes
jointly.

* Research eligibility for government-sponsored plans: Check to see if
you are eligible for insurance through a government program, such as
Medicaid or Medicare. For more information, visit
www.cms.hhs.gov/home/medicaid.asp or www.medicare.gov.

* Purchase a private plan: You can purchase coverage through private
providers if you meet certain criteria. A high-deductible major
medical policy will cover serious or catastrophic health costs if you
cannot afford a comprehensive plan. Just remember, these plans will
require you to pay more out-of-pocket costs should you need medical
care.

* Join a state-sponsored risk pool: For those who have been denied
affordable health coverage from a private insurer because of a
pre-existing condition, high-risk pools provide the option of
purchasing a state-sponsored insurance plan. These types of plans can
be an alternative for individuals who are not yet eligible for
Medicare or for those who are temporarily unemployed and need
insurance in the interim. Thirty-four states offer high-risk pools,
but the terms of coverage vary by state. Check with your state
insurance department to see if your state has a high-risk pool and,
if so, what your options are. Go to the NAIC's Web site for a link to
your state insurance department: www.naic.org/state_web_map.htm.

Maximize Existing Health Insurance Coverage

Those who have health coverage should also explore ways to take full advantage of existing benefits.

* Switch to generic prescriptions: If you are insured through your
employer, your health plan likely provides a discount for generic
medication. This discount can help you save on monthly out-of-pocket
health costs. If generic options are not available for your
medications, work with your doctor to help ensure your medications
are listed among your health plan's list of preferred prescriptions.
If a drug is not on the formulary, then there is higher cost-sharing
(co-insurance or co-pay).

* Schedule an annual check-up: Annual physicals can catch health
problems before they become serious, saving you money in the long
run. Many insurance plans cover 100 percent of wellness care for
routine exams, immunizations and diagnostic tests.

* Stay in-network: Before booking an appointment, verify that your
doctor is included in your plan at preferred rates. Sticking to
network providers helps ensure lower co-payments and out-of-network
costs. If you need to have a procedure done at an out-of-network
provider, research the costs and be prepared to negotiate the price.

* Use preventive benefits: Some employers offer a subsidized gym
membership or nutrition program. Staying healthy and active will
reduce your chances of needing costly high-risk medical procedures
throughout your lifetime.

More Information

If you have questions or are confused about your insurance coverage, contact your state insurance department. Visit www.naic.org to find contact information for your state insurance department.

Get smart about your insurance needs. For more information about auto, home, life and health insurance options -- as well as tips for choosing the coverage that is right for you and your family -- visit www.InsureUonline.org.

(1) U.S. Bureau of Labor Statistics

About the NAIC

Formed in 1871, the National Association of Insurance Commissioners (NAIC) is a voluntary organization of the chief insurance regulatory officials of the 50 states, the District of Columbia and five U.S. territories. The NAIC has three offices: Executive Office, Washington, D.C.; Central Office, Kansas City, Mo.; and Securities Valuation Office, New York City. The NAIC serves the needs of consumers and the industry, with an overriding objective of supporting state insurance regulators as they protect consumers and maintain the financial stability of the insurance marketplace. For more information, visit www.naic.org.

Contacts

Communications Division
(816) 783-8909
news@naic.org

Scott Holeman
Communications
Director

Jeremy Wilkinson
Electronic Communications
Manager

Heidi Gleeson
Communications
Specialist

Vanessa Sink
Communications
Specialist

Carly Halvorson
Communications
Intern

Visit the PRESSROOM to search news releases and for more media information

Join Our E-mail List

Receive the latest news releases and other information from the NAIC Communications Division!


SOURCE National Association of Insurance Commissioners

NewCardio to Introduce Technology at Heart Rhythm Society Conference

Platform Technology, QTinno(TM) and Visual3Dx(TM) to be introduced at prestigious conference

Information located at booth 468

SANTA CLARA, Calif., May 14 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that the Company will introduce the NewCardio platform, QTinno(TM) and Visual3Dx(TM) at Heart Rhythm 2009, today through May 16, 2009. The Company will be located at booth number 468 at the Boston Convention and Exhibition Center (BCEC), at 415 Summer Street, Boston, MA.

The Company believes that its QTinno(TM), software-based, analytical technology is the industry's first solution for the reliable automated analysis of ECGs used to determine cardiac toxicity during drug development. Visual3Dx(TM) will generate 3D information from the heart using standard 12-lead ECG data. It is expected to provide clinicians additional information on the extent and location of damage to the heart caused by a myocardial infarction to improve the speed and accuracy of diagnosis.

HRS is the international leader in science, education and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education and optimal health care policies and standards. The Annual Scientific Sessions attract more than 9,000 professionals representing the allied specialties of cardiac pacing and cardiac electrophysiology.

Mr. Vincent Renz, NewCardio's president and chief operating officer commented, "Our 3D technology brings a new dimension to the way the medical world looks at ECGs, the most widely used diagnostic test in cardiology. We are excited and proud to introduce our innovative applications, based on our platform technology, at this important and well-respected conference."

About NewCardio, Inc.

NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio's three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit www.newcardio.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2008 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.

To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0

Investor Contact:
Hayden IR
Jeff Stanlis
Partner and Vice President of Communications
(602) 476-1821
jeff@haydenir.com


SOURCE NewCardio, Inc.

Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever

SAN DIEGO, May 14 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational product candidate, Acetavance(TM) (intravenous acetaminophen), for the treatment of acute pain and fever in adults and children. If approved, Acetavance would become the first new intravenous analgesic approved in the United States in more than 20 years and the only approved intravenous agent for the treatment of fever in the United States.

"Submission of the Acetavance NDA is a major milestone for Cadence and demonstrates our commitment to develop products that address unmet needs in the hospital market," said Ted Schroeder, President and Chief Executive Officer of Cadence. "We believe that the data supporting the NDA for Acetavance are strong and look forward to working with the FDA throughout the regulatory review process."

The company's 505(b)(2) NDA submission for Acetavance includes data from one pivotal clinical trial for the treatment of acute pain in patients following orthopedic surgery and one pivotal clinical trial for the treatment of endotoxin-induced fever. The NDA is also supported by data from a total of nine placebo-controlled clinical trials, four active-controlled clinical trials, and seven other safety or pharmacokinetic clinical trials. The submission includes safety data from over 1,400 patients who received Acetavance in clinical trials, including 350 children, and data from safety reports that collectively represent more than 53 million patient exposures to intravenous acetaminophen in countries outside the United States.

Acetavance is Cadence Pharmaceuticals' proprietary intravenous formulation of acetaminophen. Acetaminophen is the most widely used medication for the treatment of pain and fever in the United States and is available in more than 600 combination and single-ingredient prescription and over-the-counter products. Cadence acquired the exclusive rights to Acetavance in the United States and Canada in 2006 from Bristol-Myers Squibb Company, which markets the product as Perfalgan(R) in Europe and other parts of the world. Intravenous acetaminophen is approved in approximately 80 countries, including major markets in Europe, where the product is the market leader among all injectable analgesics. Approximately 90 million vials of intravenous acetaminophen were sold in Europe in 2008.

There is an unmet medical need for new agents to treat pain or fever in hospitalized patients who cannot take medications by mouth. Only two classes of intravenous analgesics, opioids and non-steroidal anti-inflammatory drugs, or NSAIDs, are currently available in the United States for the treatment of acute pain. Opioids may be associated with a variety of unwanted side effects, including respiratory depression, excessive sedation, nausea, vomiting, constipation, cognitive impairment, and others. The only non-opioid intravenous analgesic currently available in the United States is the NSAID, ketorolac. Post-operative use of intravenous ketorolac is limited due to its potential to cause increased bleeding. Renal toxicity and the potential for increased cardiovascular events further limit the post-operative use of NSAIDs. Dipyrone (metamizole) was the last injectable drug for the reduction of fever in the United States, but since it was taken off the market in 1976, there has been no approved parenteral antipyretic drug available.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company is currently developing Acetavance(TM) (intravenous acetaminophen), its product candidate for the treatment of acute pain and fever. For more information about Cadence, visit www.cadencepharm.com.

Forward-Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements that are based on Cadence's current beliefs and expectations. Forward-looking statements include statements regarding the potential that FDA will accept for filing and, ultimately, approve Cadence's NDA for Acetavance; the company's belief in the strength of the data supporting the NDA; and statements regarding unmet medical needs in the United States and the commercial and therapeutic potential for Acetavance. The inclusion of forward-looking statements should not be regarded as a representation by Cadence that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the company's business, including, without limitation: Cadence's dependence on the success of Acetavance, and uncertainty as to whether this product candidate will receive regulatory approval or be successfully commercialized; the potential that the FDA may not accept the Acetavance NDA for review, or that the clinical trial data and other information included in the company's NDA for Acetavance may not adequately support this product candidate's safety and efficacy; the potential that the prevalence or severity of adverse side effects associated with Acetavance may be greater than anticipated, which could prevent or significantly delay its regulatory approval; the potential that changes made in transferring the manufacturing process for Acetavance may result in a lack of comparability between the commercial product and the material used in clinical trials, and that the FDA may require the company to perform additional non-clinical or clinical studies; the potential that the FDA may impose other requirements to be completed before or after regulatory approval; the company's reliance on third parties to assist with its clinical trials, regulatory submissions, manufacturing and other important aspects of the Acetavance development program, and the risk that regulatory approval may be delayed if their performance is found to have been substandard; risks associated with FDA heightened scrutiny over the new drug approval process and the potential for accidental and intentional overdoses of acetaminophen, primarily in the outpatient setting; intense competition from existing and new products, which could diminish the commercial potential for Acetavance; the possibility that the patent rights covering Acetavance, which are limited to a specific intravenous formulation of acetaminophen and do not cover the active ingredient, may not be sufficient to preclude other formulations of intravenous acetaminophen from being developed by competitors; the potential that Cadence may require substantial additional funding in order to obtain regulatory approval of Acetavance and, if approved, to successfully launch this product candidate, and that the company may not be able to raise sufficient capital when needed, or at all; and other risks detailed in Cadence's prior press releases as well as in Cadence's periodic public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Cadence(TM) and Acetavance(TM) are trademarks of Cadence Pharmaceuticals, Inc. Perfalgan is a registered trademark of Bristol-Myers Squibb Company.

Contact: William R. LaRue
SVP & Chief Financial Officer
Cadence Pharmaceuticals, Inc.
858-436-1400

SOURCE Cadence Pharmaceuticals, Inc.

U.S. Mobile Robot Co. Reveals Pacific Rim Sales Forecasts

CONYERS, Ga., May 14 /PRNewswire-FirstCall/ -- GeckoSystems Intl. Corp. (Pink Sheets: GCKO) announced today their Pacific Rim personal robot sales forecasts in the eldercare markets for the years 2010 to 2014. GeckoSystems is a dynamic leader in the emerging Mobile Service Robot (MSR) industry revolutionizing their development and usage with "Mobile Robot Solutions for Safety, Security and Service(tm)."

For over ten years the company has had numerous market size discussions with significant international firms in China, Japan, South Korea, Hong Kong, and Taiwan. The Delphi market research methodology indicates two disparate markets in China: One is the very large market segment (i.e. many millions of families) of new millionaires looking to make prestige purchases of new Buicks, etc. Last month GM sold over 38,000 Buicks in China. At an annual run rate of over $10B, these prestige purchasers are very profitable for GM and can be for GeckoSystems. The other significant Chinese market is for care of the 20,000,000 plus elderly living in dormitories due to their only child working in the industrialized cities. These two market segments alone indicate a Chinese marketplace of several billions of dollars in the next five to seven years.

In the last decade, the Japanese government has granted over $100M in aggregate R&D funding to their leading international manufacturers to develop personal robots suitable for eldercare. Sources within the Japanese government project their domestic market to range from $26B in 2010 and to nearly $70B by 2025 for personal robots.

"Consequently, at minimum, we project the available Pacific Rim market size in dollars for cost effective, utilitarian, multi-tasking personal robots suitable for eldercare in 2010 to be $22.0B; in 2011 to be $23B; in 2012 to be $24B; in 2013 to be $25B; and in 2014 to be $26B. With market penetrations of 0.009% in 2010, 0.024% in 2011, 0.077% in 2012, 0.29% in 2013, and 0.61% in 2014, we expect international sales, from these consumer markets only, of $2.0M, $5.5M, $18.5M, $72.6M, and $158.6M, respectively," stated Martin Spencer, President/CEO, GeckoSystems.

About GeckoSystems International Corporation:

In the nearly twelve years since its founding, GeckoSystems has developed a suite of proprietary, fundamental technologies that enable their robots to automatically self-navigate the home or workplace using advanced sense and avoid technologies for reliable, unattended collision avoidance while patrolling, following and/or errand running. The Company's mobile robot solutions are appropriate for the consumer, professional healthcare, commercial security/public safety and defense markets. The consumer needs cost effective family care assistance for their children, chronically ill, and elderly family members with remote monitoring and adverse event notification. Professional healthcare needs cost effective errand running, portable telemedicine, etc. The Company's business model is very much like that of an automobile manufacturer.

Safe Harbor:
Statements regarding financial matters in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, technology efficacy and all other forward-looking statements be subject to the Safe Harbors created thereby. The Company is a development stage firm that continues to be dependent upon outside capital to sustain its existence. Since these statements (future operational results and sales) involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results.

Contact:
http://www.GeckoSystems.com
or
Investor Relations: 1-866-227-3268
International: +1 678-413-9236


SOURCE GeckoSystems Intl. Corp.

Cord Blood America Receives Commitment for $2.3 Million to Fund Its Own Stem Cell Laboratory

SANTA MONICA, Calif., May 14 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today it has received a commitment for up to $2.3 million to acquire or build its own state-of-the-art laboratory for the storage of multiple stem cell products including umbilical cord blood stem cells.

"The funding is from a private, institutional investor and allows us to focus even further on our due diligence efforts that I announced last week," said Company founder and CEO Matthew Schissler. "Certain properties of the funding will be recorded as both an asset and a liability on our books." Three hundred thousand dollars of the funding has already been received by the Company to begin the lab purchase or build out, with the additional $2 million to be paid out in future installments.

"Having our own secure cryogenic stem cell bank will provide Cord Blood America with tremendous growth potential not only with our existing cord blood processing and storage business but also emerging sciences for other types of stem cells, including peripheral blood stem cell and adipose tissues," Mr. Schissler said. "We've discussed having our own lab for quite some time. Having this funding gives us the resources needed to vigorously pursue and ultimately acquire or build our own state of the art stem cell processing and storage facility."

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

CONTACT:
Paul Knopick
E & E Communications
949/707-5365
pknopick@eandecommunications.com


SOURCE Cord Blood America, Inc.

Pelosi Remarks at amfAR Conference on Future Directions in Fight Against HIV/AIDS

WASHINGTON, May 13 /PRNewswire-USNewswire/ -- Speaker Nancy Pelosi received an "Award of Courage" from amfAR at the research foundation's conference today on future directions in the fight against HIV/AIDS. amfAR's "Awards of Courage" are bestowed each year on select individuals in recognition of the vision, determination, and courage that mark them as leaders in the fight against AIDS. Other 2009 awardees are Senator Edward Kennedy, Dr. C. Everett Koop and Earvin "Magic" Johnson. Below are the Speaker's remarks as prepared:

"Thank you, Kenneth Cole, for that kind introduction. And thank you to amfAR for the 2009 amfAR Award of Courage.

"I am honored to be receiving this award along with three respected leaders in the fight against HIV/AIDS:

Senator Edward M. Kennedy, whose forceful advocacy in the Senate for people living with HIV/AIDS helped invest federal research dollars to confront this crisis and created our existing system of care and treatment through enactment of the Ryan White CARE Act;
Dr. C. Everett Koop, whose efforts in the very early days helped educate Americans about the risks of HIV/AIDS and about sensible prevention efforts; and,
Magic Johnson, whose 1991 announcement that he was living with HIV showed the world his enormous courage, and whose philanthropy and AIDS advocacy have revealed his remarkable compassion.

"America and the world owe amfAR a debt of gratitude for your nearly quarter-century history of advancing HIV prevention, treatment and care. Your work has saved lives, achieved dignity for those living with the disease, and advanced research that is bringing help and hope to those with HIV/AIDS.

"Moments like this bring me back to my first day in Congress - and remind me to honor those who have helped us make phenomenal progress in the fight against HIV/AIDS.

"When I said in my first House floor speech in 1987 that I came to Congress to fight AIDS, people were shocked. Other Members asked me: 'Why would you want to be labeled that way?'

"My reply was: 'That's why I came to the Congress.' Because San Francisco had suffered the most, we now had an opportunity to be a model for America - and eventually the world.

"We have made a great deal of progress since then, but so much more work remains.

"As the new Kaiser Family Foundation survey shows, Americans' sense of urgency about HIV/AIDS has fallen, but serious challenges remain and our commitment remains strong.

"We simply cannot rest until we have done everything we can to prevent new infections, including ensuring access to effective interventions like needle exchange. We cannot rest until every person living with HIV has access to the care and medications they need to stay healthy. And we cannot rest until we have a cure.

"We can take heart from President Obama's pledge in his inspirational Inaugural Address to 'restore science to its rightful place.' Some say we must choose between faith and science. We say that science is the answer to our prayers.

"That is why President Obama and Congress worked to invest $10 billion for lifesaving biomedical research in the recently enacted Recovery Act.

"With NIH-supported research, and the nearly $275 million contributed by amfAR, we will achieve the next great advances in HIV/AIDS prevention, treatment and care.

"Thank you again for honoring me with the 2009 amfAR Award of Courage. I will proudly display this award in the Speaker's Office so that all who visit will see this symbol of our continued commitment to fighting HIV/AIDS."


SOURCE Office of the Speaker of the House

ADA Foundation Hosts Second Give Kids A Smile Awards Gala

Three Members of Congress Honored at Charitable Affair

CHICAGO, May 13 /PRNewswire-USNewswire/ -- The American Dental Association Foundation held its second annual Give Kids A Smile Awards Gala at the Library of Congress yesterday in Washington, DC.

Give Kids A Smile is the American Dental Association's (ADA) signature charitable program, delivering free oral health care to millions of underserved children and enlisting hundreds of thousands of volunteers since its inception in 2003.

The Awards Gala honors Members of Congress who have supported the ADA's oral health advocacy goals and is a forum to announce grants to other programs that care for underserved children. The event is held during the ADA's annual Washington Leadership Conference.

Congressional awards presented

This year's congressional honorees are:

Sen. Susan M. Collins (R-ME) and Sen. Russell D. Feingold (D-WI) receive the ADA's Oral Health Champion Award. Collins and Feingold co-authored the Dental Health Improvement Act in 2002 and then worked to have it re-authorized last year. Since its inception, the law has provided almost $17 million to states to improve oral health access through enhanced dental workforce programs.

Rep. Michael Ross (D-AR), who receives the ADA's Leadership in Oral Health Advocacy Award. Ross is a member of the House Energy and Commerce Committee's Health Subcommittee and will play a key role in the health care reform debate. Ross is the lead sponsor of the Essential Oral Health Care Act of 2009, the cornerstone legislation of the ADA's oral health care reform proposal.

Give Kids A Smile grants awarded

The Gala honored five 2009 grantees, all receiving $20,000 grants from the ADA Foundation's Give Kids A Smile Fund for their pediatric oral health initiatives. Give Kids A Smile Program Champion Grantees are the America's Dentists Care Foundation (Missions of Mercy) and TeamSmile(TM). Program Growth grantee, the Hispanic Dental Association, will fund four community oral health projects led by student and local chapters to provide screenings and treatment for underserved populations. The National Dental Association (NDA), Program Growth grantee will fund the Deamonte Driver Dental Project, a grassroots endeavor of NDA's Robert T. Freeman Dental Society to support a school-based mobile dental van servicing nine schools in Prince Georges County, Md. Oral Health America will use its Program Growth grant to fund three Smiles Across America(R) affiliates to improve oral health of underserved children in targeted schools and enhance access to restorative dental care.

About the ADA Foundation The ADA Foundation is a catalyst for uniting people and organizations to make a difference through better oral health. Since 1991, the ADA Foundation has disbursed nearly $31 million dollars to support such charitable activities. In addition to funding grants for dental research, education, scholarships and access to care, the Foundation supports Charitable Assistance Programs such as relief grants to dentists and their dependents that are unable to support themselves due to injury, a medical condition or advanced age; and grants and loans to those who are victims of disasters. http://www.adafoundation.org

About the American Dental Association

Celebrating its 150th anniversary, the not-for-profit ADA is the nation's largest dental association, representing more than 157,000 dentist members. The premier source of oral health information, the ADA has advocated for the public's health and promoted the art and science of dentistry since 1859. The ADA's state-of-the-art research facilities develop and test dental products and materials that have advanced the practice of dentistry and made the patient experience more positive. The ADA Seal of Acceptance long has been a valuable and respected guide to consumer dental care products. The monthly Journal of the American Dental Association (JADA) is the best-read scientific journal in dentistry. For more information about the ADA, visit the Association's Web site at www.ada.org


SOURCE American Dental Association

New Consumer Fact Sheets on Medical Liability, Tort Reform and National Health Care

NEW YORK, May 13 /PRNewswire-USNewswire/ -- Americans for Insurance Reform (AIR) has released 14 new "fact sheets" covering various medical malpractice and tort issues that may be part of discussions by Congress and the Administration in developing national health care proposals. The "fact sheets" together support the view that the legal rights of injured patients should be preserved and that any weakening of those rights will unfairly burden malpractice victims. They also show that eliminating medical malpractice claims will result in negligible health care savings while increasing errors and their costs.

Joanne Doroshow, AIR co-founder and Executive Director of the Center for Justice & Democracy, said, "AIR and patients' rights advocates favor guaranteed health insurance coverage to help anyone in need of medical care. However, provision of such care should never be accomplished by taking away the right to trial by jury for someone legitimately injured, or reducing the accountability of any hospital or provider that endangers patients. We hope these fact sheets will be helpful to anyone examining this issue."

The fact sheets are titled as follows:

Insurance Industry's Investment Practices - Not The Legal System - Cause High Malpractice Insurance Costs;

Costs Of The Current Medical Malpractice System Are Much Lower Than People Think;
The Defensive Medicine Myth;

Health Courts Are Unconstitutional;

Health Courts And Other Alternative Systems Are Intolerably Unfair To Injured Patients;

The Significant Costs Of Alternative Systems;

The Problem With Medical Malpractice Is The Amount Of Malpractice Itself;

Far From Being "Broken," The Current Medical Malpractice System Works Well;

Litigation Improves Patient Safety And Establishes Responsibility For Errors;

Fear Of Litigation Is Not Why Doctors Fail To Report Errors Or Communicate With Their Patients;

Juries V. Cost Savings - An Unacceptable Trade-Off;

Eliminating Juries Means Few Cases Will Settle;

Lowering Insurance Costs For Doctors Requires Insurance Industry Reform;

A Critical Patient Safety Solution: Remove Or Sanction The Small Number Of Bad Doctors Committing Most Malpractice.

AIR is a coalition of public interest organizations from around the country that seek stronger oversight over property/casualty insurance industry practices. It is a project of the Center for Justice & Democracy, a national consumer organization.

For more information and for copies of these fact sheets, see http://insurance-reform.org. or http://centerjd.org/.


SOURCE Americans for Insurance Reform

Health Savings Account Enrollment Reaches Eight Million

HSA accountholders come from all income levels

WASHINGTON, May 13 /PRNewswire-USNewswire/ -- Eight million Americans are covered by Health Savings Account (HSA)-eligible insurance plans, an increase of more than 31 percent since last year, a new census released today by America's Health Insurance Plans (AHIP) finds. Health Savings Accounts were authorized starting in January 2004. Since then, AHIP has conducted a periodic census of its members participating in the HSA/high-deductible health plan (HDHP) market.

Another report released today found HSA accountholders have a broad range of incomes across the country. The report, Estimated Income Characteristics of HSA Accountholders in 2008, used a geo-coding technique to estimate the income characteristics of HSA accountholders.

"HSA plans provide coverage to a number of consumers of all ages and incomes across the country, and they represent an important choice for employers and individuals when looking at the portfolio of coverage options available," said Karen Ignagni, President and CEO of AHIP.

Key findings from the census include:

There was an increase of approximately 1.9 million Americans enrolled in an HSA plan since January 2008. Previous AHIP census reports found that 6.1 million were enrolled in January 2008, 4.5 million were enrolled in January 2007, 3.2 million were enrolled in January 2006, and 1.0 million were enrolled in March 2005.

30 percent of individuals covered by an HSA plan were in the small group market, 47 percent of individuals covered by an HSA plan were in the large-group market, and the remaining 23 percent were in the individual market.

A majority of HSA enrollees are covered by Preferred Provider Organization (PPO) products (83 percent) and Health Maintenance Organization (HMO) products (10 percent). In the individual market, almost 92 percent of enrollees in HSA plans were in PPO products, while approximately 85 percent of enrollees in large-group and 76 percent of enrollees in small-group HSA plans were in PPO plans.

States with the highest levels of HSA/HDHP enrollment were California (854,000), Florida (524,000), Illinois (497,000), Texas (476,000), Ohio (464,000), and Minnesota (388,000).

Key findings from the income characteristics analysis include:

Households with a wide range of incomes hold HSA accounts, with almost half (49 percent) of accountholders living in neighborhoods with median incomes under $50,000 (incomes based on 2000 Census data).

Average total deposits (including personal deposits, employer contributions, and interest) for all HSA accounts were $1,634 and average total withdrawals (including fees) were $1,063.

For more information about the 2009 census and the income report, please visit www.AHIPResearch.org.

America's Health Insurance Plans - Providing Health Benefits to More Than 200 Million Americans


SOURCE America's Health Insurance Plans

An Interactive Health Caring Conversation With SAVE THE PATIENT

CHICAGO, May 13 /PRNewswire-USNewswire/ -- Continuing its efforts to educate, inform, and empower the people of Chicago, SAVE THE PATIENT, a not-for-profit patient-focused organization, is hosting its 25-minute live call-in show, "Community Health," on Chicago Access Network Television (CAN-TV) on Monday, May 18, 2009 at 6:00 PM on Channel 21.

Monday's program will feature Founder and President of SAVE THE PATIENT, Lenore Janecek who will have an intimate health caring conversation with her viewers on the third anniversary of her live interactive television program, letting viewers know that they are not alone in their efforts to secure access to quality health care. She will tell positive stories and share invaluable information gleaned from health professionals on the show each month to help viewers make wise health care choices using objective resources.

The goal of the series is to give everyday people the confidence to enact their patient rights, so that they can effectively manage their families' health encounters.

All the efforts of SAVE THE PATIENT promote positive and productive interactions between patients and medical professionals by encouraging individuals to know and implement their rights to ask questions, receive understandable answers, and explore medical options. "SAVE THE PATIENT's mission is to assist the public in becoming better health care consumers," noted President and Founder Lenore Janecek.

Viewers who wish to join discussions can call-in to pose questions or share concerns. "This new televised platform gives Chicago's diverse population a voice in matters affecting their use of health care," explained Janecek. "The open discussion format is designed to help mend the disparity between the wealth of health care resources available and people who are actually aware of them." Ms. Janecek, a nationally known health care expert and author, is the host of this groundbreaking program.

Check your local cable television listings for scheduled air times. For additional information call: CAN-TV at 312-738-1400, www.savethepatient.org, or e-mail savethepatient@aol.com.

SAVE THE PATIENT(SM) is a nonprofit organization dedicated to the support and education of individuals on health care matters. Founded in 2001 to fulfill the need for a non-biased, non-commercial community-based non-profit organization to educate, inform, and empower patients as they attempt to make sound health care decisions, SAVE THE PATIENT provides information and education through patient advocacy, community outreach, educational seminars and its signature tool: the Health Caring Card.

Contact:
Lenore Janecek, President
E-mail: savethepatient@aol.com
Phone: 312-399-3532


SOURCE SAVE THE PATIENT

Tampa Disinfection Company Booming After Swine Flu Scare

TAMPA, Fla., May 13 /PRNewswire/ -- Three-year-old Air & Surface Disinfection (ASD) announced today their business has dramatically increased since the latest Swine Flu scare. ASD treats homes, businesses and other facilities with disinfectant solutions that provide continuous residual antimicrobial activity for up to 6 months.

Kevin Renner, President and Founder said, "Since we started three years ago, we were fairly busy disinfecting homes and offices to remove smells and kill germs, but the recent Swine Flu scare has really created a demand for an affordable way to disinfect a home or office for up to six months. At 13 cents per square foot, the average home is around $350; not that you can put a price tag on health, but to most families and businesses it's worth it."

Renner had planned to start this business when he lived in New Orleans but Hurricane Katrina halted those plans and resulted in his relocation to the Florida area. Interestingly, the same storm was something of a rebirth for the products that ASD uses, which have been around for over 30 years.

ASD's state-of-the-art equipment disperses a disinfectant solution that cleans and deodorizes. The active ingredient within the spray is Phenol, which is found in most chloraseptic sprays. Prior to treating, ASD will also use a HEPA air scrubber machine to clean the air and remove airborne toxins. The products that ASD uses are hypoallergenic and EPA-registered for mold remediation, air duct cleaning and carpet decontamination. They provide a 99.9% kill rate of pathogenic, vegetative organisms and continuous residual bacteriostatic and mold inhibiting activity for up to 6 months. The solution is non-corrosive to surfaces including plastics, latex, vinyl, glass, treated wood, metal and glazed porcelain.

The only side-effect is a hospital-like smell, which will last a couple of days after the treatment. Other chemicals are available to treat mold and additional contaminants, but they can be expensive with insurance companies cracking down on mold claims. Air & Surface Disinfection's services can provide a handy remedy.

For more information on Air and Surface Disinfection, please visit their Web site at www.airandsurfacedisinfection.com or call (813) 313-9801.


SOURCE Air & Surface Disinfection

Stanford Center on Longevity Releases New Findings About Voter Attitudes on Health Care Reform

Voters willing to engage in discussion about trade-offs

STANFORD, Calif., May 13 /PRNewswire-USNewswire/ -- Americans want answers to tough questions about the trade-offs involved in health care reform, according to new data released today by the Stanford Center on Longevity (SCL).

The findings are the result of a unique, bipartisan project that spanned nearly two years and united the typically disconnected worlds of politics, academia and the public.

"As lawmakers are preparing large-scale legislation with the goal of improving health care in our country, it is critical that leaders engage the public in an intelligent discussion about the options for change and what they mean both for individuals and for the system broadly," said Dr. Laura Carstensen, SCL Director.

"The degree of conversation we've been having about the existing problems with the system must be mirrored with conversation about solutions to those problems. There is anxiety among the public about changes to their health care, which necessitates building public support for proposed changes to the system if they are to be successful."

SOME KEY FINDINGS:

While voters rate health reform as a very high priority, they do not form a consensus around any one of the six proposals, expressing instead ambivalence as they weighed the tradeoffs involved in the implementation of each. Notably, none of the six proposals are clearly rejected outright either. Instead the findings reflect voters' willingness to engage in a serious and substantive way on the topic of health care reform and their desire for more detailed information about the relative pros and cons of various reform proposals;

The findings also reveal that voters' reactions to various health care proposals are heavily tied to political party affiliation. In particular, Democrats show a real willingness to support proposals designed to expand access to health care. Voters across the partisanship spectrum -- Democrats, Republicans and Independents --- share strong concerns about health care costs;

While 62 percent of Americans feel the health care system works well for them, 68 percent believe it does not work well for most Americans;

58 percent of Americans are not satisfied with cost and affordability of health care, but 50 percent are satisfied with the quality.

For more information, please visit http://longevity.stanford.edu.


SOURCE Stanford Center on Longevity

CMSA Delivers Important Message to Congress: Case Management Services Improve Patient Care and Should Be Key Strategy in Health Care Reform Initiative

CMSA holds its third Public Policy Day in Washington, D.C.

LITTLE ROCK, Ark., May 13 /PRNewswire-USNewswire/ -- The Case Management Society of America (CMSA) held its third annual Public Policy Day on Capitol Hill on April 28 to increase awareness of case management and the vital care coordination services case managers perform across the health care continuum, as well as how these services can support federal health care reform efforts.

"Case management is still one of the best kept secrets in health care for improving clinical outcomes for patients and for lowering costs," stated Margaret Leonard, MS, RN-BC, FNP, CMSA President-Elect and Chairman of the CMSA Public Policy Committee. "CMSA hopes to build continued awareness with legislators and regulators on how case managers work collaboratively with physicians, pharmacists, and others to coordinate and manage individualized services to patients and their family caregivers."

Members of CMSA's Board of Directors, its Public Policy Committee, and various state chapter liaisons attended a total of 70 scheduled meetings with their respective congressional representatives or their staff. The 30 individuals representing 18 states saturated Capitol Hill to stress the significance of the following health care issues:

Case managers are licensed health care professionals providing patient assessment, treatment planning and health care facilitation pursuant to CMSA's national Standards of Practice.

They play a central role in promoting smooth transitions of care -- especially for the chronically ill.

Case management programs should become a centerpiece to health care reform at federal and state levels.

New guidelines are required to align payment incentives for case management services, including the establishment of new CPT Codes to help pay for these vital services.

Barriers to efficient case management should be reduced, such as promoting interstate nursing licensure compacts and promoting interoperable health IT platforms that include the treatment plans generated by case managers.

CMSA's Public Policy Day is an annual activity, and while the visits on Capitol Hill take place in a single day, this effort is only one component of a larger strategy to help CMSA members build continued awareness with legislators.

"The energy and enthusiasm of Case Management leaders at the third annual CMSA Lobby Day was infectious to say the least," said President, Jeff Frater, RN, BSN. "What was even more exciting for me was the warm reception and recognition that we experienced when visiting with legislators and their legislative aides. There in an increasing recognition of the value case management brings to the health care experience and a ripe opportunity to influence the future as health care reform is a front burner issue with significant momentum."

About Case Management Society of America (CMSA)

Established in 1990, the Case Management Society of America is an international non-profit 501(c)(6) multi-disciplinary professional association dedicated to the support and advancement of the case management profession through educational forums, networking opportunities, legislative advocacy, and establishing standards to advance the profession. It is based in Little Rock, AR, and serves more than 20,000 members/subscribers and 73 affiliate and pending chapters. Since its inception, CMSA has been at the forefront of setting professional standards for the industry, which allows for the highest level of efficiency and integrity, as well as developing national and local leaders who are recognized for their practice and professional excellence. For more information on CMSA, call CMSA at (501) 225-2229 or go to www.cmsa.org.


SOURCE Case Management Society of America

Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference

SAN FRANCISCO, May 13 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference on Wednesday, May 20 in New York.

Dr. Hung will provide an overview of Medivation and its clinical development programs at 10:30 a.m. Eastern Time, which will be webcast. In addition, Dr. Hung will participate in an expert panel discussion titled, "New Developments in Solid Tumors, Focusing on GU and GI Cancers," on the same day at 8:10 a.m. Eastern Time.

A live audio webcast of the corporate presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The program also includes additional trials planned to begin this year in Alzheimer's disease, as well as further development of Dimebon in patients with mild-to-moderate Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at http://www.medivation.com.


SOURCE Medivation, Inc.

Association for the Treatment of Tobacco Use and Dependence Supports the FDA Ban of 'Electronic' Cigarettes

BURLINGTON, Vt. and ROCHESTER, Minn., May 13 /PRNewswire/ -- The Association for the Treatment of Tobacco Use and Dependence (ATTUD), the premier professional organization of tobacco treatment specialists, today announced its support of the FDA ban on so-called "electronic" or e-cigarettes. The letter addressed to Acting Commissioner Sharfstein (see below) stated that there is no scientific evidence that the e-cigarettes are safe and effective.

"As tobacco treatment professionals we are concerned that smokers desperate to quit will place their faith in unproven therapies," said John Hughes, MD, President-elect of ATTUD and professor of psychiatry at the University of Vermont College of Medicine. "Money spent on unproven treatments is money unavailable for proven, FDA-approved treatments," Dr. Hughes continued.

Furthermore, an unsuccessful attempt can precipitate a sense of failure, which can delay another quit attempt for years. Unfortunately, this can mean that some smokers will die or suffer serious disease after an unsuccessful quitting effort. While ATTUD supports the quit attempts of all tobacco users, it strongly encourages all smokers to use FDA-approved and proven medications with the support of tobacco treatment professionals.

Organization Info: http://www.ATTUD.org

The Association for the Treatment of Tobacco Use and Dependence is a non-profit organization of providers dedicated to the promotion of and increased access to evidence-based tobacco treatment for the tobacco user.

Full text of letter to Acting Commissioner Sharfstein: http://www.ereleases.com/pr/2009-ATTUD.pdf

Contact:

Matthew Bars, MS, CTTS
Matt.Bars@yahoo.com
201-225-1600

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


SOURCE Association for the Treatment of Tobacco Use and Dependence

HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials

ABBOTT PARK, Ill., May 7 /PRNewswire-FirstCall/ -- The Abbott RealTime HIV-1 Assay and Abbott m2000 System have been recommended as a standard protocol for viral load testing in HIV/AIDS clinical trials sponsored by the National Institutes of Health (NIH).

This recommendation was made by the Cross-Network Laboratory Focus Group (LFG), which consists of representatives from five of the NIH-sponsored HIV/AIDS clinical trials networks. The LFG recently issued a consensus statement, which was reviewed and approved by the leadership of the five networks, recommending the use of the Abbott RealTime HIV-1 assay and m2000 system for upcoming clinical trials in 2009 and beyond that have a primary focus on viral load measurements. The recommendation applies to testing performed at adult and pediatric therapeutic HIV/AIDS clinical trial sites both in the United States and internationally, as well as the centralized network laboratories in the United States.

Viral load testing is a monitoring tool used to determine the amount of virus in the blood and the efficacy of anti-HIV therapy. The growing prevalence of HIV-1 subtype variant and circulating recombinant strains has made accurate viral load detection more complex and has prompted increasing numbers of clinical laboratories to adopt the Abbott RealTime HIV-1 Assay on the m2000 System. The system is one of the fastest and most sensitive viral load tests available, with the ability to detect and precisely measure group M, N and O strains of HIV-1, as well as all known non-B subtypes.

"We're pleased that the LFG has recommended the Abbott RealTime HIV viral load assay to be the standard testing system for NIH-sponsored HIV/AIDS clinical trial networks," said Stafford O'Kelly, head of Abbott's molecular diagnostics business. "We look forward to supporting the NIH-sponsored clinical trials networks in the global effort to evaluate and monitor HIV drug treatments."

Based on several published studies, current molecular or PCR based diagnostic tests vary in their ability to detect and reliably quantify variant strains of HIV-1 and have been found to under-quantify them. "The performance and precision of the Abbott RealTime HIV-1 assay for detecting variant subtypes allows physicians to confidently measure viral levels and provide optimal drug treatment," O'Kelly said.

The NIH-sponsored networks include the: AIDS Clinical Trials Group, International Maternal Pediatric Adolescent AIDS Clinical Trials Group, HIV Prevention Trials Network, HIV Vaccine Trials Network, and Microbicide Trials Network. The networks are an affiliated group of national and international medical research institutions and investigators that conduct clinical HIV/AIDS research to develop safe and effective drugs, prevention strategies and HIV vaccines.

About the Abbott RealTime HIV-1 Test

The Abbott RealTime HIV-1 assay is among the most sensitive viral load tests available today. The test has demonstrated the ability to detect diverse group M subtypes of HIV (including all known non-B subtypes) as well as group N and O isolates.

The Abbott RealTime HIV-1 test is intended for use in conjunction with clinical presentation and other laboratory markers as an indicator of disease prognosis and for use as an aid in assessing viral response to antiretroviral treatment as measured by changes in plasma HIV-1 RNA levels. The assay is not intended to be used as a donor-screening test for HIV-1 or as a diagnostic test to confirm the presence of HIV-1 infection.

About the Abbott m2000 Instrument System

The Abbott RealTime HIV-1 test runs on the Abbott m2000, an automated system that uses real-time polymerase chain reaction (PCR) to amplify, detect and measure minute levels of virus in blood samples as well as extremely high levels of these infectious agents. Real-time PCR enables the production of large quantities of DNA from very small samples in a short period of time, making it possible to detect extremely low levels of a virus's genetic material. The Abbott m2000 system automates the important steps of the process, from sample preparation to data analysis, allowing laboratories to process molecular tests efficiently, accurately and confidently.

In addition to having a best-in-class assay for HIV-1, Abbott's m2000 system is faster than competitive systems, delivering 96 test results in less than six hours for HIV-1 as compared to up to two days for other systems.

About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available at the company's Web site at www.abbott.com.


SOURCE Abbott

X-Rays Help Predict Permanent Bone Damage From Bisphosphonates

CHICAGO, May 7 /PRNewswire-USNewswire/ -- Breast cancer patients, individuals at risk for osteoporosis and those undergoing certain types of bone cancer therapies often take drugs containing bisphosphonates. These drugs have been found to place people at risk for developing osteonecrosis of the jaws (a rotting of the jaw bones). Dentists, as well as oncologists, are now using X-rays to detect "ghost sockets" in patients that take these drugs and when these sockets are found, it signals that the jawbone is not healing the right way. Early detection of these ghost sockets can help the patient avoid permanent damage to their jawbone, according to an article in the March/April 2009 issue of General Dentistry, the Academy of General Dentistry's (AGD) clinical, peer-reviewed journal.

A ghost socket occurs when the jawbone is not healing and repairing itself the right way. "The good news is that even though these ghost sockets may occur, by using radiographic techniques we can see that the soft tissue above these sockets can still heal," according to Kishore Shetty, DDS, MS, MRCS, lead author of the report. Dr. Shetty states these findings are important news to learn about because early prevention and detection can halt permanent damage from happening to a patient's jawbone.

In 2006, about 191 million prescriptions of oral bisphosphonates worldwide were written. The National Osteoporosis Foundation estimates that nearly 44 million people in the United States are at risk for developing osteoporosis. Currently, approximately 10 million Americans suffer from the disease.

Bisphosphonates are a family of drugs used to prevent and treat osteoporosis, multiple myeloma, Paget's disease (bone cancers), and bone metastasis from other cancers. These drugs can bond to bone surfaces and prevent osteoclasts (cells that break down bone) from doing their job. Other cells are still working trying to form bone, but it may turn out to be less healthy bone, leading to the ghost-like appearance on X-rays.

"Healthy bones can easily regenerate," says Dr. Shetty. "But, because jawbones have rapid cell turnover, they can fail to heal properly in patients taking any of the bisphosphonate drugs. It's very important for patients to know about complications from dental surgery or extractions. Since these drugs linger in the bone indefinitely, they may upset the cell balance in how the jaws regenerate and remove unhealthy bone."

According to AGD spokesperson Carolyn Taggart-Burns, DDS, FAGD, patients who are taking bisphosphonates should inform their dentist to prevent complications from dental surgical procedures.

"Widespread use of bisphosphonates to prevent or treat early osteoporosis in relatively young women and the likelihood of long-term use is a cause for concern," says Dr. Taggart-Burns.

Drs. Shetty and Taggart-Burns agree that, "how bisphosphonates interfere with healing after dental surgery is still unclear and further research will be needed. It is imperative that the public understands there is no present treatment or cure for this problem."


SOURCE Academy of General Dentistry

Economy Impacts People Seeking Treatment for Addiction - 80% Increase Over Last Year

FARMINGTON, Conn., May 12 /PRNewswire/ -- Last month The National Alliance of Advocates for Buprenorphine Treatment, www.NAABT.org, saw an 80% increase in patients seeking treatment for painkiller or heroin addiction compared to April of 2008. As of this morning May is on track for an astounding 200% gain.

Dr. Michael Stein, author of new best-selling book The Addict, reviewed in Oprah Magazine and The New York Times, tells NAABT, "With the economic downturn, and the loss of jobs all around us, my buprenorphine practice has been swamped with new patients, as well as with former patients who have relapsed to opiate use in order to relieve, seemingly, the pressures of being out of work and losing one's home. Of course, the relief provided by the use of addictive medication is usually short-lived and one's troubles only re-emerge with greater force in the face of the new demands of uncontrolled drug use now compounding ongoing financial woes. Seeking appropriate care early on, either before relapse, or as soon as one can get into to see a provider for help, will limit the damage of this deadly cycle."

Recently unemployed patients tell us they are trying to get into addiction treatment before their insurance runs out. Others unsure of the future of their employment status want to get treatment in the privacy of a doctor's office while employed and insured.

As word spreads that new pharmaceutical treatments for addiction are safe and effective, patients are flocking to treatment. For the first time these medications allow patients to be treated in the privacy of a doctor's office. This is a much more viable option for people who may not have sought treatment if it meant a long inpatient stay that requires time off of work.

With unemployment still rising addiction to both alcohol and drugs are likely to increase.

Dr. Harold Urschel, author of Healing the Addicted Brain, and special guest on the Dr. Phil show's "How to Stay Sober" episode last week, tells NAABT, "In response to the abrupt, significant economic fallout and stress from the current banking crisis/recession, many people have turned to using alcohol and/or drugs to cope with this stress. Unfortunately, many of these people have become heavy abusers or even addicted, which then causes even more stress on their families and support networks. I have seen a 50% increase in the new admissions to both my private practice and our EnterHealth Life Recovery Center Residential program in Dallas, Texas, especially in the area of heroin or prescription narcotic addition. It is very important to get anyone that has developed addiction or even heavy abuse to find effective, scientifically-sound treatment as soon as possible, in order to minimize the worsening of stress that this chronic brain illness will add to their lives and those of their families/friends."

Live map of patients seeking treatment right now:

http://www.naabt.org/patients-seeking-treatment-fs.cfm

What to do:

www.TreatmentMatch.org is a free service that uses web technology to help patients find the doctors who can help them. It is a way for patients to reach out for help 24/7 -- over 21,000 patients have been connected with physicians this way.

www.AddictionSurvivors.org is a community of people going through similar circumstances and can offer advice and support. It helps to know you're not alone.

www.naabt.org


SOURCE NAABT.org

Beverage Industry Fighting Childhood Obesity by Helping Children Balance Calories

Cutting calories in schools reinforces skills for a lifetime; discriminatory taxes just raise revenue

WASHINGTON, May 12 /PRNewswire-USNewswire/ -- Childhood obesity is a serious issue that requires comprehensive and thoughtful solutions, but discriminatory taxes on soft drinks and other beverages are the wrong public policy for such a complex problem, said Susan Neely, president and CEO of the American Beverage Association.

As Washington leaders begin discussing ways to improve health care in America, the beverage industry believes they need to focus on solutions that work when it comes to reducing childhood obesity. Solutions like the successful national School Beverage Guidelines, which cut calories in schools and help reinforce with children the importance of balancing calories.

"Together as a society, we need to focus on the hard work of teaching our children how to balance calories consumed with calories burned and, by doing so, give them the skills to maintain a healthy weight throughout their lives," Neely said today. "A tax won't teach children these skills or have a lasting, meaningful impact on reducing childhood obesity."

In May 2006, the beverage industry developed national School Beverage Guidelines with the Alliance for a Healthier Generation, a joint initiative of the William J. Clinton Foundation and the American Heart Association. The industry committed to changing the beverage mix in schools across America by removing full-calorie soft drinks, as well as capping calories and reducing portion sizes on other beverages and providing nutritious beverage options by the beginning of the 2009-2010 school year.

The beverage companies not only committed to a tough policy, but they are delivering results and exceeding their goals.

At the start of the current school year, nearly 80 percent of America's schools under contract were in compliance with the School Beverage Guidelines - beating the agreed-upon goal of 75 percent after two years. And calories from beverages in schools have been cut by 58 percent during that time.

"America's beverage industry stepped up years ago to cut calories in schools because we recognize the important need to address childhood obesity in a meaningful way," Neely said. "Our school beverage guidelines contribute to children developing lifetime skills on balancing calories."

Another benefit of the Alliance for a Healthier Generation program is its focus on the calories burned side of the equation - the need for more physical education in schools. Beverage companies have long supported programs that promote physical activity in addition to the Alliance effort.

"Soft drinks are a fun, refreshing beverage meant to be enjoyed. You can be a healthy person and enjoy soft drinks, as millions of Americans, including parents and their children, prove every day," Neely said. "As we've seen in countless studies, the right formula is about calories in and calories out, not about added taxes."

Neely said the School Beverage Guidelines provide an encouraging model for effective public policy development to address a complex social challenge. Through the Alliance for a Healthier Generation and its partners, the non-profit sector came together with the private sector to forge a solution with real, measurable impact for our children.

"The School Beverage Guidelines are the right policy that strikes the right balance," Neely said. "It's why the guidelines have drawn strong support from parents, educators, doctors and nutritionists."

Furthermore, the data simply doesn't support singling out products like soft drinks as a unique contributor to obesity. The data shows soft drinks have declined annually since 2000 (an overall 9.6 percent decline from 2000-2008, according to Beverage Digest), while childhood and adult obesity rates have risen throughout the decade.

Neely said the beverage industry applauds President Obama and the Congress for seeking effective ways to prevent childhood obesity and other diseases by improving the health care system in America. She encourages the leaders to keep seeking the best ideas, not the most convenient.

"If we're going to truly make an impact on childhood obesity, our leaders need to pursue more of these smart, common-sense solutions that work, rather than simply imposing regressive taxes and hoping for the best," Neely said. "Taxes distract from meaningful solutions. People view government as over-reaching when it uses the tax code to tell them how to eat or feed their children. Taxes are just the wrong public policy for a complex problem like childhood obesity."

The American Beverage Association is the trade association representing the broad spectrum of companies that manufacture and distribute non-alcoholic beverages in the United States.


SOURCE American Beverage Association

Report Reveals Disparities in Pharmaceutical Treatment for Minority Patients

WASHINGTON, May 12 /PRNewswire-USNewswire/ -- A new report from the National Minority Quality Forum finds that appropriate medications for a variety of diseases often are under-prescribed, over-prescribed, or mis-prescribed for African Americans, Hispanics and Asian Americans. This comprehensive review of studies on medication use in U.S. minority groups, entitled Origins and Strategies for Addressing Ethnic and Racial Disparities in Pharmaceutical Therapy: The Health-Care System, the Provider, and the Patient, reveals disparities in treatment of minority patients with cardiovascular illness, asthma, psychiatric illness, pain and other conditions.

The report, authored by Richard Levy, Ph.D., Robert C. Like M.D., M.S., and Harry S. Shabsin, Ph.D., finds disparities in access to medications through insurance programs, in the prescribing of medications and in adherence to medication regimens. The report offers recommendations for health-care planners and advocates, clinicians and health-care organizations to improve prescribing and use of medications in a diverse society.

"Since medications are a cornerstone of treatment for many diseases, addressing unequal or inappropriate medication use should be a focus for practitioners and organizations committed to the goal of eliminating health-care disparities. We hope this report raises awareness of the extent of medication disparities and will stimulate solutions to address the problem," said Dr. Like, Professor and Director of the Center for Healthy Families and Cultural Diversity of the UMDNJ-Robert Wood Johnson Medical School.

The report points out that improving access to and use of medications in diverse groups requires policies that enable affordable, personalized therapy. Ethnic/racial background should, like other factors such as age or gender, be considered in selecting drugs and dosages, in the composition of drug formularies and preferred drug lists, and in determining the scope of drug substitution policies. The report emphasizes that therapy must be tailored to individual needs and stereotyping and overgeneralization in caring for diverse populations should be avoided.

Dr. Levy, a health care consultant and former vice president of the National Pharmaceutical Council, states: "Differences in response to pharmaceuticals in minority populations indicate the importance of including diverse groups in comparative-effectiveness assessments. Failure to do so may reduce, rather than improve, the quality of care for ethnic and racial minorities".

Key Findings from the Report

Many studies have revealed ethnic/racial disparities in prescribing (under-prescribing, over-prescribing or mis-prescribing) for specific diseases or classes of medication, including medications for asthma, depression, psychosis, cardiovascular disease, diabetes, pain and infectious disease.

Medication disparities can stem from a relative lack of health and drug insurance, aggressive cost containment in pharmacy benefits plans and reduced services at pharmacies in minority neighborhoods. All of these situations can limit access to medications or cause patients to reduce or discontinue therapy.

Most state Medicaid programs utilize pharmaceutical cost containment polices which include prior authorization, generic substitution, preferred drug lists, copayments and caps. While fulfilling their intent to save drug costs, these policies may have the unintended consequences of limiting access to necessary medications. This limitation has been associated with increased utilization of medical services by minority patients.

Suboptimal prescribing may reflect a clinician's lack of knowledge about the patient's culture or to the clinician's beliefs about that culture. Clinicians who have that knowledge and who communicate well can positively affect treatment outcomes.

Relatively low adherence in filling initial prescriptions, refilling prescriptions and taking medications according to directions has been reported in minority patients being treated for asthma, depression, psychosis, cardiovascular diseases, osteoporosis, diabetes and in receiving vaccinations. Low medication adherence in minority populations has been correlated with reduced health status.

Much of the association between race/ethnicity and low adherence is explained by low household income, lack of insurance, poor education, low health literacy, language barriers and cultural beliefs. Low adherence may also reflect poor communication by providers, often due to lack of cultural competence training and time/resource constraints.

Use of herbal or other folk remedies by persons from various cultural backgrounds can complicate, interact and sometimes detract from treatment with western medicines.

Response to medications and optimal dosages may differ due to genetic or environmental factors, or diet. Ethnic differences have been consistently reported in the metabolism, effectiveness and frequency of side effects of many important drugs. Failure to account for these differences when prescribing or selecting agents for formularies or preferred drug lists may lead to suboptimal treatment and disparities.

The report is available online at http://store.nmqf.org/p-13-nmqf-e-books.aspx.

The National Minority Quality Forum (NMQF) (http://www.nmqf.org) is a nonprofit, nonpartisan organization research and educational organization dedicated to ensuring that high-risk racial and ethnic populations and communities receive optimal health care. NMQF integrates data and expertise in support of initiatives to eliminate health disparities.

SOURCE National Minority Quality Forum

UnitedHealthcare Children's Foundation To Award More Medical Grants for Child Health Care Needs in New Jersey

NEWARK, N.J., May 12 /PRNewswire/ -- For 7-year-old Alexander, it's meant orthotics and physical therapy so he can run with minimal assistance. For 7-year-old Rebecca, it's an insulin pump for her Type 1 Diabetes. And for 2-year-old Jacob, who has cerebral palsy, it's a wheelchair.

All these children and more than a thousand others have received medical grants from the UnitedHealthcare Children's Foundation (UHCCF) in recent years to help pay for desperately needed medical care or equipment.

UHCCF is currently accepting grant applications from families in the New Jersey area in need of financial support for child health care treatment, services or equipment not covered or not fully covered by their health insurance benefit plans. UHCCF provides medical grants to qualified families enrolled in an employer-sponsored health plan, or who have purchased an individual policy, to help pay for child health care services such as speech, physical or occupational therapy, prescriptions, and medical equipment such as wheelchairs, orthotics and hearing aids.

"Contributions from UnitedHealth Group employees and people across the country have enabled the UnitedHealthcare Children's Foundation to help hundreds of children improve their health and quality of life," said UHCCF President Matt Peterson. "Our goal is to grow the UnitedHealthcare Children's Foundation grant program so we can help even more children."

In 2008, UHCCF helped nearly 600 children nationwide whose families were struggling to pay their share of the cost of medically-related services and equipment. Some other examples:

11-year-old Simone has a UHCCF grant to get speech therapy to help overcome her speech delay.
7-year-old Marcus has dysphaligia, which makes it difficult for him to swallow. Through a UHCCF grant, Marcus now receives intensive feeding therapy.
A UHCCF grant enables Abigail's parents to pay for medication for sclerosis and epilepsy.

Parents and legal guardians may apply for grants of up to $5,000 for child medical services and equipment by completing an online application at www.uhccf.org. To be eligible for grants, children must be 16 years of age or younger. Families must meet economic guidelines, reside in the United States and be covered by a commercial health benefit plan.

About UnitedHealthcare Children's Foundation

The UnitedHealthcare Children's Foundation (UHCCF) is a nonprofit 501(c) (3) public charity that strives to enhance either the clinical condition or quality of life of children who have health care needs not fully covered by their commercial health benefit plan. UHCCF provides medical grants of up to $5,000 for costs associated with medical services and equipment. UHCCF's funding is provided by contributions from individuals, corporations and UnitedHealth Group employees. Donations to help provide assistance are deeply appreciated. To donate or learn more, please visit www.uhccf.org.


SOURCE UnitedHealthcare Children's Foundation

More Dire Warnings for Social Security

RetireSafe Calls for Action to Protect Older Americans

RESTON, Va., May 12 /PRNewswire-USNewswire/ -- In response to the dire warnings issued in today's Social Security and Medicare Trustees Report, RetireSafe and its 400,000 senior supporters called on the President and Congress to take immediate action to secure the promised benefits older Americans rely on.

"With unfunded liabilities of up to $100 trillion and the Social Security Trust Fund scheduled to pay out more than it takes in by 2016, America's seniors deserve to know that the Social Security benefits they rely on to make ends meet will still be there for them," said RetireSafe President Michelle Plasari.

According to Plasari, there are simple ways to make Social Security more secure for current and near retirees:

Guaranteed Benefits. Currently, Social Security benefits are not a sure thing. They can be cut by Congress on a whim. Congress has continually used incoming Social Security dollars for other projects -- including pork barrel spending. For years, RetireSafe has supported legislation that would provide a certificate of guarantee to Social Security beneficiaries.

Fair COLA (Cost of Living Adjustment). Seniors' annual cost-of-living-adjustments are calculated based on the spending habits of younger workers. The formula used doesn't account for increased spending on health insurance, long-term care or prescription drugs. For decades, the government has maintained an "experimental" index that tracks seniors' true cost of living. To see just how much more seniors could get over their retirement visit RetireSafe's Fair COLA Calculator at www.retiresafe.org/cola_calculator.html.

Repeal Double Tax. Seniors are subject to unfair taxation during their retirement years. After spending their whole lives paying taxes to the government -- the IRS still gets to tax 85% of their Social Security benefits if their retirement earnings reach a certain level.

Abolish the Early Retiree Earnings Limit. Early retirees who continue to work are penalized for doing so by earning limits. The limit taxes seniors at an outrageous amount -- more than many multi-millionaires. In today's economy more and more early retirees are returning to work to make ends meet -- and being penalized by the tax man for doing so.

Prohibit Totalization. The Social Security Administration has signed a totalization treaty with Mexico. The agreement would allow millions of illegal immigrants to collect Social Security benefits. This is a slap in the face to older Americans who worked hard their whole lives yet continue to struggle on their current benefit.

RetireSafe is a grassroots advocacy organization of almost 400,000 older Americans nationwide. We are dedicated to protecting the options, benefits, and choices of older Americans in retirement. For more information, visit www.retiresafe.org.


SOURCE RetireSafe

Flashing Lights Help Kids Avoid the Swine Flu

Parents invent device that gets kids to want to wash their hands

DALLAS, May 12 /PRNewswire/ -- Parents worried about their kids picking up the swine flu virus from not washing their hands enough finally have some help. Two parents who became frustrated that their kids were getting sick too often thought the reason might be that their kids didn't wash their hands enough. Those frustrations led to SOAPRISE by Soap Labs LLC, a unique device that gets kids to want to wash their hands.

(Photos: http://www.soaplabs.com/media_gallery.html)

Their invention was not just another kid's hand soap. With SOAPRISE, the entire bottle LIGHTS UP for 15 seconds after the soap is dispensed. This is the amount of time advised by the Centers for Disease Control for washing your hands in order to effectively kill the germs that cause illness. Children get excited by the flashing lights and their hands get clean by simply learning to "WASH UNTIL THE LIGHT SHOW ENDS."

Kids become very susceptible to viruses like the swine flu because they don't like to wash their hands after going to the bathroom or touching common items at school. "As a parent I always try to find ways to prevent my kids from getting sick. One of the easiest ways to do that is keeping their hands clean," said Jeff Kacines, one of the founders of Soap Labs.

SOAPRISE has been extensively field tested in homes, day cares and schools and the response has been overwhelming. Parents and teachers say the job of reminding kids to wash their hands has never been easier as kids want to use SOAPRISE. SOAPRISE has become a valuable preventive weapon for parents especially with the recent spread of the swine flu virus.

Flashing lights, foaming soap and kid friendly fragrances all combine to make children excited about getting clean. The lights in the bottles last for MULTIPLE refills, making it also an economical purchase during these tight financial times.

SOAPRISE is available at Duane Reade, Pathmark A&P, Amazon.com and Drugstore.com

"SOAPRISE" and "WASH UNTIL THE LIGHT SHOW ENDS" are registered trademarks of Soap Labs LLC.

To see SOAPRISE in action visit www.soaprise.com. For more information on Soap Labs LLC visit www.soaplabs.com


SOURCE Soap Labs LLC

ACLU Challenges Patents on Breast Cancer Genes

Gene Patents Stifle Patient Access To Medical Care And Critical Research

NEW YORK, May 12 /PRNewswire-USNewswire/ -- The American Civil Liberties Union and the Public Patent Foundation at Benjamin N. Cardozo School of Law (PUBPAT) filed a lawsuit today charging that patents on two human genes associated with breast and ovarian cancer stifle research that could lead to cures and limit women's options regarding their medical care. Mutations along the genes, known as BRCA1 and BRCA2, are responsible for most cases of hereditary breast and ovarian cancers. The lawsuit argues that the patents on these genes are unconstitutional and invalid.

"Knowledge about our own bodies and the ability to make decisions about our health care are some of our most personal and fundamental rights," said Anthony D. Romero, Executive Director of the ACLU. "The government should not be granting private entities control over something as personal and basic to who we are as our genes. Moreover, granting patents that limit scientific research, learning and the free flow of information violates the First Amendment."

Today's lawsuit was filed in U.S. District Court for the Southern District of New York on behalf of breast cancer and women's health groups, individual women and scientific associations representing approximately 150,000 researchers, pathologists and laboratory professionals against the U.S. Patent and Trademark Office (PTO), as well as Myriad Genetics and the University of Utah Research Foundation, which hold the patents on the BRCA genes. It is the first to apply the First Amendment to a gene patent challenge.

The patents granted to Myriad give the company the exclusive right to perform diagnostic tests on the BRCA1 and BRCA2 genes and to prevent any researcher from even looking at the genes without first getting permission from Myriad. According to the lawsuit, such monopolistic control over these genes hampers clinical diagnosis and serves as a disincentive for research because Myriad not only has the right to enforce its patents against other entities but also has the rights to future mutations discovered on the BRCA2 gene. The gene patents are also illegal under patent law because genes are "products of nature."

"Patents are meant to protect inventions, not things that exist in nature like genes in the human body," said Chris Hansen, a staff attorney with the ACLU. "Genes isolated from the human body are no more patentable than gold extracted from a mountain."

Many women with a history of breast and ovarian cancer in their families opt to undergo genetic testing to determine if they have the mutations on their BRCA genes that put them at increased risk for these diseases. This information is critical in helping these women decide on a plan of treatment or prevention, including increased surveillance or preventive mastectomies or ovary removal. However, the fact that Myriad can exclude others from providing this testing has several negative consequences for patients: many women cannot afford the more than $3,000 Myriad charges for the test; patients cannot get second opinions on their test results; and patients whose tests come back with inconclusive results do not have the option to seek additional testing elsewhere.

"Women whose doctors recommend genetic testing should be able to find out whether they have the gene mutations linked to breast and ovarian cancer so that they are able to make choices that could save their lives, and these patents interfere with their ability to do so," said Lenora Lapidus, Director of the ACLU Women's Rights Project.

"The patents on the BRCA genes block women's access to medical information necessary for making vital health care decisions, impeding their control over their own bodies," said Sandra Park, staff attorney with the ACLU Women's Rights Project.

Because the ACLU's lawsuit challenges the whole notion of gene patenting, it could have far reaching effects beyond the patents on the BRCA genes. Approximately 20 percent of all human genes are patented, including genes associated with Alzheimer's disease, muscular dystrophy, colon cancer, asthma and many other illnesses.

"Scientific research and testing have been delayed, limited or even shut down as a result of gene patents, stifling the development of new diagnostics and treatments," said Tania Simoncelli, ACLU science advisor. "The government should be encouraging scientific innovation, not hindering it."

"Patenting human genes is counter to common sense, patent law and the Constitution," said Daniel B. Ravicher, Executive Director of PUBPAT and co-counsel in the lawsuit. "Genes are identified, not invented, and patenting genetic sequences is like patenting blood, air or e=mc2."

If Myriad's BRCA genes patents were invalidated, the clinicians, pathologists and researchers represented by the ACLU would be able to engage freely in research, testing and clinical practice involving the BRCA1 and BRCA2 genes, and the patients would be able to obtain second opinions on test results and have access to genetic testing services from multiple, and perhaps more affordable, sources.

In addition to several individual women patients, plaintiffs in the case include:

Association for Molecular Pathology

American College of Medical Genetics

American Society for Clinical Pathology

College of American Pathologists

Haig Kazazian, MD, Professor in the Department of Genetics at the University of Pennsylvania School of Medicine

Arupa Ganguly, PhD, Associate Professor in the Department of Genetics at the Hospital of the University of Pennsylvania

Wendy Chung, MD, PhD, Director of Clinical Genetics at Columbia University

Harry Ostrer, MD, Professor of Pediatrics, Pathology and Medicine and Director of the Human Genetics Program at New York University School of Medicine

David Ledbetter, PhD, Professor of Human Genetics and Director of the Division of Medical Genetics at the Emory University School of Medicine

Stephen Warren, PhD, William Patterson Timmie Professor of Human Genetics and Chair of the Department of Human Genetics at Emory University

Ellen Matloff, M.S., genetic counselor

Elsa Reich, M.S., Professor in the Department of Pediatrics (Human Genetics Program) at New York University

Breast Cancer Action

Boston Women's Health Book Collective (Our Bodies Ourselves)

Attorneys on the case, Association for Molecular Pathology, et al. v. U.S. Patent and Trademark Office, et al., include Hansen and Aden Fine of the ACLU First Amendment Working Group; Lapidus and Park of the ACLU Women's Rights Project; and Ravicher of PUBPAT. Simoncelli, the ACLU's science advisor, provides expert guidance on the case.

Plaintiff and supporter statements and a copy of the complaint can be found online at: www.aclu.org/brca


SOURCE American Civil Liberties Union

Breast Cancer Action Sues to End Gene Patenting

Lawsuit Seeks Increased Access to Information for Breast Cancer Patients

SAN FRANCISCO, May 12 /PRNewswire-USNewswire/ -- Breast Cancer Action (BCA) is challenging the legality of patenting human "breast cancer genes." BCA is joining the American Civil Liberties Union in suing Myriad Genetics (a private biotechnology company based in Utah), that currently holds the patent on the two human genes known as BRCA1 and BRCA2.

The BRCA1 and BRCA2 genes are present in every human. However, people with certain genetic mutations on these genes are at an increased risk of developing breast and ovarian cancer. Myriad holds exclusive rights to these genes and their mutations and to the research performed on them. Testing for the BRCA1 and BRCA2 mutations can only be performed at Myriad labs and currently costs over $3,000.

Since 1998, when BRCA1 & 2 were first patented, BCA has maintained that the patenting of human genes interferes with patients' access to genetic testing and medical care.

"The time has finally arrived for the courts to decide who owns our genes," said Barbara Brenner, executive director of Breast Cancer Action.

When one company controls all the testing, less information and resources are available to both patients and researchers. Women unable to afford the $3,000 fee are prevented from access to the test; women seeking second opinions on any results they might receive have nowhere to go; and women of African, Hispanic, or Asian decent are at a significant disadvantage because they disproportionately receive ambiguous results when tested by Myriad.

"There are so many injustices and inequities in breast cancer," Brenner said. "The time has come to address them in all their forms -- as they affect genetic risk, as well as social, political, and economic realities. This case is an important first step."

BCA joins this litigation in hopes that it will open doors to better research and information, and ultimately better health care for women regardless of their economic situation or their racial background.

The case, Association for Molecular Pathology, et al. v. U.S. Patent and Trademark Office, et al., is filed in the U.S District Court for the Southern District of New York.

Breast Cancer Action (www.bcaction.org) -- is a non-profit education and advocacy organization that does not accept funding from pharmaceutical companies or any other organizations that profit from or contribute to the breast cancer epidemic.


SOURCE Breast Cancer Action

Blue Cross Blue Shield of Michigan Plans to Offer Customer Groups Ability to Purchase Coverage of Autism Treatment Programs that Provide Intensive Ear

DETROIT, May 11 /PRNewswire/ --Blue Cross Blue Shield of Michigan today announced it plans to offer its customer groups the ability to purchase coverage for autism treatment programs that provide intensive

early intervention. The new benefit option covers children aged two to five years old who use a treatment called Applied Behavioral Analysis (ABA). The new benefit option is subject to approval by the Michigan

Office of Financial and Insurance Regulation.

The benefit coverage, which consists of up to 60 treatment sessions (usually 12 weeks) can be used once per child, will be available for purchase by customer groups that already have outpatient mental health coverage. The Blues plan to begin offering the coverage July 1, pending regulatory approval. Many Michigan insurers do not currently provide customer groups with the ability to purchase the benefit option.

"We saw a need in the community and moved to find a way to address it," said Thomas Simmer, M.D., Blues senior vice president and chief medical officer. "We developed this coverage option as part of our commitment to improving the health and wellness of all Michigan children and families."

The change will not in any way affect current BCBSM medical coverage that has been available to children with autism. BCBSM currently pays for some services for children with autism including an initial exam and evaluation for speech therapy.

"This is a reasonable new offering which does not unduly create a price impact on customer groups that would affect their ability to continue to provide health care coverage to their employees," Simmer said.

BCBSM customer groups can contact their agent or BCBSM sales representative for further information once the coverage option receives regulatory approval.

Blue Cross Blue Shield of Michigan, a nonprofit organization, provides and administers health benefits to 4.7 million members residing in Michigan in addition to members of Michigan-headquartered groups who reside outside the state. The company offers a broad variety of plans including: Traditional Blue Cross Blue Shield; Blue Preferred, Community Blue and Healthy Blue Incentives PPOs; Blue Care Network HMO; BCN Healthy Blue Living; Flexible Blue plans compatible with health savings accounts;

Medicare Advantage; Part D Prescription Drug plans, and MyBlue products in the under-age-65 individual market. BCBSM also offers dental, vision and hearing plans. Blue Cross Blue Shield of Michigan and Blue

Care Network are nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association. For more company information, visit bcbsm.com


SOURCE Blue Cross Blue Shield of Michigan

Salty Chicken Doesn't Fly: New Survey Reveals Shoppers Feel Deceived By 'Natural' Labeling of Saltwater-Injected Poultry

Foster Farms maintains commitment to 100% Natural and launches new consumer awareness campaign exploring economic and health impact of 'plumped' chicken

LIVINGSTON, Calif., May 11 /PRNewswire/ -- Amidst an increasing national focus on sodium as a critical health issue, West Coast poultry producer Foster Farms today launches a comprehensive consumer campaign to raise awareness of saltwater-injected or "plumped" chicken. "Plumping" -- or the injecting -- of fresh, raw chicken with saltwater is a practice employed by many chicken companies which costs consumers money and contributes to serious health issues. Under current USDA labeling laws, brands that plump their poultry may still label their chicken as "100% Natural" or "All-Natural." According to a new survey released today, consumers are largely unaware of plumping and would prefer that only non-injected chicken be labeled as "All-Natural."

"Our survey found that most consumers have no idea that the fresh, raw chicken they purchase intending to season or marinate themselves can contain such high levels of salt," said Ira Brill, Director of Marketing for Foster Farms. "At a time when consumers are paying attention to their health and their budget, this deserves attention. Many poultry brands contend that injected poultry yields juicier, more flavorful meat, but our survey demonstrates consumers want to know what they're paying for. Foster Farms' 100% Natural, fresh chicken line is never plumped."

Today, Foster Farms publicly releases the results of a new survey conducted in March indicating that the majority of consumers (63.1%) are largely unaware of the hidden salt in many poultry brands and felt deceived after learning about it. Among the survey findings(1):

Despite the fact that 71.3% of consumers try to watch their sodium intake at least some of the time, many consumers are still unaware of some of the "fine print" in product labels, even for USDA-labeled "100% Natural," minimally-processed foods like chicken.

85.9% of consumers surveyed did not realize that a serving of some brands' fresh, raw chicken could contain more salt per serving than a large order of french fries. (Some brands of plumped chicken can contain 440 mg of sodium, versus 350 mg of sodium in a large order of french fries from a national fast food chain.)

74.5% of consumers believe fresh chicken labeled as "natural" should contain no additives or preservatives; 82.4% believe that fresh chicken carrying the "natural" label should not be injected with saltwater.

Upon learning that the saltwater in injected chicken could cost them nearly $1.50 per package(2), 69.2% of consumers felt deceived and 37.2% felt angry.

After learning about "plumping," 70.7% will change the way they shop for fresh chicken: 85.4% will read nutrition labels and avoid saltwater-injected chicken, while 71.7% percent vowed to warn a friend.

Research has shown that high sodium intake is linked to many diseases, including high blood pressure and heart disease(3). A close examination of some raw poultry nutrition labels reveals that a four-ounce serving of plumped chicken could contain as much as 440 mg of sodium, more than 700% more than truly natural chicken(4). Based on the Center for Disease Control's new dietary guidelines of 1500 mg per day or less(5) of sodium, eating just one single serving of some brands' poultry could add up to nearly a third of their recommended daily intake. From an economic standpoint, it also means that a family of four could spend more than $150 annually on saltwater alone(6).

"Today's families are looking for ways to get higher value and quality in the products they buy," said Brill. "In our 70-year history, Foster Farms has never injected our fresh, raw chicken labeled "100% Natural" with saltwater or any other additives and we will maintain this commitment to consumers. We've launched a multifaceted communications campaign to inform consumers about this common practice and provide them with new information to help them make better choices for their families. As a family-owned company, Foster Farms remains committed to providing consumers with products that meet their value and quality needs."

Foster Farms' "SAY NO TO PLUMPING" public information campaign includes online and traditional media elements including television advertising featuring the Foster Imposters (available online at www.fosterfarms.com). Unique to this campaign will be the company's participation in several high-profile events during the summer, where the brand will utilize street teams to spread the word about plumping with entertaining, compelling visuals. Foster Farms today launches a new online resource (www.saynotoplumping.com) where consumers can learn more about plumping and take action. The Foster Farms web site, www.fosterfarms.com, features low-sodium recipes, as well as shopping and eating tips from the company's nutritionist.

About Foster Farms

Since 1939, West Coast families have depended on Foster Farms for premium quality chicken and turkey products. Family-owned and operated, the company continues its legacy of excellence and commitment to quality established by its founders, Max and Verda Foster. Foster Farms specializes in fresh, all natural chicken and turkey products free of preservatives, additives or injected sodium enhancers. Based in California's Central Valley, with ranches also in the Pacific Northwest, the company's fresh chicken and turkey are produced in or near each region served. Foster Farms also produces delicious pre-marinated, ready-to-cook and fully cooked products that meet the quality and convenience needs of today's home cooks, retailers, warehouse clubs and foodservice customers. The company's commitment to excellence, honesty, quality, service, and people is a source of great pride, and, a longtime family tradition.

(1) Survey conducted by NSON Opinion Research (March 25, 2009 - April 2, 2009)

(2) Average price for boneless, skinless chicken breast is $3.33/lb (USDA) and up to 15% saltwater content by weight (Truthful Labeling Coalition); assuming average weight of a package of boneless, skinless chicken breasts is 3 lbs.

(3) UCSF "Coronary Artery Risk Development in Young Adults" study, March 2009.

(4) Foster Farms all-natural chicken breasts contain 67 mg of sodium per serving.

(5) Application of Lower Sodium Intake Recommendations to Adults --- United States, 1999--2006." Morbidity and Mortality Weekly Report. 27 March 2009.

(6) Average chicken consumption of 86 lbs/capita per year (USDA), average price for chicken breast at $3.33/lb (USDA) and up to 15% saltwater content by weight (Truthful Labeling Coalition).


SOURCE Foster Farms

President Obama, Sens. Kennedy & Baucus: Don't Buy Insurer 'Compromise' for Bush-era Plan to Gut State Consumer Protection Laws

WASHINGTON, May 11 /PRNewswire-USNewswire/ -- President Obama and U.S. Senate health care reform leaders must not override state consumer protection laws as suggested by health insurers last week, a move long-supported by insurers and the Bush Administration, said Consumer Watchdog in a letter to the president and senators. The hard-fought state laws enacted in nearly every state over the last 10 years were made necessary because Congress failed to enact Patients' Bill of Rights legislation.

Download Consumer Watchdog's letter here: http://www.ConsumerWatchdog.org/resources/ltrObamaKennedyBaucus.pdf

In the letter, Consumer Watchdog wrote:

"Federal regulation would be a boon to the industry, and has long been on the insurer's wish list because over the last decade almost every state has developed comprehensive patient protection laws that the insurers loathe.

"Insurers would like to take advantage of the moment of reform to eviscerate HMO Patients' Bill of Rights laws enacted in nearly every state and replace them with window-dressing federal rules that clear the way for the worst of the industry's practices."

The insurers' proposal was floated last Tuesday during the U.S. Senate Finance Committee by Karen Ignagni, CEO of the HMO and health insurer lobbying organization, America's Health Insurance Plans.

Consumer Watchdog called the insurers' proposal to kill the "public option" to private insurance coverage -- the reform that the industry hates most because of its value to consumers -- in exchange for new federal regulation of the industry a "false compromise."

In the letter, Consumer Watchdog wrote:

"Insurers are not conceding a thing. They are trying to turn the squelching of a beneficial public option into a double victory. They need all of you to play along with the charade in order to succeed in killing state patient protections as well as any government competitor. If you allow the insurance industry to prevail in this deception, the worst public fears about insurers' lobbying power in Washington will be proven correct."

A similar window-dressing federal regulation scheme was last brought forward in Senator Mike Enzi's (R-WY) bill, S. 1955, in 2006 which would have gutted HMO Patients' Bill of Rights laws and state common law access to courts by enacting President Bush's promised "Association Health Plans" expansion.

In the letter, Consumer Watchdog wrote:

"The Enzi bill was described in terms similar to those used by Ignagni ... to describe the federal 'standards' the insurers are willing to accept if the public option is taken off the table. Such 'harmonization' at the federal level of 'inconsistent' state laws will result in lowest common denominator regulations enforced from an impossible distance. Done the industry's desired way, an individual's state common law right to sue an insurer for even the most egregious misbehavior would also be erased."

Ignagni has also promised the industry's agreement to cover all Americans regardless of health, and not to charge more based on characteristics like health status or gender. Even these apparent concessions are far from hardships for the insurance industry, said Consumer Watchdog, in the context of their demand that all Americans be required to purchase their product.

** Read Consumer Watchdog's analysis of health insurer and drug company contributions to members of Congress. Senator Max Baucus (D-MT), chairman of the Senate Finance Committee, received more campaign contributions from the health insurance and pharmaceutical industries than any other current Democratic member of the House or Senate; the third highest contributions of any member of Congress. http://www.consumerwatchdog.org/patients/articles/?storyId=25468

** Read about a recent national poll that found that 65% of voters support giving every American of any age the option of joining Medicare; 60% are willing to pay more in payroll deductions for this option. http://www.consumerwatchdog.org/patients/articles/?storyId=24826

** Read about a national poll that found, by contrast, that only 16% of U.S. voters support, and 53% oppose, the insurance industries' plan of requiring every American to provide proof of private health insurance or face tax penalties or other fines. http://www.consumerwatchdog.org/patients/articles/?storyId=24110

Consumer Watchdog is a non-profit and non-partisan consumer advocacy organization with offices in Washington, D.C. and Santa Monica, California. For more information, visit us on the web at: http://www.ConsumerWatchdog.org.


SOURCE Consumer Watchdog

Secretary of Health Unveils Pennsylvania's New Portable Hospitals in Lehigh County

Hospitals Bolster State's Ability to Provide Medical Care During Disasters

OREFIELD, Pa., May 11 /PRNewswire-USNewswire/ -- Health Secretary Everette James today toured one of Pennsylvania's new portable hospitals and underscored the important role the systems will play in providing medical care to people who become ill or are injured during an emergency.

"The current 2009 Novel Influenza A (H1N1) outbreak is a timely reminder of how important it is to be prepared for public health emergencies," said Secretary James. "Portable hospitals are a key part of Pennsylvania's preparedness plans. These systems are flexible and can be used in areas that don't have hospitals, to support existing hospitals or as alternate care sites. And, because they can be operational within two hours of an emergency notification, enable us to quickly provide life-saving treatment."

The commonwealth received funding through the U.S. Department of Health and Human Services to purchase eight, 50-bed portable hospital systems that are packaged as tow-behind trailer systems. The hospitals are positioned in strategic locations across Pennsylvania.

The systems can function in a variety of capacities including triage, acute care and inpatient treatment. They can also be adapted for use as first aid stations, field hospitals, mass immunization or negative pressure isolation units for suspected infectious disease outbreaks.

The portable hospital tent systems can be inflated in five minutes by six trained people. Portable hospital staffing will be complemented by various volunteer organizations, including Emergency Medical Services Strike Teams, the State Emergency Registry of Volunteers in Pennsylvania or SERVPA, Medical Reserve Corps, and State Medical Response Teams.

"These systems would be of little use to us if we didn't have the volunteers in place to deploy them. We're grateful to them for taking on this important responsibility," James added.

The secretary made his remarks during a visit to the Eastern PA EMS Council, which hosted an all-day event to train volunteers to set up the hospitals. Additional May training events are scheduled in Montgomery, Allegheny and Centre counties.

The portable hospitals were purchased by the Office of Public Health Preparedness, which supports the Department of Health's efforts to prepare for, protect against, respond to, and recover from all acts of bioterrorism and other public health emergencies.

To learn more about health preparedness for Pennsylvanians, visit www.health.state.pa.us.

CONTACT: Stacy Kriedeman
(717) 787-1783


SOURCE Pennsylvania Department of Health

PhRMA Statement on Healthcare Reform Coalition

WASHINGTON, May 11 /PRNewswire-USNewswire/ -- Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Billy Tauzin issued the following statement today on a new healthcare reform coalition:

"PhRMA echoes the sentiment shared by President Obama and members of Congress that it is critical for all Americans to have access to high-quality, affordable healthcare coverage and services. With this central goal in mind, we are working with a variety of healthcare stakeholders to help ensure that a comprehensive healthcare reform bill gets to the White House this year.

"At the same time, we also recognize the importance of tackling the rate of health spending growth. As part of our outreach efforts, PhRMA recently joined forces with a coalition of other healthcare providers to develop consensus proposals aimed at creating a stronger, more stable healthcare system. We appreciate that all healthcare stakeholders will need to make changes that help lower the growth of overall health costs.

"Improving the population's health through public health initiatives, continuously improving quality of care, encouraging advances in medical treatments, encouraging delivery system changes that foster adherence to evidence-based best practices and therapies that reduce hospitalization and manage chronic disease more efficiently and effectively, and reducing under- and over-use of health care are key elements of the proposals to contain overall cost growth.

"PhRMA has long-supported public health initiatives to turn back the epidemic of chronic illness that is driving up health costs. Reducing the need for healthcare services because fewer Americans have costly conditions like diabetes and heart disease will pay both human and economic dividends. Today, treatment of chronic conditions accounts for nearly 75 percent of all healthcare spending. The President's call for a new focus on disease prevention will help transform our sick-care system into a 21st century healthcare system.

"A focus on improving quality of care and adherence to evidence-based best practices that manage chronic disease more efficiently can help improve the way medicines are used. Evidence shows that proper use of medicines can be one of the most effective ways to achieve better health outcomes and reduce costs. For example, non-adherence to prescribed medicines has been estimated to cost $100 billion-$300 billion annually, including costs from avoidable hospitalizations and nursing home admissions. Addressing this issue is part of a quality-focused way to lower healthcare cost growth.

"The coalition also recognizes the importance of encouraging medical innovation as a key element in both improving patient health and reducing the growth of overall health costs. Preserving policies that foster innovation -- both technological innovation and innovative approaches to service delivery -- is critical as we work to improve our healthcare system.

"For example, recent research has estimated that delaying the onset or slowing the progression of Alzheimer's disease by five years could save $126 billion by 2025 in Medicare and Medicaid costs. Without the development of new treatments, the number of cases of Alzheimer's -- and the related costs -- could increase dramatically. America's pharmaceutical research and biotechnology companies currently are working on more than 90 medicines for Alzheimer's, which could afflict 16 million people by 2050 unless a cure or preventative approach is found.

"PhRMA member companies also are answering President Obama's challenge to stamp out cancer in our lifetime. A record 861 medicines and vaccines are currently being researched and developed for cancer, compared to 124 in development for cancer in 1993, the last time Congress took on healthcare reform.

"Our commitment to innovation is unfaltering, as reflected in the record $65.2 billion invested in R&D by pharmaceutical research and biotechnology companies last year.

"Prescription medicines currently account for only 10 cents of every healthcare dollar spent in the U.S., according to the Centers for Medicare and Medicaid Services (CMS). This 10% share of health care costs is projected to continue through 2018.

"In its most recent analysis of national health spending, CMS reported that overall spending growth in 2007 was at its lowest rate since 1998 -- and attributed half of the decline to lower growth in prescription drug spending. In 2007, retail spending on prescription medicines grew by 4.9% -- well below the 6.1% growth rate for health care overall, CMS said. What's more, recent data from IMS Health show that spending on prescription medicines in the U.S. last year increased by 1.3% -- the lowest growth rate in 48 years.

"PhRMA looks forward to working with Administration, Congress, the coalition members and other healthcare stakeholders on ways to help get a comprehensive health reform package on the President's desk this year."

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $50.3 billion in 2008 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.2 billion in 2008.

PhRMA Internet Address: http://www.phrma.org

For information on stories of hope and survival, visit: http://sharingmiracles.com/

For information on how innovative medicines save lives, visit: http://www.innovation.org

For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org

For information on the danger of imported drugs, visit: http://www.buysafedrugs.info

For more information on public health emergencies, visit http://www.rxresponse.org/


SOURCE Pharmaceutical Research and Manufacturers of America

New Board Members Join American College of Medical Genetics Foundation (ACMGF): Distinguished Executive, Medical and Philanthropic Leaders Bring Addit

BETHESDA, Md., May 11 /PRNewswire-USNewswire/ -- The American College of Medical Genetics Foundation (ACMGF) has announced the election of four new directors, following its 2009 annual meeting. The board members are active participants in serving as advocates for the Foundation and for advancing the policies and programs of the ACMGF.

The incoming directors, who will serve a term of 5 years, are:

Wayne W. Grody, M.D., Ph.D., FACMG, Professor in the Departments of Pathology & Laboratory Medicine, Pediatrics, and Human Genetics at the UCLA School of Medicine. He is the founder and director of the Diagnostic Molecular Pathology Laboratory within the UCLA Medical Center. Dr. Grody is also an attending physician in the Department of Pediatrics. He has been one of the primary developers of quality assurance and ethical guidelines for DNA-based genetic testing for a large number of governmental and professional agencies including FDA, AMA, CAP, ACMG, ASHG, NCCLS, CDC, NIH-DOE Human Genome Project (ELSI program), and PSRGN. He did his undergraduate work at Johns Hopkins University, received his M.D. and Ph.D. at Baylor College of Medicine, and completed residency and fellowship training at UCLA. He is an ex-officio member of the Foundation Board as president-elect of the American College of Medical Genetics.

Richard A. King, M.D., Ph.D., FACMG, Associate Director of the Institute for Human Genetics at the University of Minnesota and Director of the Genetics Division, is a renowned geneticist and former Editor-in-Chief of the peer-reviewed journal, Genetics in Medicine. Dr. King graduated from Pennsylvania State University and Jefferson Medical College. He was an intern and resident, and completed the clinical component of a rheumatology fellowship in the University of Minnesota, Department of Medicine. Following two years at the Atomic Bomb Casualty Commission in Hiroshima, he returned to the University of Minnesota and obtained his Ph.D. in genetics in 1975.

Timothy T. Stenzel, M.D., Ph.D., FACMG, Chief Medical Officer and Vice President of Diagnostic Research and Development at Asuragen, Inc. Dr. Stenzel currently serves on the Strategic Planning Committee for the Association for Molecular Pathology. He graduated with honors in chemistry from Grinnell College and is a graduate of the Duke University Medical Scientist Training Program where he studied the molecular biology of DNA replication and received his M.D./Ph.D. His residency training in pathology, a NIH-funded genetics fellowship, and his fellowship in Clinical Molecular Genetics occurred at Duke as well. He is a member of the following national professional organizations: ACMG, AMA, AMP, and CAP.

Karen O'Connor Urban, is a community advocate and volunteer who serves as a member of the Board of Directors of the American Bank, as well as a number of not-for-profit organizations. She is an active fundraiser whose leadership has resulted in many successful annual and capital campaigns. Her extensive background in volunteer service has benefited a diverse array of charitable organizations which span the visual and performing arts to universities, health and hospitals. These include, in part, Texas A&M University at Corpus Christi, Christus Spohn Health System Foundation, the Art Museum of the South and the South Texas Botanical Gardens and Nature Center.

"These four highly qualified leaders each bring a new perspective and talent to the ACMG Foundation and will help our Board to further the important work of the Foundation to ensure that genetic discoveries are translated into better health for all," said R. Rodney Howell, M.D., FACMG, president of the ACMGF. "The work of the Foundation is critical to the field of medical genetics today. We are indebted to our current and new leaders for their longstanding dedication to medical genetics and to the public's health. Each board member brings important new perspectives and I look forward to working with them to realize ACMGF's goals."

A complete list of the ACMGF Board of Directors is available at www.acmgfoundation.org.

The American College of Medical Genetics Foundation is currently comprised of 13 board members who are responsible for formulating long-term goals and advancing the policies and programs of the Foundation, and for fundraising to ensure the Foundation's annual and capital goals.


SOURCE American College of Medical Genetics Foundation

AHIP Statement on Cost Containment Framework

WASHINGTON, May 11 /PRNewswire-USNewswire/ -- Karen Ignagni, President and CEO of America's Health Insurance Plans, issued the following statement today on the cost containment framework presented to President Obama:

"Health plans are honored to join with leading stakeholders to help advance a framework for cost containment, which is essential to make the system more affordable for working families and purchasers and preserve the competitiveness of our country. We strongly believe that all Americans must have access to affordable, high-quality health care coverage. We also agree with others that universal coverage will not be sustainable, and that Medicare and Medicaid will not remain solvent, unless the nation addresses the cost issue head on.

"As the nation pursues health care reform, stakeholders have a responsibility to offer solutions. The health plan community embraces this responsibility and welcomes this challenge.

"Our community is proud of the contributions health plans make to quality, affordable health care in America. Health plans are: leading on care coordination, helping patients and doctors manage chronic conditions, offering benefit plans that help keep health care affordable for working families and small employers, rewarding high-quality medical care, and helping patients stay healthy through prevention and wellness initiatives.

"We are committed to reform, to innovation, and to challenging old assumptions. We are committed to ensuring that no one in America falls through the cracks of our health care system. We are committed to providing efficient, cost-effective service to individuals, families, and employers. We are committed to streamlining health care administration so physicians can focus on treating their patients.

"Our message is clear: the private sector will do its part to bend the health care cost curve. We are initiating the reforms needed to make health care more affordable for families and employers and to put our health care system on a sustainable path.

"We look forward to working with the other stakeholders, the Administration, and members of Congress from both parties to advance this framework and ensure that all Americans have access to affordable health care coverage."

America's Health Insurance Plans -- Providing Health Benefits to More Than 200 Million Americans


SOURCE America's Health Insurance Plans

Custom Briefings Launches E-Newsletter For the Academy of Managed Care Pharmacy

RESTON, Va., May 8 /PRNewswire-USNewswire/ -- The Custom Briefings network of Bulletin News, LLC, announced today the launch of AMCP eNews, a daily e-newsletter produced solely for the members of the Academy of Managed Care Pharmacy (AMCP). AMCP eNews is emailed Monday through Friday to nearly 6,000 AMCP members--pharmacists and health professionals.

AMCP eNews' content is drawn from each day's most important news as reported by top media outlets nationwide. Arriving before 8:00 A.M., this member benefit provides a thorough executive summary of the most relevant medical news specific to pharmacists working in the managed care environment.

Judith Cahill, the executive director of the Academy, reports that member feedback on AMCP's highly tailored news briefs from Custom Briefings has been extremely positive. "We gave Custom Briefings a huge challenge to identify the news and information that would appeal to our diverse membership base, and they delivered a high-quality product that exceeded every expectation," she said. "We're giving our members valued news content that they can really use, and we're confident this new benefit of membership will help us attract and retain members."

Paul Roellig, CEO of Bulletin News said, "Our mutual goal is to make AMCP eNews the most efficient and relevant daily read for managed care pharmacists."

AMCP eNews joins a network of medical briefings that reach over 450,000 medical professionals daily. With an overall daily audience of over one million, the Custom Briefings network of e-newsletters provides highly-targeted vehicles for advertisers to reach top professionals in the fields of engineering, education, law, business, and healthcare.

About Bulletin News

Bulletin News, LLC, is a quiet leader in delivering customized business and political intelligence to top-level corporate and government decision makers. Founded in 1990 as a pioneer in the electronic publishing industry, privately-held Bulletin News has been profitable each year since.

The Custom Briefings network of e-newsletters delivers daily, executive-level news briefings to influential and affluent members of leading professional associations. Briefings are prepared overnight and published by 8:00 A.M. daily, analyzing content from over 10,000 sources. The influential audience is comprised of physicians, attorneys, CEOs, government executives, and educators--all professionals at the tops of their fields and with notable purchasing influence. Briefings are advertiser-supported.

For more information on Custom Briefings, visit CustomBriefings.com


SOURCE Bulletin News, LLC

X-Rays Help Predict Permanent Bone Damage From Bisphosphonates

CHICAGO, May 7 /PRNewswire-USNewswire/ -- Breast cancer patients, individuals at risk for osteoporosis and those undergoing certain types of bone cancer therapies often take drugs containing bisphosphonates. These drugs have been found to place people at risk for developing osteonecrosis of the jaws (a rotting of the jaw bones). Dentists, as well as oncologists, are now using X-rays to detect "ghost sockets" in patients that take these drugs and when these sockets are found, it signals that the jawbone is not healing the right way. Early detection of these ghost sockets can help the patient avoid permanent damage to their jawbone, according to an article in the March/April 2009 issue of General Dentistry, the Academy of General Dentistry's (AGD) clinical, peer-reviewed journal.

A ghost socket occurs when the jawbone is not healing and repairing itself the right way. "The good news is that even though these ghost sockets may occur, by using radiographic techniques we can see that the soft tissue above these sockets can still heal," according to Kishore Shetty, DDS, MS, MRCS, lead author of the report. Dr. Shetty states these findings are important news to learn about because early prevention and detection can halt permanent damage from happening to a patient's jawbone.

In 2006, about 191 million prescriptions of oral bisphosphonates worldwide were written. The National Osteoporosis Foundation estimates that nearly 44 million people in the United States are at risk for developing osteoporosis. Currently, approximately 10 million Americans suffer from the disease.

Bisphosphonates are a family of drugs used to prevent and treat osteoporosis, multiple myeloma, Paget's disease (bone cancers), and bone metastasis from other cancers. These drugs can bond to bone surfaces and prevent osteoclasts (cells that break down bone) from doing their job. Other cells are still working trying to form bone, but it may turn out to be less healthy bone, leading to the ghost-like appearance on X-rays.

"Healthy bones can easily regenerate," says Dr. Shetty. "But, because jawbones have rapid cell turnover, they can fail to heal properly in patients taking any of the bisphosphonate drugs. It's very important for patients to know about complications from dental surgery or extractions. Since these drugs linger in the bone indefinitely, they may upset the cell balance in how the jaws regenerate and remove unhealthy bone."

According to AGD spokesperson Carolyn Taggart-Burns, DDS, FAGD, patients who are taking bisphosphonates should inform their dentist to prevent complications from dental surgical procedures.

"Widespread use of bisphosphonates to prevent or treat early osteoporosis in relatively young women and the likelihood of long-term use is a cause for concern," says Dr. Taggart-Burns.

Drs. Shetty and Taggart-Burns agree that, "how bisphosphonates interfere with healing after dental surgery is still unclear and further research will be needed. It is imperative that the public understands there is no present treatment or cure for this problem."


SOURCE Academy of General Dentistry

Press Ganey Supports National Hospital Week

Health Care Improvement Firm Recognizes Efforts in Patient Satisfaction

SOUTH BEND, Ind., May 11 /PRNewswire/ -- In honor of National Hospital Week, Press Ganey Associates, Inc., is proud to recognize all of its hospital partners for their daily dedication to improving the quality of care they provide.

"The doctors, nurses, and staff at our partner hospitals are consistently striving to improve quality, and they deserve to be commended," said Rick Siegrist, Press Ganey's president and CEO. "We partner with nearly 50 percent of the nation's hospitals to help them improve quality across their organizations, and we're constantly impressed with the efforts they put forth to make their hospitals the best they can be."

Press Ganey data show that patients are noticing, as satisfaction with the care and service being provided by Press Ganey partner hospitals has been rising. Most recently, a Press Ganey analysis of 1.5 million patient responses at 1,158 hospitals across the country in 2008 found the most significant increase in inpatient satisfaction scores in the quarter century that the company has been tracking such data. Press Ganey partner hospitals are making similar improvements in other aspects of quality--from increasing employee and physician engagement to improvements in patient safety and clinical quality.

To honor its top performing hospital clients, Press Ganey presents several awards at its annual National Client Conference. Press Ganey client hospitals are also honored with the industry's top awards throughout the year including:

2008 H&HN Most Wired Hospitals -- 76 of 100 are Press Ganey clients.

2008 US News & World Report America's Best Hospitals -- 64% of the awards were given to Press Ganey clients and 14 of the 19 Honor Roll recipients are Press Ganey clients.

Magnet Hospitals -- 69% of all Magnet Hospitals are Press Ganey clients.

2008 Thomson Healthcare's list of Top 100 Hospitals - 61 of 100 are Press Ganey clients.

Malcolm Baldrige National Quality Award - Eight out of the nine Malcolm Baldrige National Quality Award winners are Press Ganey clients.

"At a time when hospitals are under intense scrutiny to provide the best possible care, and when competition is heating up due to public reporting, it's imperative that hospitals are recognized for all the work they do to help patients," Siegrist said.

National Hospital Week

Sponsored by the AHA, National Hospital Week began in 1921 and, over the decades, has helped revolutionize the public view of hospitals. The health care industry employs more than 14 million workers throughout the U.S.

American Hospital Association

The AHA is a not-for-profit association of health care provider organizations and individuals that are committed to the improvement of health in their communities. The AHA is the national advocate for its members, which includes more than 5,000 member hospitals, health systems and other health care organizations, and 38,000 individual members. Founded in 1898, the AHA provides education for health care leaders and is a source of information on health care issues and trends.

Press Ganey Associates, Inc.

For more than 20 years, Press Ganey has been committed to providing insight that allows health care organizations to improve the quality of care they provide while improving their bottom-line results. The company offers the largest comparative customer feedback databases, actionable data, solution resources, and unparalleled consulting and customer service. Press Ganey currently partners with more than 7,000 health care facilities to measure and improve the quality of their care. For more information, visit www.pressganey.com.


SOURCE Press Ganey Associates, Inc.

BANDIT Questions the H1N1 Media Craze, and Tries to Give AIDS Its Sexy Back!

What's flu got to do, got to do with AIDS?

COPENHAGEN, May 8 /PRNewswire/ -- Swine flu aka H1N1 (and money) is all we seem to hear about in the news at the moment. Mixed messages on the severity of the so called pandemic. The big problems in Mexico, USA spreading fear amongst its people - where it is in Europe - and where should you go or not go, breathe or not breathe.

But more than a disease, it's now also a fashion illness... yes you read right. The good people of Mexico City have by now gotten so used to wearing surgical masks, a "trend" that the bird flu started a few years ago.

But that just makes the important question we ask seem even bigger! Did the media forget about AIDS? We all know falling in love with something new is very easy, most of us do constantly. But AIDS hasn't been media "sexy" for a long time now, what needs to happen? Africa imploding? Or need we look no further than USA?

Read the full blog post here: http://thisisbandit.com/?p=3291

Contact BANDIT here: bandit@thisisbandit.com

The BANDIT Blog: http://www.thisisbandit.com/?page_id=216


SOURCE BANDIT

Anthem Blue Cross to Support Members and Communities Impacted by Santa Barbara Fires

WOODLAND HILLS, Calif., May 8 /PRNewswire/ -- Anthem Blue Cross announced today that it is making a $10,000 donation to the American Red Cross to bring aid to Californians in the Santa Barbara area who have been impacted by the recent fire that continues to burn and threaten homes.

In addition, Anthem announced today several additional actions it is taking to assist members affected by the fire.

Prescriptions: Anthem Blue Cross members may have left their homes without their prescriptions or they may have been damaged during this disaster. While many prescriptions are refillable on a 30-day cycle, for any prescription ordered from May 6 through May 15, 2009, Anthem is providing a one-time 30-day supply override on affected members' prescriptions. This will enable members to refill their prescriptions now, even if it is not due at this time.

For members in the impacted communities who participate in the Anthem mail order prescription program, Anthem is checking in advance of shipping, that the member will be able to receive his/her mail order. Anthem will re-route orders as needed at no charge to impacted members. Members who cannot get to their homes to receive their mail prescriptions but feel the medication was sent prior to the fires occurring are encouraged to contact their local post office for details of where mail for their area is being deposited at this time.

Member Medical Claims: There may be medical facilities that have been impacted by this disaster. In addition, members may be staying in temporary shelters or with friends and relatives who are located far from their homes. During emergency medical situations, Anthem always encourages members to seek care at the nearest medical facility. Also, understanding that members may not have access to their usual provider for non-emergency care, during this period of member dislocation, Anthem will pay all claims for those in the impacted areas at the higher in-network reimbursement levels, even if the facility is not in the Anthem Blue Cross network.

Anthem Blue Cross - California Employee Assistance Program (EAP):

Free Counseling Services: The Anthem Blue Cross Employee Assistance Program is offering free counseling services for the next thirty days, to all Anthem members throughout the impacted area. Services include access to a resource rich website and telephonic consultations with professional counselors. The EAP program is available 24 hours a day by calling toll-free 1-800-765-4446 or members may visit our website at www.anthemeap.com and use the password "fires."

Commenting on these actions, Leslie A. Margolin, president of Anthem Blue Cross said, "We are all saddened as we watch media reports of the beautiful Santa Barbara area being ravaged by these intense fires. The health and safety of our members, our associates and our communities is always our primary concern. At Anthem Blue Cross, we want to do all we can to help."

Members with questions pertaining to their Anthem Blue Cross coverage can contact customer service through the number listed on the back of their membership card.

Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Anthem Blue Cross Life and Health Insurance Company are independent licensees of the Blue Cross Association. (R) ANTHEM is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross names and symbols are registered marks of the Blue Cross Association.


SOURCE Anthem Blue Cross

Diabetes Experts Issue New Recommendations for Inpatient Glycemic Control - Call for Systemic Changes in Hospitals Nationwide

American Association of Clinical Endocrinologists logo. (PRNewsFoto/American Association of Clinical Endocrinologists)

JACKSONVILLE, FL UNITED STATES

JACKSONVILLE, Fla. and ALEXANDRIA, Va., May 8 /PRNewswire-USNewswire/ -- New recommendations released today by a consensus group of the American Association of Clinical Endocrinologists (AACE) and the American Diabetes Association (ADA) are calling for major changes in the way health care professionals treat hospitalized patients with high blood glucose (sugar) levels. The authors recommend revised glucose targets of 140-180 mg/dL in the ICU setting, and between 100-180 mg/dL for most patients admitted to general medical-surgical wards.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090324/DC88061LOGO-b)

The recommendations, which were published online today and will appear in the June issues of Endocrine Practice (Link here) and Diabetes Care (Link here), come at a time when attempts to intensively manage glucose targets in the ICU setting have shown inconsistent results in patient outcomes. Several recent randomized controlled clinical trials in critically ill patients in ICUs with diabetes or elevated blood glucose levels have failed to show a significant improvement in mortality with intensive insulin therapy to achieve near normal glucose levels. Moreover, a large newly-published randomized controlled trial showed an increase in mortality risk associated with intensive control of glycemia targeting blood glucose of 80-110 mg/dL. These outcomes have raised concerns regarding specific glycemic targets and the means for achieving them in both critically and non-critically ill patients.

Recognizing the importance of glycemic control across the continuum of care, experts from AACE and ADA were invited to develop an updated consensus statement on inpatient glycemic management.

After a thorough analysis of all the published trials, the authors believe that patients with elevations in blood glucose should continue to be carefully treated, but to less intensive blood glucose targets than were previously suggested. The authors recommend revised glucose targets of 140-180 mg/dL for critically ill patients in ICU settings.

"We are witnessing an evolution in the management of hyperglycemia in inpatient settings," Dr. Etie S. Moghissi, AACE Chair of the Inpatient Glycemic Control Consensus Panel said. "Despite some inconsistencies in the clinical trial results, it would be a serious error to conclude that judicious control of glycemia in hospitalized patients is not warranted."

The complexity of inpatient glycemic management necessitates a system approach that facilitates safe practices that reduce the risk for errors and episodes of severe hypoglycemia. The consensus group recommends a multidisciplinary approach for care from admission to discharge from the hospital.

"The responsibility for management of hyperglycemia shifts from the health care team to the patient following hospital discharge," said Dr. Mary Korytkowski, ADA Chair of the Inpatient Glycemic Control Consensus Panel. "It is therefore important that patients receive the information necessary to safely manage this aspect of their care once they are at home."

Members from the AACE/ADA Inpatient Glycemic Control Task Force will discuss the new AACE/ADA consensus statement highlighting the relationship between glycemic control and clinical outcomes during special symposium scheduled on Friday 7:15 p.m., May 15, 2009 at the AACE 18th Annual Meeting & Clinical Congress in Houston, Texas.

About the American Association of Clinical Endocrinologists (AACE)

AACE is a professional medical organization with more than 6,200 members in the United States and 92 other countries. Founded in 1991, AACE is dedicated to the optimal care of patients with endocrine problems. AACE initiatives inform the public about endocrine disorders. AACE also conducts continuing education programs for clinical endocrinologists, physicians whose advanced, specialized training enables them to be experts in the care of endocrine disease such as diabetes, thyroid disorders, growth hormone deficiency, osteoporosis, cholesterol disorders, hypertension and obesity. For more information, please call the AACE office at 904-353-7878 or visit www.aace.com.

About the American Diabetes Association (ADA)

The American Diabetes Association is leading the fight against the deadly consequences of diabetes and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.


SOURCE American Association of Clinical Endocrinologists; American Diabetes Association

One Step Closer: Novel Opioid Receptor Compound in Phase I Clinical Trials

TROY, N.Y., May 8 /PRNewswire-USNewswire/ -- For more than 10 years, Mark Wentland, professor of chemistry and chemical biology at Rensselaer Polytechnic Institute, led a Rensselaer team in the discovery of a family of novel opioid receptor compounds with the potential to treat nervous system disorders and addiction. The family of compounds was licensed to Alkermes Inc., and the company identified a lead product candidate from the library. Clinical trials with the candidate, known as ALKS 33, began in December 2008.

Wentland said the "eureka moment" occurred with the realization that an opioid drug that his group discovered had triggered significant, long-acting activity in the targeted area. This breakthrough held unusual promise for treating reward disorders and a number of diseases because of its long-lasting effect in animal tests.

"The broad goal of a medicinal chemist is to discover a drug that gets widespread use to treat human disease with an unmet therapeutic need," said Wentland, who performs both basic and applied research. With ALKS 33 now in clinical development, the team is one very important step closer to realizing that goal. "Medicinal chemistry, foremost among traditional approaches to drug discovery and development, retains its value in a high-tech world," noted Wentland, who joined Rensselaer from the pharmaceutical industry in 1994.

"This is a wonderful example of progress under The Rensselaer Plan in the areas of biotechnology and technology transfer that demonstrates Rensselaer's unique strength in its ability to translate scientific discoveries into practical application," said Ron Kudla, executive director of the Office of Intellectual Property, Technology Transfer and New Ventures at Rensselaer. "Most importantly, this is a testament to the fact that if the results of your research are going to have an impact on the public, it has to be patented in order to be commercialized."

Therapeutic opportunity

In September 2006, Rensselaer signed a licensing agreement granting Massachusetts-based biotechnology company Alkermes exclusive rights to a library of compounds discovered by Wentland and his team.

According to Alkermes, the library represents an opportunity for the company to develop numerous products as important therapeutics for the treatment of a broad range of diseases and medical conditions, including addiction, pain, and other nervous system disorders. Alkermes screened the library of compounds from Rensselaer and is responsible for the continued research and development of any resulting product candidates.

This year, Alkermes held its Research and Development Day meeting for analysts and investors in Cambridge, Mass., on April 7 and provided an overview of its product candidates, including ALKS 33. Preclinical studies of ALKS 33 suggested that it was not readily metabolized by the liver, a unique advantage over existing oral therapies for addiction. According to the company, initiation of the phase 1 trial of ALKS 33 was based on the compound's potential for a superior pharmacokinetic profile and the compound's pharmacological properties relative to other commercial opioid antagonists.

According to Alkermes, data from the phase 1 study of ALKS 33 showed that the compound is absorbed rapidly into the bloodstream, and has a pharmacokinetic profile that could support once-daily dosing.

"This latest discovery is the result of an interdisciplinary collaboration between chemists and biologists," Wentland said. "In the process, we are working together to identify novel therapies to treat human diseases and find possible solutions that work. Most importantly, this discovery allows us to see the significant role that biotechnology plays in improving health, creating new materials for myriads of applications, and addressing some of the world's most challenging scientific problems. I am pleased to see this exciting technology move from the laboratory toward treating patients."

"There are few medications available to help patients struggling to overcome addictions, and new treatment options are desperately needed," said Elliot Ehrich, M.D., chief medical officer of Alkermes. "We believe that the addiction field will evolve in a similar way to other CNS markets, such as mental illnesses, where treatments include both oral and injectable medications. This flexible approach offers patients and doctors the option to build the most appropriate therapies into treatment programs and fit the needs of individual patients."

Linking discoveries of the lab and classroom to the marketplace

Historically, American research universities, responsible for so many groundbreaking discoveries and life-saving innovations, did not provide their professors a direct route to move their work to store shelves, medical offices, and industry. Promising discoveries were introduced in the scholarly press, in hopes of drawing bigger grant awards and perhaps the interest of a company willing to spend the money to convert concept into product. Researchers sometimes took their work off campus, establishing their own companies on the side.

But the Bayh-Dole Act passed in 1980 opened up new avenues by allowing universities to keep discoveries disclosed using federal grants instead of returning them to the government, often to languish. The law brought new incentives to commercialize discoveries, along with bragging rights and, in a few cases, big money. University discoveries -- in the United States, Canada, and abroad -- have had an impact on everything from health care (the pacemaker from the University of Minnesota, the CAT scan from Georgetown, laser cataract surgery from the University of California-Los Angeles) to better living at home (plexiglass from McGill University, a Kentucky bluegrass hybrid from Rutgers, and even television's V-Chip from Simon Fraser University), among others.

Founded in the 1990s, Rensselaer's Office of Technology Commercialization (OTC), affiliated with the Incubator Program and the Rensselaer Technology Park, helps the Institute protect intellectual property and forges relationships with industry to bring Rensselaer's discoveries to the marketplace. The OTC also contributes to the local economy by spinning off new companies that are based upon technology developed by university faculty, students, and researchers. Discoveries in nanotechnology, electronics, energy, biotechnology, and terahertz are all part of the Institute's expanding intellectual property portfolio and reflect Rensselaer's aggressive, expanding research initiative.

The initial research leading to Wentland's latest discovery was funded in 1999 through a $826,000 grant from the National Institutes of Health/National Institute on Drug Abuse (NIH-NIDA) in an effort to discover novel drugs to treat cocaine abuse. In 2002, Wentland's NIH grant was renewed for an additional $1.6 million, and he was awarded new funding from Albany Molecular Research Inc. for a postdoctoral associate position. In 2007, the NIH grant was renewed again for $1.25 million.

"My life's ambition has been to identify a compound that's actually helping people. That has been my entire focus for the last 39 years," Wentland said. He had a choice: Go the traditional route of publishing findings in a scientific journal and then seek additional research grants, or try for development and clinical trials through a licensing agreement with a pharmaceutical company. Given that therapeutics are largely developed by such companies, Wentland said the decision wasn't difficult. He began discussions with the OTC.

After six years of work, which included the investment in and securing a number of patent applications in the U.S. and overseas, in January 2007, Rensselaer announced a license agreement granting Alkermes rights to the patented and patent pending technologies. Soon after, the Institute began to receive payments for the licensing.

OTC success

With the establishment of the OTC, Rensselaer has staked its claim in the changing landscape of American research universities, where researchers are increasingly encouraged to protect their discoveries and hopefully effectively license them to industry for life-enhancing products. This year, through OTC's efforts, licensing revenues and patent reimbursements paid to the Institute are expected to be approximately $1,067,000, building upon a steady annual growth since 2002 when Rensselaer only generated $62,000.

Since 2000, more than 250 inventors have filed patent disclosures with the OTC. In addition, more than 110 patents have been issued and Rensselaer has over 45 active licenses and averages 12 to 15 new deals a year, according to Kudla.

And thanks to the OTC, Wentland is a step closer to his dream that serves as a promising next step for a medical advance he has been chasing for his entire drug discovery career. The license agreement also culminates years of research work by his team that includes more than 20 undergraduate, graduate and postdoctoral students in Rensselaer's Department of Chemistry and Chemical Biology, along with Jean Bidlack, professor of pharmacology and physiology at the University of Rochester, and members of her pharmacology group, and funding by the National Institutes of Health.

"I didn't do it myself," Wentland said. "With the OTC, it went very smoothly. In the last 39 years I have had many drugs enter the clinic and then fail. And now I'm here again with another chance and I'm absolutely proud of our entire team. The only way academic research collaboration can get a therapeutic into the clinic and approved for human use is to partner with a pharmaceutical company."

In the future, Wentland and this team will continue to work with Alkermes to develop the existing family of compounds, as well as identify back-up and/or second-generation drugs for possible application to other diseases.

This news release was issued on behalf of Newswise(TM). For more information, visit http://www.newswise.com.


SOURCE Rensselaer Polytechnic Institute

International Breast Milk Project Helps Mothers Worldwide

NEW YORK, May 8 /PRNewswire-USNewswire/ -- This Sunday, individuals all over the nation will be celebrating a very special holiday to honor the women who gave them life: their mothers. While people in the United States turn their attention toward their caregivers, the International Breast Milk Project (IBMP) hopes to inspire some to also think of mothers abroad.

The IBMP is an organization that helps mothers in the United States send their breast milk to infants in need, who have either lost their mothers or whose mothers are not able to breast feed due to HIV infection, untreated tuberculosis, serious illness, and/or severe anemia or malnourishment. Despite the fact that breast-fed infants have been proven to be healthier, IBMP is the only international organization to provide breast milk to infants in developing countries.

Specifically, the organization focuses on infants in South Africa, where it is estimated that 1.5 million children have lost their parents due to HIV/AIDS, and many more have mothers who are unable to breastfeed because they are ill. By the end of 2009, IBMP will have sent an estimated 262,655 ounces (7,767 liters or 2052 gallons) of healthy breast milk to infants in South Africa. That is equivalent to the amount of milk needed to feed 2,188 babies one bottle of milk a day for 30 days.

In 2007, the organization started with just one donor, the organization's Executive Director Jill Youse, and it is estimated that by the end of 2009 IBMP will have 1,750 donors nationwide. As it grew in size, the IBMP partnered with two organizations, Prolacta Bioscience, which covers most of the cost involved in milk collection, and Quick International Courier, responsible for transporting the milk to South Africa.

Youse explained the donor process to MediaGlobal: "Applications are completed online, blood work is done in the donor's home, and coolers are shipped directly to doorsteps, making the process seamless and easy for a mom with a new baby at home."

Once the milk has made it to South Africa, it is split three-ways and sent to partner organizations in Durban, Uitenhage and Cape Town. At its final destination, the milk is given free-of-charge to mothers in need.

For more information about International Breast Milk Project, email Jill Youse at jill@breastmilkproject.org and/or visit www.breastmilkproject.org.


SOURCE MediaGlobal News Service

Blue Cross and Blue Shield Funds Diabetes Education at Saints Mary and Elizabeth Medical Center

CHICAGO, May 8 /PRNewswire/ -- Saints Mary and Elizabeth Medical Center, 2233 W. Division St., Chicago, received a $65,000 grant from Blue Cross and Blue Shield of Illinois' Childhood Health and Wellness Initiative to fund the Medical Center's program for children at risk for obesity and diabetes. This is the first year the grant has been awarded.

Obesity is an epidemic in the United States. Since the 1970s, obesity has more than doubled for preschool-aged children and tripled for school-aged children. Today, nearly twice as many Hispanic children are overweight as compared to a decade ago.

The staff of Saints Mary and Elizabeth Medical Center's Childhood Awareness of Nutrition, Diabetes and Obesity (CAN DO) Program is working hard to combat this problem. An important facet of this program is that it targets children at a young age - where they can begin to make healthy choices that can positively impact their futures.

Since its inception, the CAN DO Program has reached more than 700 children and 550 parents. In addition to providing education about diabetes, diet and exercise, this bilingual program also checks cholesterol and glucose blood levels. Nurse educators identify children at risk of diabetes or pre-diabetes and alert their parents to the need for follow-up medical care. The program is conducted within schools located in the West Town, Logan Square and Humboldt Park neighborhoods. Children participating in the program attend classes during the school day, usually a total of 10 sessions.

"It is important to address obesity issues at an early age," said Gladys Aguirre, R.N., Manager of the Medical Center's Community Health Education Department. "Teaching healthy eating behaviors and exercise early in a child's life is important since what they experience as children contributes significantly to their habits as adults," she added.

Resurrection Health Care is a family of health care services providing advanced medical care and exceptional customer service with compassion and hope. Our hospitals, nursing homes, retirement communities, home health services, behavioral health programs and other services are located in many Chicagoland neighborhoods.

Resurrection Health Care is a not-for-profit Catholic organization sponsored by the Sisters of the Holy Family of Nazareth and the Sisters of the Resurrection.


SOURCE Resurrection Health Care

Phish Frontman Trey Anastasio Visits Capitol Hill to Support Drug Courts and Calls on Congress to Put a Drug Court Within Reach of Every American in N

ALEXANDRIA, Va., May 7 /PRNewswire-USNewswire/ -- Trey Anastasio, lead singer of the rock band Phish and proud Drug Court graduate, visited Capitol Hill on Wednesday, May 6, to participate in a day-long celebration marking the 20th Anniversary of Drug Court.

Mr. Anastasio joined the National Association of Drug Court Professionals (NADCP) in calling for a Drug Court within reach of every American in need. Mr. Anastasio recognized over fifteen members of Congress for their support of Drug Court in the Fiscal Year (FY) '09 appropriations process.

In the evening Mr. Anastasio attended an NADCP 20th Anniversary of Drug Court reception.

"We are here today to celebrate the 20th birthday of Drug Courts: Twenty years of restoring lives, reuniting families and protecting public safety," said NADCP CEO West Huddleston. "In the twenty years since the first Drug Court was founded, there has been more research published on the effects of Drug Courts than on virtually all other criminal justice programs combined. The scientific community has put Drug Courts under the microscope and concluded that Drug Courts significantly reduce drug abuse and crime and do so at less expense than any other justice strategy."

Drug Courts are the nation's most successful strategy for dealing with drug-addicted offenders. In the twenty years since the first Drug Court was initiated in Miami-Dade, Florida, Drug Courts have revolutionized the justice system and saved the lives of over 1 million people. There are currently 2,301 Drug Courts located in every state and U.S. territory. Drug Courts annually serve over 120,000 people and a recent study funded by the Department of Justice showed that Drug Courts save $3.36 for every $1.00 invested. This savings is due in part to the fact that 75% of Drug Court graduates are never arrested again. Still, Drug Courts serve only about 5% of the adult offender population estimated to be in need.

"I would like every community in America to have the option of sentencing drug offenders to Drug Court," said Mr. Anastasio, "When we imprison people for minor drug offences, we waste money -- and we waste lives. Prison will turn a person with a substance abuse problem into a lifetime felon. Drug Courts can change that same person into a sober citizen, someone who takes responsibility for their actions and who stands ready to help others."

Drug Courts strike the proper balance between the need to protect public safety and the need to improve public health, between the need for treatment and the need to hold people accountable for their actions. Drug Court participants receive intensive treatment and other services they need to change their lives, all while being regularly and randomly drug tested. In addition, Drug Court participants are required to appear frequently before a specially trained judge to review their progress. They are given rewards for doing well and sanctions for not living up to their obligations to society, themselves and their families.

To learn more about Drug Courts and how they restore lives, reunite families and protect public safety, please visit www.NADCP.org.

For AP photo: Trey Anastasio supports Drug Courts, saying "I would like every community in America to have the option of sentencing drug offenders to Drug Court." Click here:

http://news.search.yahoo.com/search/news?ei=UTF-8&p=trey+anastasio&fr=&c=images

For AP photo: Trey Anastasio looks on as NADCP CEO West Huddleston blows out twenty candles in honor of the 20th Anniversary of Drug Court. Click here:

http://news.search.yahoo.com/search/news?ei=UTF-8&p=trey+anastasio&fr=&c=images

For a complete listing of Members honored with the 2009 NADCP Congressional Leadership Award, click here:

http://ga4.org/drugcourts/DrugCourtFunding_clone.html


SOURCE National Association of Drug Court Professionals

Lucile Packard Children's Hospital at Stanford to Raise Its Voice for Kids in Health Care Reform Debate

Online Mobilization Campaign Urges Congress to Make Health Reform Work for Children

STANFORD, Calif., May 7 /PRNewswire/ -- Lucile Packard Children's Hospital at Stanford is joining the National Association of Children's Hospitals (N.A.C.H.) as it gears up to launch a grassroots mobilization campaign asking Congress and the Obama Administration to make health care reform work for children.

"Our hospital is extraordinarily proud to be taking part in Speak Now for Kids," said Christopher Dawes, president and chief executive officer at Packard Children's. "It is imperative that those of us who care for children, as parents, health care providers and advocates, speak up to ensure that the health care needs of children are included in the health care reform legislation currently being drafted in Washington. The time to act is now - our children are depending on us."

What: National Speak Now for Kids in Health Reform Campaign

The campaign utilizes interactive Web technology to allow advocates to register online as champions for children's health, express their priorities for children in health reform and upload testimonials about experiences with children's health care. Gathered data will be broken out by Congressional district and rolled up nationally to display advocates' opinions in a user friendly dash board.

Who: Lucile Packard Children's Hospital at Stanford and the National Association Children's Hospitals (N.A.C.H.)

National campaign partners also include the American Academy of Pediatrics, Children's Defense Fund, Children's Health Fund, First Focus and March of Dimes.

When: Ongoing throughout the month of May

Where: Visit www.SpeakNowforKids.org

Contact:
Julie Panna
202-491-5995
jpanna@adfero.com

Robert Dicks
650-497-8364
rdicks@lpch.org


About Lucile Packard Children's Hospital

Ranked as one of the nation's best pediatric hospitals by U.S. News & World Report, Lucile Packard Children's Hospital at Stanford is a 272-bed hospital devoted to the care of children and expectant mothers. Providing pediatric and obstetric medical and surgical services and associated with the Stanford University School of Medicine, Packard Children's offers patients locally, regionally and nationally the full range of health care programs and services, from preventive and routine care to the diagnosis and treatment of serious illness and injury. For more information, visit www.lpch.org.

About N.A.C.H.

The National Association of Children's Hospitals - N.A.C.H. - is the public policy affiliate of NACHRI. N.A.C.H. is a trade organization of 141 children's hospitals and supports children's hospitals in addressing public policy issues that affect their ability to fulfill their missions to serve children and their families. N.A.C.H. fulfills its mission and vision through federal advocacy, collaboration and communication designed to strengthen the ability of children's hospitals and health systems to influence public policy makers, understand federal and state policy issues, advance access and quality of health care for all children, and sustain financially their missions of clinical care, education, research and advocacy. http://www.childrenshospitals.net/AM/Template.cfm?Section=About_N_A_C_H_


SOURCE Lucile Packard Children's Hospital

Universal Capital Management Reports Vystar(TM) Corporation Receives FDA Clearance for Envy(TM) Natural Rubber Latex Condom Made with Vytex(TM) NRL

WILMINGTON, Del., May 8 /PRNewswire-FirstCall/ -- Universal Capital Management, Inc. (OTC Bulletin Board: UCMT), a Wilmington, Delaware business development company that provides management and strategic growth resources to emerging growth companies, is pleased to report that Vystar(TM) Corporation ("Vystar") and Alatech Healthcare, LLC announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell Alatech's Envy(TM) condom manufactured with Vytex(TM) Natural Rubber Latex (NRL). The Envy condom will be the first consumer medical product available in the U.S. made from Vystar's patented Vytex(TM) NRL, which has less than 2 micrograms/dm2, virtually undetectable levels, of the antigenic proteins that can cause an allergic response, while retaining and improving upon all the desirable qualities of latex.

The Envy condom will carry labeling that will reflect the lowest antigenic protein content currently available in a natural rubber latex medical device in the U.S. Natural rubber latex contains over 200 proteins, similar to other natural plant materials, of which 13 are known allergens. The Vytex NRL process was created to significantly reduce these known proteins. Vystar's business model is to assist all manufacturers in marketing the Vytex component of their products.

According to Vystar's CEO, William Doyle, "Vystar is thrilled to work with Alatech in introducing the first natural rubber latex condom with this level of reduction in antigenic proteins to the U.S. market. The Envy condom made with Vytex represents a revolutionary consumer product in which the antigenic proteins that can cause allergic reactions to natural rubber latex have been reduced to a virtually undetectable level."

Doyle added that, "Natural rubber latex is known to be the best material for both tactile sensitivity, strength and barrier protection, which are very important in a condom for user acceptance and maximum protection. Now, consumers can have the best material for protection plus the added benefit of the reduced antigenic proteins."

Alatech will market and sell the Envy(TM) NRL condom to retailers and through other distribution channels, and expects the product to be available to consumers in the coming months. More than 50 manufacturing trials are underway worldwide for other products made with Vytex NRL including medical and non-medical gloves, foam mattresses and pillows, bandages, adhesives and more.

According to Michael Queen, CEO of Universal Capital Management, "We believe Vystar is one of UCM's most exciting holdings. The company has come a long way in a short time, from conception to imminent commercialization due in large part to its professional management team headed by Bill Doyle. This market changing event will certainly help Vystar's sales and profits going forward."


About Vystar Corporation: Based in Duluth, GA, Vystar Corporation is a privately-held biotechnology company and the exclusive creator of Vytex(TM) Natural Rubber Latex (NRL). Vytex NRL is a patented, all natural raw material that significantly reduces antigenic proteins found in natural rubber latex and can be used in over 40,000 products. Vystar holds two U.S. patents, and additional pending application, and multiple international patent filing for Vytex(TM) NRL technology. In 2007, Vystar was named a Top 10 Innovative Technology Company in Georgia by the Technology Association of Georgia (TAG). For more information, visit www.vytex.com.

About Alatech Healthcare, LLC

Based in Eufaula, Ala., Alatech Healthcare, LLC is a leading manufacturer and supplier of condoms and latex gloves. For more information, visit www.alatechhealthcare.com.

About Universal Capital Management, Inc.: Universal Capital Management, Inc. is a publicly traded Business Development Company created under the Investment Act of 1940. Its purpose is to assist its portfolio companies with funding and management to facilitate growth, and increase their value. Please refer to the company's website at http://www.unicapman.com/.

Forward-Looking Statements:

Certain matters discussed in this press release are "forward- looking statements." These forward-looking statements can generally be identified as such because the context of the statement will include words, such as "expects," "should," "believes," "anticipates," or words of similar import. Similarly, statements that describe UCM's and Vystar's future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of Vystar as appropriate, which would cause actual results to differ materially from those currently anticipated. Although UCM and Vystar believe the expectations reflected in any forward-looking statements are based on reasonable assumptions, they cannot give any assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward-looking statements are only made as of the date of this press release and UCM and Vystar do not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.


SOURCE Universal Capital Management, Inc.

Grey Ribbon Crusade(TM) Promotes National Unification in the Fight Against Brain Tumors

Encouraging People to Become Involved During May's "National Brain Tumor Awareness Month"

WASHINGTON, May 8 /PRNewswire-USNewswire/ -- This week American Idol David Cook and his family shared the sad news of his brother's death from a brain tumor. Unfortunately many other families will suffer this same type of loss -- over 200,000 people will be diagnosed with a brain tumor in the United States this year. In an effort to bring awareness and ultimately find a cure, the newly formed consortium known as the "Heroes of Hope" announce the debut of the Grey Ribbon Crusade to commemorate National Brain Tumor Awareness month. Over 200 individuals and 48 not-for-profit charitable organizations representing all 50 states have joined together to solidify the presence of the brain tumor community while raising the level of awareness and funding for brain tumors.

Like the well-recognized pink ribbon for breast cancer awareness, the grey ribbon is the symbol for brain tumors, which are the leading cause of solid tumor death in children and affect over 200,000 people each year. People and organizations can join the cause at www.greyribboncrusade.org. There is no fee and everyone who joins will receive a grey ribbon to wear in an effort to spread awareness of the cause.

"The work the medical community can accomplish in its quest to find a cure for brain tumors is greatly enhanced by the involvement of organizations that make up 'Heroes of Hope'," said Henry Friedman, MD, Deputy Director of The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center. "Now having one cohesive resource across the nation brings more focus and strength to this cause."

The Grey Ribbon Crusade seeks to create dynamic action in the drive for funding of brain tumor research through a united force against brain tumors. The goal is to increase visibility through a strong national brand; allowing for the utilization of a combined scale of accomplishments and resources, while preserving individual and organizational goals without additional financial commitment.

The Grey Ribbon Crusade website allows members to post research requiring immediate funding, events and meetings as well as shared ideas and resources. It also provides a venue for individuals to become active in their community by partnering with the nearest not-for-profit member.

The Grey Ribbon Crusade was formed after three existing charitable organizations dedicated to brain tumor research began assisting each other in distinct areas of each other's missions, while still continuing in the specific direction of their own goals. Realizing that unification carried many benefits toward finding a cure for brain tumors, they launched the "Heroes of Hope" Grey Ribbon Crusade. The concept continues to grow as those touched by the disease join forces and take action toward a cure.

The group's first fundraiser, a national text message campaign, "Hope for a Cure is at Your Fingertips" allows you to text "BRAIN" to 40579 on your cell phone, and automatically donate $5 to brain tumor research. The one time $5 donation will be added to your mobile phone bill. Verizon users should make their donation at www.greyribboncrusade.org/donate. For more information contact Lisa Kaminsky Millar at DNL1231@aol.com or at 1-866-48-4CURE (2873)


SOURCE Heroes of Hope

Filters Fast Challenges Universities and Colleges to Kick the Bottled Water Habit

New "Drop the Bottle!" program aims to save the environment while saving students money

CHARLOTTE, N.C., May 8 /PRNewswire/ -- Drinking bottled water isn't just an American obsession, it's a bad habit. And it's one that doesn't just put the consumer at direct risk but threatens the environment as well. Since plastic virtually lasts forever, it's filling up our landfills and oceans, infiltrating major ecosystems, seeping into plants, and being eaten by animals that can't eliminate the toxin. Plastic is a plague on the planet that simply has to stop, which is why Filters Fast (http://www.filtersfast.com), a retailer of air and water filters, is challenging college and university students to kick the habit through its "Drop the Bottle!" program.

"Nationwide, many colleges and municipalities are starting to minimize the use of plastic, and the incentive has been to eliminate waste and prevent the associated health and environmental problems," says Ray Scardigno, president of Filters Fast. "Our Drop the Bottle! program provides an added incentive to stop using plastic bottles and choose filtered tap water instead. It offers discounted products specifically designed to stop the purchase and consumption of bottled water. Since everyone knows bottled water is expensive and that filtered tap water is practically free, this means you save money by not buying water and then save again with our discounted products."

With the Drop the Bottle! program, Filters Fast is giving colleges and universities 10 percent off its product line that provides an alternative to the repeat purchase of plastic bottles. Specifically, the special savings applies to items such as Brita filtration pitchers, faucet filters, reusable and BPA-free plastic bottles, and glass decanters. Virtually anything that could sway a student from purchasing bottled water is now on sale through Drop the Bottle!

"There's no doubt that many of today's environmentally conscious college students also like to save money, and if they can both save money while protecting their health and the planet, even better," Scardigno continues. "And considering how many young adults are purchasing bottled water, the Drop the Bottle! program is giving educational institutions a way to take advantage of the discount and pass that savings to the students, prevent future health problems, go green and foster sustainable business practices."

Universities and colleges wishing to participate in the Drop the Bottle! program can sign up by contacting Filters Fast's Daniel Hartis at Daniel@filtersfast.com. Participants will be set up with a discount code specific to their particular school.

For more information, visit http://www.filtersfast.com/dropthebottle/.

About Filters Fast

Filters Fast is the definitive online resource for air and water filter products. Shipping is speedy and affordable -- Filters Fast can sell and deliver products to a consumer's doorstep for less than a local store. Filters Fast is a 2007 winner of the BizRate circle of excellence platinum award.

Drop the Bottle! logo:

http://www.ereleases.com/pr/Drop-The-Bottle-Logo.jpg

Contact:

Daniel Hartis
Filters Fast
866-438-3458
fax: 704-821-4436
http://www.filtersfast.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


SOURCE Filters Fast

New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Bl

PARSIPPANY, N.J., May 8 /PRNewswire/ -- Daiichi Sankyo, Inc. announced today that new data presented at the American Society of Hypertension, Inc. (ASH) Annual Scientific Meeting and Exposition (ASH 2009) in San Francisco from the BeniSILVER study found that BENICAR(R) and BENICAR HCT(R) provided a mean reduction in 24-hour ambulatory systolic blood pressure (SBP) of 25.7 mm Hg among patients with an average age of 72 years, demonstrating efficacy without compromising safety. Patients age 65 years and older also saw their 24-hour ambulatory diastolic blood pressure (DBP) drop a mean of 12.3 mm Hg. The BeniSILVER study was designed to investigate the safety and blood pressure (BP)-lowering efficacy of BENICAR and BENICAR HCT in patients age 65 and older with mild to moderate (Stage 1) or challenging (Stage 2) hypertension.

Studies have found that both the prevalence and severity of hypertension increase as people get older, making it critical to achieve strict BP control in elderly populations.(1) In fact, in 2008, the HYpertension in the Very Elderly Trial (HYVET) demonstrated that decreasing BP in the elderly can have significant benefits in reducing the incidence of heart failure, heart attack and stroke.(2) BENICAR and BENICAR HCT are indicated for the treatment of hypertension. There are no studies with either treatment demonstrating a reduction in cardiovascular events.

In the BeniSILVER study, researchers evaluated the percent of elderly patients achieving mean 24-hour ambulatory BP targets of <135/85, <130/80 and <120/80 mm Hg. ABPM is generally considered a better indicator of target organ injury than cuff measurement, since it provides a 24-hour measurement of patient BP.(3) BENICAR and BENICAR HCT were able to safely and effectively achieve a 24-hour ambulatory target blood pressure of <135/85 mm Hg in 83 percent of elderly patients (age 65 and older). In addition, 73 percent and 44 percent reached the ambulatory targets of <130/80 mm Hg and <120/80 mm Hg, respectively.

"The ability of Benicar(R) to bring elderly patients to blood pressure targets is very important, since attaining blood pressure targets can be so challenging in this group," said Dr. Joel M. Neutel, MD, director, Orange County Heart Institute and Research Center. "Although some physicians may be reluctant to use aggressive treatments for fear of an increased risk of adverse events, the findings show hypertension treatment can be accomplished safely and effectively in the elderly."

Benicar was well tolerated by elderly patients, with only nine of the initial 178 patients discontinuing treatment because of treatment emergent adverse events (AEs). In this trial, occurrence of drug-related AEs included: dizziness (3.4 percent), hypotension (2.2 percent), and/or headache (1.1 percent).

High blood pressure can cause permanent changes to blood vessels and the heart that may create serious problems elsewhere in the body.(4) Hypertension is one of the most prevalent conditions in the United States, affecting approximately one in three American adults (about 73 million people age 20 and older) and approximately one billion people worldwide.(5),(6) It is often difficult to control, and of those with high blood pressure, approximately 55 percent do not reach recommended BP levels.(7) The number of people with high blood pressure is expected to reach about 1.6 billion worldwide by 2025.(8)

Patients Older Than 75

A sub analysis of the trial found that 82.5 percent and 67.5 percent of patients over age 75 treated with BENICAR and BENICAR HCT(R) were able to achieve an ambulatory BP target of <135/85 and <130/80 mm Hg, respectively. Adverse events were also found to be similar for patients above and below 75 years of age.

About the BeniSILVER Study

BeniSILVER was a 14-15 week, prospective, open-label, single-arm, dose-titration, study to investigate the safety and BP-lowering efficacy of the proposed titration of olmesartan medoxomil and olmesartan medoxomil/hydrochlorothiazide in 178 patients age 65 years or older with mild to moderate (Stage 1) or challenging (Stage 2) hypertension. Following a 2-3 week placebo period, 176 patients started olmesartan (OM) 20 mg. If SBP remained greater than or equal to 120 mm Hg or DBP remained greater than or equal to 70 mm Hg, patients were titrated at 3-week intervals until BP was normalized as follows: OM 40mg, olmesartan medoxomil/hydrochlorothiazide (OM/HCTZ) 40mg/12.5mg and OM/HCTZ 40mg/25mg. Patients (asymptomatic) with BP <120/70 mm Hg continued on their current assigned dose (maintenance treatment) unless BP was uncontrolled, SBP greater than or equal to 140mm Hg and/or DBP greater than or equal to 90 mm Hg, at which time the titration schedule was resumed.

The primary endpoint was change in mean SBP from baseline after 12 weeks of treatment as measured by a 24-hour ABPM. The secondary endpoints included change from baseline in mean 24-hour ambulatory DBP, change from baseline in mean SeSBP and SeDBP and proportion of patients achieving BP goal (<140/90, <135/85, <130/80 & <120/80 mm Hg), at each titration period and study end and a subgroup analysis by age (greater than or equal to 75 years or >75 years). Mean baseline ABPM was 148.8/80.9 mm Hg and mean baseline seated BP was 165.5/87.7 mm Hg, indicating predominant systolic hypertension in this elderly patient cohort with a mean age of 71.9 years and 65.9 percent challenging (Stage 2) hypertension.

Treatment emergent adverse events (TEAE) were seen in 56 patients, 32.6% of the treatment population. The most common were dizziness (8 patients, 4.5%) diarrhea (4 patients, 2.2%), upper respiratory tract infection (4 patients, 2.2%), headache (4 patients, 2.2%), and hypotension (4 patients, 2.2%). Among individual treatment regimens, headache (4 patients, 2.4%) and dizziness (4 patients, 2.4%) were reported for OM 40 mg and dizziness (6 patients, 3.8%) was reported for OM/HCTZ 40/12.5 mg. Nine patients (5.1%) discontinued participation in the study due to TEAE.

The results of this open-label trial differ from those obtained in the pivotal, placebo-controlled US MATRIX trial.

About BENICAR(R) and BENICAR HCT(R)

Angiotensin II is a hormone that interacts with a receptor on arterial blood vessels, which results in constriction and increasing blood pressure. In addition, angiotensin II stimulates the release of another hormone that causes enhanced sodium and chloride (salt) retention, with a resultant increase in vascular water retention and blood volume that also contributes to an elevation in blood pressure. BENICAR is a member of the ARB class of antihypertensive medications that help lower blood pressure by blocking the angiotensin II receptor on the blood vessels and antagonizing the release of the hormone which causes salt retention and increased blood volume. BENICAR HCT(R) combines BENICAR(R) with the diuretic hydrochlorothiazide.

BENICAR and BENICAR HCT are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents. BENICAR HCT is not indicated for initial therapy.


IMPORTANT SAFETY INFORMATION ABOUT BENICAR(R) and BENICAR HCT(R)

USE IN PREGNANCY

When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, BENICAR or BENICAR HCT should be discontinued as soon as possible. See WARNINGS, Fetal/Neonatal Morbidity and Mortality in the prescribing information.

Hypotension in Volume- or Salt-Depleted Patients

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (eg, those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with BENICAR. Treatment should start under close medical supervision. If hypotension does occur, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized.

Impaired Renal Function

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. There has been no long-term use of olmesartan medoxomil in patients with unilateral or bilateral renal artery stenosis, but similar results may be expected.

The prescribing information for BENICAR HCT also includes the following warnings regarding its hydrochlorothiazide component:

BENICAR HCT is not recommended in patients with severe renal impairment and is contraindicated in patients with anuria or hypersensitivity to other sulfonamide derived drugs

Fetal/Neonatal Morbidity and Mortality

Thiazides cross the placental barrier and appear in cord blood. There is a risk of fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions that have occurred in adults.

Hepatic Impairment

Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.

Hypersensitivity Reaction

Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history.

Systemic Lupus Erythematosus

Thiazide diuretics have been reported to cause exacerbation or activation of systemic lupus erythematosus.

Lithium Interaction

Lithium generally should not be given with thiazides.

Adverse Events

The withdrawal rates due to adverse events (AEs) were similar with BENICAR(R) and BENICAR HCT(R) to placebo: BENICAR (2.4% vs 2.7%); BENICAR HCT (2.0% vs 2.0%)
The incidence of AEs with BENICAR and BENICAR HCT was similar to placebo

-- The only AE that occurred in >1% of patients treated with BENICAR(R) and more frequently than placebo was dizziness (3% vs 1%)

-- AEs reported in >2% of patients taking BENICAR HCT(R) and more frequently than placebo included nausea (3% vs 0%), hyperuricemia (4% vs 2%), dizziness (9% vs 2%), and upper respiratory tract infection (7% vs 0%)

Dosing and Administration

No initial dosage adjustments are recommended with BENICAR in elderly or in moderate to marked renal impairment*/hepatic dysfunction

-- In patients with possible depletion of intravascular volume (eg, patients on diuretics, particularly with impaired renal function), BENICAR should be initiated under close medical supervision and consideration given to use of a lower starting dose

For BENICAR HCT, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosage range

*Creatinine clearance <40 mL/min.

Please see full prescribing information for BENICAR and BENICAR HCT.

About Daiichi Sankyo

A global pharma innovator, Daiichi Sankyo Co., Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research and development are thrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmune disorders. Equally important to the company are hypertension, hyperlipidemia or atherosclerosis and bacterial infections. For more information, visit www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd. For more information on Daiichi Sankyo, Inc., please visit www.dsi.com.


(1) Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005;294:466-472

(2) Beckett, et al. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med. 2008;358;1887-98

(3) National High Blood Pressure Education Program, JNC 7: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure, December, 2003. pg. 19.

(4) National Heart, Lung and Blood Institute, High Blood Pressure Key Points. Available at: http://www.nhlbi.nih.gov/health/dci/Diseases/Hbp/HBP_Summary.html. Accessed August 28, 2008

(5) American Heart Association. 2004 High Blood Pressure Statistics. Available at: http://www.americanheart.org/presenter.jhtml?identifier=4621. Accessed August 27, 2008

(6)Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560-2572

(7) American Heart Association. 2004 High Blood Pressure Statistics. Available at: http://www.americanheart.org/presenter.jhtml?identifier=4621. Accessed August 28, 2008.

(8) Kearney PM, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217-23.


SOURCE Daiichi Sankyo, Inc.

ChildCare Education Institute Gives Child Care Staff Access to Professional Development Courses in Honor of Provider Appreciation Day, May 8th

DULUTH, Ga., May 8 /PRNewswire/ -- ChildCare Education Institute (CCEI), a distance training institution dedicated exclusively to the child care industry, is proud to give professional development training hours to early child care providers in honor of Provider Appreciation Day.

Early child care providers can log in to CCEI's learning management system at www.cceionline.com, between May 8th, 2009 and May 15th, 2009 and receive five (5) hours of professional development. These hours can be applied to any of CCEI's online professional development courses. CCEI has an English and Spanish offering of over 100 online courses pertinent to the child care industry including Health and Safety, Nutrition and Food Service, Child Development, Classroom Management, Guidance and Discipline, Administration, and many others. Each one hour course is granted 0.1 IACET CEU. To get the five hours of courses, log in, go to the purchase individual hours tab under registration/purchasing, choose five hours, and reference promotion code 090805 when prompted. Once completed, you can choose your courses and take them at your convenience.

"Provider Appreciation Day is an opportunity for CCEI to recognize and reward early childhood professionals, teachers, center directors and staff for the valuable role they play in the development of children. Research has shown that the early years in a child's life are the most vital for development and high-quality child care is a critical component. It's important to appreciate those professionals who devote their careers to caring for young children," said Maria C. Taylor, President and CEO.

About ChildCare Education Institute, LLC

ChildCare Education Institute (CCEI), a distance training institution, is dedicated to providing the child care industry with professional development programs and courses to meet their education requirements. Over 100 professional development courses are available to meet annual training and licensing requirements, as well as continuing education options including the Child Development Associate (CDA) Programs of Study, Director's Certificate Program of Study and others. CCEI is approved by the International Association for Continuing Education and Training (IACET) to award IACET Continuing Education Units (CEUs). CCEI is authorized under the "Nonpublic Postsecondary Educational Institutions Act of 1990." License Number 837.

For more information, visit www.cceionline.com.


SOURCE ChildCare Education Institute

Do a Show on Money, Marriage and Mental Health in a Tough Economy

SANTA ROSA, Calif. and HERRIMAN, Utah, May 8 /PRNewswire/ --

A Recession Is the Best Time to Make Your Millions!

More people become millionaires during a recession than at any other time, according to research. Former BBC newsreader Stephanie Hale has interviewed 16 self-made millionaires around the world. They've all overcome major obstacles such as homelessness, chronic illness, single parenthood, huge debt, low school grades, and childhood poverty. With their backs against the wall, these remarkable individuals took charge of their lives and built the wealth they always dreamed of. They say anyone can do the same no matter what their background. Interview Hale on your show so she can tell your audience how they can start building their wealth.

CONTACT: Stephanie Hale, 011-44-186-575-1004 (UK); stephaniejhale@yahoo.co.uk; http://www.womenmillionairesbootcamp.com

AVAILABILITY: England, nationwide by arrangement, and via telephone

The Economy's Effect on Marriage and Divorce

No marriage is immune to the effects of money. Financial stress can quickly tear apart already fractured marriages and break apart even the strongest relationships. The compounding hardships people are facing in this economic downturn are pushing many couples over the edge. As a Marriage Family Therapist (MFT), Sharon Rivkin has 27 years of experience working with couples and families in her private practice and knows what tools couples can use to heal their broken relationships. Her book, THE FIRST ARGUMENT: Cutting to the Root of Intimate Conflict, reveals the insight couples need to better understand how they arrived at their present situation and how they can make improvements. Invite Rivkin to answer questions from your audience.

CONTACT: Sharon Rivkin, (707) 696-7542 (CA); sharonrivkin@aol.com

AVAILABILITY: California, nationwide by arrangement, and via telephone

Children Facing the Emotional Stress of Debt

Some of the hardest-hit victims of America's economic stress are also some of the youngest. While parents work hard to keep their families financially stable, it can be extremely difficult to shield children from very grown-up concerns like debt and foreclosure. In her 30 years of professional experience, child behavior expert Jaydra Hymer says that kids see how distressed their parents are and worry because they can't do anything to help. Hymer can offer your audience tips on how parents can minimize the negative effects of economic stress on their children.

CONTACT: Jaydra Hymer, (801) 637-2736 (UT); jaydra@rarefamilies.com

AVAILABILITY: Utah, nationwide by arrangement, and via telephone

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


SOURCE WomenMillionairesBootCamp.com et al.

Food and Drug Administration Accepts Isolagen's Biologics License Application for Full Review

EXTON, Pa., May 8 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (NYSE Amex: ILE) today announced that the United States Food and Drug Administration ("FDA") has completed its initial review of the Company's Biologics License Application ("BLA") related to its Nasolabial Fold/Wrinkles product candidate and that the FDA has accepted (or filed) the BLA for full review.

In a communication received from the FDA on May 7, 2009, the FDA noted that it had completed its initial review of the Company's BLA to determine its acceptability for filing and that the FDA has filed the Company's application. The FDA noted that its review completion target date is January 4, 2010.

The FDA's filing review is only a preliminary review, and deficiencies may be identified during full review of the BLA. Also, the acknowledgment of filing by the FDA does not mean that the FDA has issued a license, nor did the FDA represent any evaluation of the adequacy of the data submitted.

About Isolagen, Inc.

Isolagen(TM), Inc. (NYSE Amex: ILE) is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic potential applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) Laboratories, Inc. For additional information, please visit www.isolagen.com.

Isolagen Forward Looking Statements

All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release, include, without limitation, the FDA's review completion target date and the Company's ability to obtain license approval from the FDA with respect to its Nasolabial Fold/Wrinkles product candidate in the timeframe discussed above, if at all. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2008, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q filed since the annual report. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2008, as well as other public filings with the SEC since such date.


SOURCE Isolagen, Inc.

Early Childhood Funding is Focus of Star Power Event

1,000 supporters to gather May 21 at Capitol to meet with legislators

LANSING, Mich., May 8 /PRNewswire/ -- One thousand parents, children and other early childhood investment supporters are expected at the Capitol Thursday, May 21, to tell state legislators that funding for our youngest citizens is critical to Michigan's economic future.

It will be the largest Star Power Event since it began in 2007.

"This issue is more important than ever as the state makes cuts to balance the current budget and works on the 2010 budget," said Judy Y. Samelson, CEO of the Early Childhood Investment Corporation (ECIC). "We cannot sacrifice services for families and children."

Many of the rally participants will be members of the 55 Great Start Collaboratives that help communities develop, implement and evaluate local, comprehensive early childhood systems. After a 10 a.m. parade and program recognizing champions of early childhood investment on the Capitol steps, participants will meet with their state representatives and senators until 2 p.m.


"We now have a full contingent of Great Start Collaboratives, which will allow thousands of Michigan children to gain access to the development programs they deserve," Samelson said. "Maintaining funding for the collaboratives will be just one of the important issues supporters will discuss with legislators."

The Great Start initiative was launched in 2004 as a movement to create public understanding that learning begins at birth and that investment in early childhood health, development and learning is crucial to the state's economic future. The ECIC is a unique public, nonprofit corporation created to invest in Michigan's children. By educating, motivating and involving Michigan citizens in efforts to build and promote a system of supports for young children and their families, all Michigan children can make a Great Start!

The ECIC and the Great Start Collaboratives, the two primary units of Great Start, are sponsoring the Star Power Event.

For more information about the ECIC, visit http://www.ecic4kids.org.


SOURCE ECIC

Removing Medical Device Preemption Impacts Jobs, Health Care Costs, Patient Access

BOSTON, May 6 /PRNewswire-USNewswire/ -- In a white paper released today by Ernst Berndt and Mark Trusheim of the Massachusetts Institute of Technology, research shows that eliminating FDA's preemption protection would decrease patients' access to life-enhancing medical devices, increase health care costs and reduce medical device industry employment.

The paper, "The Economic Impact of Eliminating Federal Preemption for Medical Devices on Patients, Innovation and Jobs," comes as Congress considers legislation that would remove Federal preemption of state rules and litigation that exists for a small percentage of medical devices that undergoes the most rigorous FDA review. The report highlights the damaging economic, health and societal impacts the legislation would have on patients, medical device industry innovation and employees, and the public health.

"As economic and health care researchers, we felt it was important to examine how this regulatory change could harm innovation, and ultimately impact the patients who rely on these treatments and the people who are employed by the device industry" said co-author Ernst Berndt, Ph.D., Louis E. Seley Professor in Applied Economics, MIT Sloan School of Management. "Congress should carefully weigh any policies that could increase health care costs and reduce high-paying jobs, particularly during an economic downturn."

The authors' research highlights the consequences to multiple stakeholders - patients and the public health, medical device inventors and manufacturers, their employees and the government - if medical device preemption were eliminated. For example,

Patients' access to medical devices and the benefits they provide would be reduced; as prices increase, products may be withdrawn, and fewer new products will be developed.

Physicians will increasingly practice defensive medicine to avoid litigation and expose patients to added risks of otherwise unnecessary procedures.

For those employed by the medical device industry, the increased manufacturers' costs would discourage investment in medical device development, reducing the R&D pipeline of innovative new products created and brought to market, and lead to layoffs of high-paying jobs.

Medical innovation would be affected, as decisions about health care products shift from expert, science-based regulators to untrained, non-expert juries, creating a duplicative, fragmented and inconsistent national framework administered by state and federal courts.

The government would experience increased costs, as Medicare and Medicaid spend more than they otherwise would due to fewer new product innovations, and government pays for increasing judicial system, tort and duplicative state regulatory costs.

"The question is not whether eliminating preemption will reduce innovation, but rather by how much and how rapidly," said co-author Mark Trusheim, Visiting Scientist at the MIT Sloan School of Management. "High levels of tort risk discourage investment in new technology. Eliminating preemption substantially alters the benefit/risk ratio of complex medical devices, increases the costs for all stakeholders, and negatively affects patients' future access to treatment options."

"Given these findings, and current economic circumstances, Congress should carefully consider any change to current law as the ramifications could substantially harm patient choice and health," Trusheim concluded.

The report was made possible by a grant from the Advanced Medical Technology Association. The views expressed are those of the authors only, and do not necessarily reflect views of the sponsor or MIT.


SOURCE Berndt Associates

Stroudsburg PA Woman Earns Governor's Achievement Award as 'Direct Care Worker of the Year'

HERSHEY, Pa., May 6 /PRNewswire-USNewswire/ -- Cari Medinas of Stroudsburg today received the first Direct Care Worker of the Year award, presented by Secretary of Aging John Michael Hall during the Governor's Achievement Awards ceremony at the PA Partners Conference.

"It is very appropriate to honor Cari Medinas for her selfless efforts. Her duties are demanding and provide her clients with essential support services," Hall said. "The important work done by Cari and all workers in this field is worthy of our thanks and appreciation."

An employee of Private Home Care Services, Inc., Medinas cares for a bed-bound woman with severe disabilities, as well as the woman's husband, who suffers from debilitating dementia and other problems. Her excellent attendance record and high level of care for her clients contributed to her being named for this award.

Subcontractors of the 52 Area Agencies on Aging or Medical Assistance-enrolled aging waiver providers who provide home- and community-based services were invited to nominate direct care workers for the award.

For more information about the Department of Aging, visit www.aging.state.pa.us.

CONTACT: Jane Crawford
(717) 783-1549


SOURCE Pennsylvania Department of Aging

Lack of Food Variety Puts Kids With Autism at Risk for Poor Nutrition

Two Studies at PAS Suggest Food Variety and Cognition-Related Fatty Acid are Important to Well Being of Affected Children

CINCINNATI, May 5 /PRNewswire-USNewswire/ -- The strong preference kids with autism have for certain foods places them at risk for nutritional deficiencies because their diets lack sufficient variety, according to research from Cincinnati Children's Hospital Medical Center at this year's Pediatric Academic Societies meeting in Baltimore.

After presenting their findings on May 4, the researchers said screening children for the amount of variety of food in their diets may be a good clinical marker to predict which children might be at risk for nutrition problems. Kids with low food variety scores who are at risk could then be referred to dieticians or therapists to help them expand food choices and improve nutrition, said Michelle Zimmer, M.D., lead investigator and a pediatrician in the division of Developmental and Behavioral Pediatrics at Cincinnati Children's.

The study is one of two presented by Dr. Zimmer and colleagues this year at PAS that deal with autism, the second one showing that the red blood cells of children with autism have low levels of a fatty acid linked to cognitive function. This finding, the researchers report, warrants further research into how the low fatty acid levels may trigger biochemical changes in the brain linked to autism.

The team found that levels of docosahexanoic acid and total omega-3 fatty acids were significantly lower in the red blood cells of autistic children than in normally developing children. Omega-3 fatty acids are nutritionally important substances considered vital to the normal development of children.

Evidence of abnormal fatty acid metabolism in children with autism runs counter to at least one previous study that suggested no difference between normally developing and autistic children. The different results between studies may be explained by the current research focusing on an older group of children, Dr. Zimmer said.

"The fatty acid docosahexanoic is linked to other mental health issues, and this raises questions about whether there are functional issues in neural cells involving a deficiency of essential fatty acids," said Dr. Zimmer. "The main point of the study is we cannot rule that fatty acids are part of the story of what is going on with kids who have autism."

Dr. Zimmer said its possible older children with autism have had more time to use up their bodies' stores of omega-3 fatty acids and are unable to replenish those stores. The 21 children with autism in this study were between the ages of 3 and 18 years, as were the 20 age-matched normally developing children and 10 of their siblings who served as control subjects.

The research team is conducting a larger study with more children to verify its PAS findings. Dr. Zimmer said another study is also under design to give essential omega-3 fatty acids, such as docosahexanonic acid, to children with autism to see what impact it has on brain chemistry and/or the disorder.

Increasing foods rich in omega-3 fatty acids in the diets of autistic children has been suggested by some researchers as potentially beneficial, Dr. Zimmer said. Although doing so would not have a negative impact on the children, until studies are conducted it isn't known what affect, if any, it might have, she added. Also, given the findings of the previous study on the lack of food variety among kids with autism, augmenting their diets could be challenging.

Most of the 19 autistic children in the food study had much lower food variety scores in their diets than typically developing children. A majority of the children with autism also suffered from nutritional deficiencies. The researchers concluded children with autism and low food variety scores are at risk for mild and serious nutritional deficiencies.

Researchers participating in studies were from the division of Developmental and Behavioral Pediatrics and division of Neurology at Cincinnati Children's. Researchers from the department of Pathology at the University of Cincinnati participated in the study on food variety.

The PAS meeting is the largest international meeting focused on research in child health. It is sponsored by the American Academy of Pediatrics, the American Pediatric Society, the Society for Pediatric Research, and the Ambulatory Pediatric Association.

Cincinnati Children's Hospital Medical Center is one of America's top three children's hospitals for general pediatrics and is highly ranked for its expertise in digestive diseases, respiratory diseases, cancer, neonatal care, heart care and neurosurgery, according to the annual ranking of best children's hospitals by U.S. News & World Report. One of the three largest children's hospitals in the U.S., Cincinnati Children's is affiliated with the University of Cincinnati College of Medicine and is one of the top two recipients of pediatric research grants from the National Institutes of Health. For its achievements in transforming healthcare, Cincinnati Children's is one of six U.S. hospitals since 2002 to be awarded the American Hospital Association-McKesson Quest for Quality Prize (R) for leadership and innovation in quality, safety and commitment to patient care. The hospital is a national and international referral center for complex cases, so that children with the most difficult-to-treat diseases and conditions receive the most advanced care leading to better outcomes. Additional information can be found at www.cincinnatichildrens.org.


SOURCE Cincinnati Children's Hospital Medical Center

NeoStem Files Patent Application for Cosmetic Stem Cell Face Lift Technology and Expands Stem Cell Collection Network into New Jersey

NEW YORK, May 6 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, has filed a patent application claiming the proprietary stem cell technology of Vincent C. Giampapa, M.D., F.A.C.S. relating to cosmetic facial rejuvenation, which NeoStem first licensed in February 2009.

The newest adult stem cell collection center in the NeoStem network, located at the Giampapa Institute for Anti-Aging Medical Therapy in Montclair, New Jersey, has received, from the state of New Jersey Department of Health and Senior Services, a blood bank license for autologous peripheral blood stem cell collection. This allows the center to open and commence operations, and together with the patent application will serve to significantly advance NeoStem's leadership in the anti-aging and regenerative medicine arena.

Dr. Giampapa, director of the Giampapa Institute for Anti-Aging Medical Therapy, is a board-certified plastic reconstructive surgeon and Assistant Clinical Professor of Plastic and Reconstructive Surgery at the University of Medicine and Dentistry of New Jersey and is one of the first certified anti-aging medical physicians in the world. His research and technology comprise a non-surgical procedure for complete facial rejuvenation that involves injecting pluripotent cells, including stem cells, into the skin of individuals whose skin has lost its firmness and texture due to age. The pluripotent cells stimulate the growth of various cells in the skin, leading to the restoration of the skin's firmness and texture. The procedure can be accomplished under local anesthesia in an office setting and typically requires only a week of recovery time.

"NeoStem is very focused on acquiring technologies related to stem cell therapies," stated Robin Smith, M.D., MBA, NeoStem's Chief Executive Officer. "We are especially delighted to strengthen our relationship with Dr. Giampapa, as anti-aging technology is one of our key pursuits. Filing a patent for stem cell facial rejuvenation technology, while launching a new NeoStem collection center at the Giampapa Institute, creates a particularly advantageous situation for NeoStem. Just last week, the Food and Drug Administration announced that Botox and similar anti-wrinkle drugs must now carry "black box" warning labels explaining the potential of these materials to spread from the injection site to distant parts of the body, creating possible problems with swallowing or breathing. People worldwide can be expected to seek safer alternatives and NeoStem believes that the use of autologous stem cell procedures ("Your Cells for Your Use") may in fact be that effective, safe and non-invasive alternative."

About NeoStem, Inc.

NeoStem is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate VSELs (very small embryonic-like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells. The Company is also pursuing other technologies to advance it position in the field of stem cell tissue regeneration.

For more information, please visit: www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results, including the success of the collection centers in its network and whether the patent application described in this press release will issue, could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K for its fiscal year ended December 31, 2008 and the Company's other periodic filings with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Contact:
NeoStem, Inc.
Robin Smith, Chief Executive Officer
T: 212-584-4180
E: rsmith@neostem.com
www.neostem.com


SOURCE NeoStem, Inc.

Oncology Social Workers Report 'Uncertain' and 'Unknown' Cancers Significantly Increase Patient Distress

- Survey of AOSW Members Highlights Need for Resources, Education, Better Diagnostic Tools to Reduce Psychological Impact of Unknown Cancer Diagnoses -

SAVANNAH, Ga., May 6 /PRNewswire/ -- Cancer patients whose primary cancer type is "uncertain" or "unknown" may experience more distress than patients whose primary cancer is definitively diagnosed, according to a recent survey of 140 oncology social workers. bioTheranostics, a company specializing in molecular diagnostics for oncology, conducted the "CUP Patient Experiences" survey among members of the Association of Oncology Social Work (AOSW). The purpose of the survey, results of which will be presented today at the AOSW 2009 conference, was to better understand the psychosocial impact of a "cancer of unknown primary origin" diagnosis.

Cancer of unknown primary origin, or CUP, is among the 10 most common malignancies in the developed world, affecting about three to five percent of all cancer patients (1) (2) -- the equivalent of 30,000-50,000 new cases each year in the United States alone.(3) Given that the origin of a tumor significantly impacts physicians' therapeutic decisions as well as patients' prognoses, the inability to diagnose patients' primary cancers makes it more difficult for physicians to determine optimal treatment plans.

"By and large, the social and psychological impact of CUP is not well defined nor well understood in the oncology community," said Les Gallo Silver, ACSW, AOSW president. "As a national organization whose members are key components of the cancer care team, we felt it is important to raise awareness of the psychological impact this diagnosis has on patients so that our members, as well as other oncology professionals, can better recognize and address CUP patients' unique needs.

"Given issues related to poor prognoses, CUP patients struggle with the psychological impact of being different and singular in ways that are perceived as dangerous and life-threatening," Gallo Silver continued. "We are committed to helping and advocating for CUP patients so that they can benefit from the therapeutic standards of care and support services that already exist for many defined cancers. Findings from this survey support oncology professionals' exploration of means to reduce the number of patients whose cancer remains uncertain or unknown."

According to the oncology social workers (OSWs) from across the United States who responded to the survey:

Relative to the distress experienced by patients who have been diagnosed with a specific type of cancer, 39 percent of OSWs felt that a CUP diagnosis is significantly more distressing/extremely distressing and 42 percent felt it is more distressing.

OSWs believe the three greatest challenges faced by patients diagnosed with CUP are "general fear associated with battling something unknown" (38 percent), "lack of a definitive best therapy for them" (37.3 percent) and "frustration and/or anger that their cancer can't be identified" (21.1 percent).

OSWs need more resources for their CUP patients. Specifically, the OSWs who participated in the survey noted that it is difficult to find other CUP patients and disease-specific organizations with which to connect their CUP patients for support and information.

Finally, 34 percent of OSWs said they felt their initial training left them only "minimally prepared" to address the distress experienced by patients who lack a definitive cancer diagnosis. Thirty-one percent reported they felt "moderately prepared." Only 2.1 percent said they felt "very well prepared".

"It is clear that CUP causes significant distress beyond even that associated with a defined cancer diagnosis," said Mark Erlander, chief scientific officer, bioTheranostics. "The oncology community needs to create resources and support services specific to CUP patients' needs. In parallel, a more direct, cost-effective and robust solution to the clinical and psychological impact of this disease is to drastically reduce the number of cancers that remain 'uncertain' or 'unknown'."


Traditional diagnostic methods often fail to diagnose hard-to-identify cancers, even after extensive work-ups that average nearly $18,000.(4) Recently, molecular diagnostic tools have demonstrated the capacity to more accurately predict the origin of tumors, thereby helping to reduce the number of cancers that remain "unknown" and guide treatment decisions.


Molecular diagnostic tests analyze the molecular "signature" of individual tumor cells and compare them to the signatures of known tumors to find genomic patterns of similarity. This results in the ability to diagnose uncertain and unknown cancers with a much higher degree of accuracy than conventional technologies. bioTheranostics' THEROS CancerTYPE ID(R), for example, has a demonstrated overall success rate of 86 percent for classification of 39 different tumor types and 64 sub-types.


AOSW will publish the results of the CUP survey on their Website in order to raise awareness of the particular difficulties CUP presents to patients.


About the Association of Oncology Social Work

The Association of Oncology Social Work (AOSW) is a non-profit, international, 501(c) 3 organization dedicated to the enhancement of psychosocial services to people with cancer and their families. Created in 1984 by social workers interested in oncology and by existing national cancer organizations, AOSW has over 1000 current members who embrace the AOSW Mission "to advance excellence in the psychosocial care of persons with cancer, their families, and caregivers through networking, education, advocacy, research and resource development." http://www.aosw.org/

About bioTheranostics

bioTheranostics discovers, develops and commercializes molecular diagnostic tests for cancer patients. Leveraging its unique expertise in genomic profiling and proprietary algorithms, bioTheranostics provides innovative tests to the oncology community that help drive personalized treatment. The company operates a CLIA-certified, CAP-accredited diagnostic service laboratory in San Diego, CA to perform its proprietary molecular diagnostic tests: THEROS CancerTYPE ID(R), a molecular cancer classifier particularly helpful for patients diagnosed with primary or metastatic cancer where the origin is uncertain or unknown; and the THEROS Breast Cancer Index(SM), a combination of THEROS H/I(SM) (HOXB13 :IL17BR) and THEROS MGI(SM) (Molecular Grade Index) that refines and improves risk stratification in patients with estrogen receptor (ER)-positive, lymph-node negative breast cancer. More information is available at www.bioTheranostics.com.


Contact: Michele Parisi
925/429-1850
mparisi@biocommnetwork.com


(1) N. Pavlidis,, E. Briasoulis, J. Hainsworth, F.A. Greco. Diagnostic and therapeutic management of cancer of an unknown primary. Euro J of Cancer. 2003; 39:1990-2005.

(2) Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer. 2004;100:1776-1785.

(3) S. Becker, Identifying Tumors of Uncertain Origin. Ad for Admin Lab. 2008;15:58.

(4) D. V. Schapira and A. R. Jarrett. The need to consider survival, outcome, and expense when evaluating and treating patients with unknown primary carcinoma. Arch Int Med. 1995; 155.


SOURCE bioTheranostics

Photo: Wisconsin Artist Wins Purex Saves Green Tote Bag Design Contest

Celebrity Tote Bag Auction Raises Funds for Earth Day Network

PHOENIX, May 6 /PRNewswire/ -- Pop-surrealist artist Jeff Sadowski has won the PurexSavesGreen tote bag design contest, Purex announced today. His environmentally-friendly "Smart and Green Purex-hilaration" slogan and funky leaf design took the top prize from among over 38,000 entries submitted by creative consumers from all 50 states. Mr. Sadowski will receive a 2009 smart(R) fortwo car and nine runners-up will receive tote bags printed with their own design and slogan.

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/purex/38133/

The contest, now in its second year, is part of the larger Purex Saves Green program that has raised a total of more than $65,000 for Earth Day Network, a non-profit organization that seeks to grow and diversify the environmental movement worldwide, and to mobilize it as the most effective vehicle for promoting a healthy, sustainable planet. The Purex Saves Green campaign is sponsored by Purex(R) Natural Elements(TM) laundry detergent, the first major laundry detergent recognized by the Environmental Protection Agency's "Design for the Environment" program (http://www.epa.gov/dfe). Over the past two months, more than 300,000 consumers visited PurexSavesGreen.com to submit original, environmentally-themed tote bag designs, learn more about what they can do at home to preserve the environment, share their own tips for eco-friendly living and bid on a selection of celebrity-designed tote bags auctioned to benefit Earth Day Network. Celebrities who created designs for the auction include Marcia Gay Harden, Martha Stewart, Chevy Chase, Dan Aykroyd, Tamara Tunie, Ed Begley, Jr., Paul Shaffer and Tom Bergeron and his daughter.

"Our consumers, like all of us at Purex, want to do what they can to help preserve our environment," says Jeffrey Huffman, senior brand manager of Purex(R) products. "We launched the Purex Saves Green program to show them where to start and to create a platform where they could share green tips and information with others. Two years later, we're proud and inspired by the level of participation, and delighted to have raised significant funds for this essential cause."

Jeff Sadowski, a resident of Brookfield, Wisconsin, is a life-long artist whose work has been featured in galleries in Wisconsin, Illinois and California. His style is "pop-surrealist," which means that his paintings focus on imaginative, fantasy icons and pop-culture. Much of his work reflects memories from his childhood. While Jeff works in acrylics, his use of deep, rich color gives his paintings the appearance of oils. He has created numerous music album covers and been published in two editions of Spectrum: The Best in Contemporary Fantastic Art. One of his paintings was shown in the Charles Allis Museum in Milwaukee. To find out more about Jeff and to view his fine art, visit www.jeffsadowskiart.com.

Jeff, his wife, Michele, and son, Jon, learned about the Purex Saves Green tote bag design contest from an ad in their local newspaper. Jon, a car enthusiast, is a longtime fan of smart(R) cars and encouraged his dad to enter the contest in hopes of winning one for the family. "We're all excited, but Jon is over the moon," Jeff reports. "My wife and I think using products such as Purex(R) Natural Elements(TM) is a great way to teach him about the importance of protecting the environment. We've also enjoyed spending time on the Purex Saves Green site learning about what else we can do at home to help preserve our precious planet."

Purex(R) Natural Elements(TM) brand is committed to creating laundry solutions that are tough on stains but easy on your wallet. The brand offers biodegradable laundry detergent with naturally-derived cleaning ingredients, available in four unique, fresh scents made with natural fragrance extracts: Linen & Lilies(TM), Apple & Melon, Cherry Blossoms & Vanilla and Lilac & Lavender HE. It is tough on dirt and stains, hypoallergenic, free of phosphates and dyes, and comes in a recyclable bottle so it's gentle on the environment.

New to the Purex(R) Natural Elements(TM) family is Purex(R) Natural Elements(TM) Fabric Softener. It comes in two fresh scents, Linen & Lilies and Apple & Melon that complement the Purex(R) Natural Elements(TM) detergent fragrances. It also contains natural fragrance extracts, is hypoallergenic, free of dyes and the formula is biodegradable. To find out more about our company's commitment to sustainability, visit www.henkel.com/sr2009.

For more than 130 years, Henkel has been a leader with brands and technologies that make people's lives easier, better and more beautiful. Henkel operates in three business areas -- Home Care, Personal Care, and Adhesives Technologies -- and ranks among the Fortune Global 500 companies. In fiscal 2007, Henkel generated sales of $19.218 billion and operating profit of $1.975 billion. Our 53,000 employees worldwide are dedicated to fulfilling our corporate claim, "A Brand like a Friend," and ensuring that people in more than 125 countries can trust in brands and technologies from Henkel. In North America, Henkel markets a wide range of well-known consumer and industrial brands, including Dial(R) soaps, Purex(R) laundry detergents, Right Guard(R) antiperspirants, got2b(R) hair gels, and Loctite(R) adhesives.


SOURCE Henkel

Report Finds Faith Organizations Building Community, Improving Health Through Healthy Foods

MINNEAPOLIS, May 6 /PRNewswire-USNewswire/ -- Parishioners at Guardian Angels Catholic Church in Minnesota do more than donate food to a local food shelf -- they actually grow it themselves. The project is one of many case studies highlighted in a new report by the Institute for Agriculture and Trade Policy (IATP) and funded by Blue Cross and Blue Shield of Minnesota (Blue Cross) that demonstrate a growing nationwide movement within the faith community to put into practice the belief that healthy foods will help feed the body and soul.

The report, Faith and Food: Action Strategies for Healthy Eating, found that churches, synagogues and other faith organizations throughout the United States are building community -- and healthier lives -- by making healthy foods available to their members and others. Faith-based organizations are embracing healthy eating, local foods, and sustainable agriculture and see it as an effective way to improve their members' health and make a difference in their communities. Examples include hosting farmers markets, connecting members with local sources of halal or kosher foods, and growing produce at a church garden to donate to a neighboring food shelf.

"Faith communities are important supporters of healthy eating because of their strong presence in neighborhoods and their commitment to the well-being of community members," said JoAnne Berkenkamp, director of IATP's Local Foods program. "It is our hope that faith members across the country will be inspired by these stories and take action in their own places of worship."

IATP joined forces with Blue Cross' Prevention Minnesota initiative, which works to improve the health of Minnesotans by combating the root causes of cancer and heart disease, of which unhealthy eating is a leading factor. Physical inactivity and unhealthy eating combined contribute to obesity, cancer, cardiovascular disease and diabetes. Together, they are the second leading cause of preventable death and disease in the United States.

"With two-thirds of Americans overweight or obese, we need many solutions to stop this alarming trend," said Dr. Marc Manley, vice president and medical director for Population Health at Blue Cross. "If we surround people with healthy food options where they live, work and play -- including their place of worship -- people will be much more successful in improving their diets. We're excited to be working with IATP to encourage more faith communities to make healthy foods the easy choice and in turn improve the health of their members."

Case studies in the report include:

St. Alban's Episcopal Church in Bolivar, Mo., manages three gardens and three orchards from which they harvest and provide both fresh and preserved fruits and vegetables for anyone who wants them.

Guardian Angels Catholic Church in Oakdale, Minn., manages a volunteer-based community garden that provides fruits and vegetables for local food shelves.

Taqwa Eco-Food, a food cooperative in Chicago, Ill., works to meet the needs of people wanting to purchase local meats raised and processed within the principles of Islam.

Central Baptist Church and Bethlehem Baptist Church of Columbia, S.C., runs the "Dash of Faith" cooking program to help church cooks prepare healthier foods.

Sixteen Interfaith Communities in Eugene, Ore., connect urban residents with local farmers and community-supported agriculture (CSA) farms in which residents purchase shares and receive deliveries of harvested fruits and vegetables.

St. Paul Jewish Community Center in St. Paul, Minn., arranges for members to purchase shares in a local CSA farm that uses farming practices based on Jewish beliefs.

Plymouth Congregational Church and Stevens Square Community Organization of Minneapolis, Minn., operate a community garden, food shelf and farmers market at the church.
Central Presbyterian Church in downtown St. Paul, Minn., provides a weekly healthy community lunch program for members and the surrounding community.

Upper Sand Mountain Parish of northeastern Alabama operates a food pantry, community and church gardens, cannery and healthy eating education program.

Body and Soul healthy eating program throughout the U.S. helps African-American congregations improve eating among their members.

The Hindu Temple of Minnesota in Maple Grove, Minn., organizes a weekend healthy lunch program for both members and non-members.

IATP is working to identify and expand opportunities for faith communities to support local foods, sustainable agriculture and healthy eating. They invite others to share the efforts of their own faith community to improve access to healthy food by visiting www.iatp.org/faith and adding their stories to complement the case studies highlighted in this report.

A PDF of the complete Faith and Food: Action Strategies for Healthy Eating report can be downloaded at www.iatp.org/faith or www.bluecrossmn.com/preventionminnesota.

The Institute for Agriculture and Trade Policy works locally and globally at the intersection of policy and practice to ensure fair and sustainable food, farm and trade systems. www.iatp.org.

Blue Cross and Blue Shield of Minnesota, with headquarters in the St. Paul suburb of Eagan, was chartered in 1933 as Minnesota's first health plan and continues to carry out its charter mission today: to promote a wider, more economical and timely availability of health services for the people of Minnesota. A nonprofit, taxable organization, Blue Cross is the largest health plan based in Minnesota, covering 2.8 million members in Minnesota and nationally through its health plans or plans administered by its affiliated companies. Blue Cross and Blue Shield of Minnesota is an independent licensee of the Blue Cross and Blue Shield Association, headquartered in Chicago. Go to www.bluecrossmn.com to learn more about Blue Cross and Blue Shield of Minnesota.


SOURCE Blue Cross and Blue Shield of Minnesota

Physicians' Choice Leverages InstaMed's Integrated Platform for Healthcare Payment & Clearinghouse Solutions

WOODLAND HILLS, Calif. and PHILADELPHIA, May 6 /PRNewswire/ -- Physicians' Choice, a medical billing service focused on the emergency room physician market, has successfully implemented InstaMed's single, integrated healthcare payments platform, which includes both payment and clearinghouse solutions. As healthcare providers and their billing partners experience increased pressure to collect from payers and patients, InstaMed's solutions are delivering new value to the revenue cycle by accelerating payments and reducing operational overhead by providing increased automation and efficiency.

Billing services like Physicians' Choice continually search for ways to increase patient collections for their provider clients, while also reining in operational burdens related to self-pay collections. By deploying the InstaMed Patient Payment Portal, Physicians' Choice has reduced collection, posting and reconciliation costs and time while increasing patient satisfaction by giving patients more flexible payment options through payment plans and online bill payments. To date, Physicians' Choice has increased patient collections while saving over 44 hours per month - time which is now being redirected towards higher value activities.

Physicians' Choice has also benefitted from implementing InstaMed's clearinghouse solutions, which have accelerated payer responses and payments, while reducing the work effort spent on claims follow up. To date, Physicians' Choice is experiencing responses up to 90% faster than those from previous clearinghouses, which expedites payer reimbursements and increases efficiency around claims follow up and troubleshooting.

"InstaMed's integrated solution gives our staff one solution to manage patient and payer payments," stated Jonathan Sturm, Vice President at Physicians' Choice. "Getting paid in healthcare is a very detail oriented process and being able to rely on a unified technology and service solution has proven very beneficial to our business and to our clients."

Bill Marvin, President and CEO of InstaMed stated, "We are excited to see the results of our partnership with Physicians' Choice. InstaMed's job is to get healthcare providers paid in spite of the complexities of managing over 2,000 healthcare payers, tens of thousands of payment cards, checks and other forms of payments."

Chris Seib, Chief Technology Officer of InstaMed stated, "By delivering one integrated platform and network that handles every healthcare and payment transaction in the revenue cycle, InstaMed's solutions dramatically simplify the healthcare payment process. Additionally, InstaMed delivers a single solution that meets and exceeds the increasing compliance and regulatory requirements that are put on healthcare providers and their billing partners to transact within the healthcare and financial services industries."

About Physicians' Choice

Physicians' Choice, LLC is an experienced billing management team dedicated to meeting the challenges of emergency physician reimbursement. Founded by a practicing ER physician & medical director, we institute a unique model approach to address issues from the clients' perspective. Physicians' Choice provides the industry's only true customizable data collection and processing system with a fully capable electronic process from start to finish. We have proven to be a beneficial information partner, and consistently gain stellar financial results. Physicians' Choice: The innovative leader in emergency physician billing

Visit Physicians' Choice on the web at www.physchoice.com.

About InstaMed

InstaMed is the industry leading healthcare payments network and platform. InstaMed's mission is to transform the healthcare payment process for healthcare Providers, Payers, Banks and Patients so their payment experience is simple, convenient, reliable and secure. InstaMed processes all of the healthcare and payment transactions in the healthcare revenue cycle and offers patent pending, integrated healthcare and payment transactions that accelerate the healthcare payment process and reduce the administrative costs to all parties. InstaMed currently supports the healthcare payment processing needs of over 900 hospital and clinic locations; practice management vendors and billing services representing over 50,000 providers; and hundreds of healthcare payers of all sizes. InstaMed is registered with Visa and MasterCard and is certified as a Payment Card Industry Data Security Standards (PCI-DSS) Level One Service Provider. InstaMed is also fully accredited by the Electronic Healthcare Network Accreditation Commission (EHNAC) as a healthcare clearinghouse. InstaMed is an AHIP Solutions Partner (America's Health Insurance Plans), a member of the C.O.R.E. Initiative (Committee on Operating Rules for Information Exchange), the Medical Banking Project, ASC X12, HBMA (Healthcare Billing & Management Association), Electronic Payments Network ACH Association Services, MGMA's Project SwipeIT (Medical Group Management Association) and WEDI (Workgroup for Electronic Data Interchange). Visit InstaMed on the web at www.instamed.com.


SOURCE InstaMed

Independent Data Monitoring Committee Supports Continuation of Picoplatin Phase 3 SPEAR Registration Trial in Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., May 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced that the independent Data Monitoring Committee (DMC), after review of available information regarding the efficacy, safety and quality of trial conduct, recommends that the SPEAR (Study of Picoplatin Efficacy After Relapse) trial continue. The international, pivotal Phase 3 trial is evaluating the efficacy and safety of picoplatin in patients with small cell lung cancer (SCLC) who were refractory to or progressed within six months of first-line therapy.

"The recommendation by the DMC to continue our SCLC registration trial represents another milestone in the development of picoplatin as a potential new treatment option for SCLC patients," said Jerry McMahon, Ph.D., chairman and chief executive officer of Poniard. "We are encouraged by the continued progress of the trial and remain on track to complete the clinical data analysis to support the initiation of a New Drug Application with the U.S. Food and Drug Administration this year."

About the Independent DMC

The DMC is an independent, multi-disciplinary group consisting of clinicians and a biostatistician that, collectively, have experience in the management of patients with SCLC and in the conduct and monitoring of randomized clinical trials. The DMC is responsible for safeguarding the interests of the SPEAR trial participants, assessing the safety and efficacy of the interventions during the trial, and for monitoring the overall conduct of the clinical trial. To contribute to enhancing the integrity of the trial, the DMC will also review whether Best Supportive Care (BSC) is qualitatively or quantitatively adequate or inadequate within and between the treatment arms.

Phase 3 SPEAR Trial Design and Special Protocol Assessment (SPA)

SPEAR is an international, multi-center, randomized, controlled, pivotal Phase 3 trial of picoplatin in patients with SCLC who were refractory to or progressed within six months of first-line, platinum-containing chemotherapy. Patients are randomized two to one to receive picoplatin plus BSC verses BSC alone. The initial dose of picoplatin is 150 mg/m squared administered as an intravenous infusion once every three weeks. BSC is designed in accordance with the National Comprehensive Cancer Network's guidelines and includes analgesics, radiation therapy for painful bone metastases, brain metastases or relief of obstructive symptoms from lesions in the chest, nutritional support and treatment of anemia, dyspnea, infections, paraneoplastic syndromes, anxiety or other clinical problems. The primary endpoint of SPEAR is overall survival. Secondary endpoints include overall response rate, progression-free survival, disease control rate and duration of response. The enrollment target for SPEAR was reached and a total of 401 patients were enrolled from over 100 sites worldwide as of March 31, 2009.

The SPEAR study design is agreed to by the U.S. Food and Drug Administration (FDA) under a SPA. Fast Track designation was granted by the FDA and an Orphan Drug designation was granted by the FDA and European Medicines Agency. The study is 90 percent powered to show a 33 percent reduction in risk in overall survival for the treatment arm compared to BSC alone (hazard ratio = 0.67) (p < 0.05). Our Phase 2 study in resistant or refractory disease or patients who relapsed within 180 days of first-line platinum therapy, demonstrated that patients treated with picoplatin showed a median overall survival of 27 weeks(1). Historical data indicates that BSC treatment of patients with recurrent SCLC have a median overall survival of 14 weeks(2). Based on patient enrollment data, the Company believes that overall survival data will be available from the SPEAR trial in the second half of 2009.

About Small Cell Lung Cancer

SCLC is the most aggressive form of lung cancer and tends to be widespread by the time of diagnosis. According to the American Cancer Society, in the U.S. in 2008 an estimated 32,000 new cases of SCLC were expected to be diagnosed and 52,000 SCLC patients were treated with therapy (American Cancer Society, Cancer Facts and Figures 2009). Patients with SCLC have few treatment options and a poor prognosis. Effective second-line treatment for SCLC is a major unmet need.

About Picoplatin

Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that it has an improved safety profile relative to existing platinum-based cancer therapies. More than 1,100 patients have received picoplatin. Results obtained to date suggest manageable hematologic adverse events with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs. Picoplatin has demonstrated anti-tumor activity in a variety of solid tumors. It is being studied in multiple cancer indications, treatment combinations and by two routes of administration.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in SCLC and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans and commercialization strategy, the timing and results of clinical trials and the potential safety and efficacy of the Company's products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the current distressed economic and financial market, the Company's research and development activities; the results of pre-clinical and clinical testing; the receipt and timing of FDA and other required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and its Quarterly Report on Form 10-Q for the period ended March 31, 2009, which will be filed with the SEC on or about May 11, 2009. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.

(1) Eckardt JR, Bentsion DL, Lipatov ON, et al. Phase II Study of Picoplatin as Second-Line Therapy for Patients With Small-Cell Lung Cancer. JCO 2009;27:2046-2051

(2) O'Brien, M. et al. J Clin Oncol. 2006 Dec ;24(34):5441-7

SOURCE Poniard Pharmaceuticals, Inc.

Dentistry and Mass Disasters: A Dentist's Role as a First Responder During a Public Health Emergency

Dental convention examines mass disaster management


ANAHEIM, Calif., May 4 /PRNewswire/ --


WHEN: Thursday, May 14, 2009 to Sunday, May 17, 2009

WHERE: Anaheim Convention Center (ACC)
800 W Katella Ave Anaheim, CA 92802

CONTACTS: Jessica Joisten 916.524.7686 and Doug Elmets 916.206.8662

WHAT: Approximately 30,000 dental professionals are expected to
attend CDA Presents The Art and Science of Dentistry, the
biannual convention of the California Dental Association.
Hundreds of courses are planned for the four days, providing
dentists from across the U.S. the opportunity to learn the
latest methods and techniques in oral health treatments.
Approximately 600 exhibitors will also be on hand to
demonstrate innovative products and services on the market. The
industry's leading dental professionals and other
internationally renowned speakers will also discuss public
interest issues, such as:


Emergency Preparedness: The Role of Dental Professionals

The majority of the public probably wouldn't think of their dentist as being a first responder during a mass disaster or health emergency, such as a swine flu epidemic. However, as of January 1, 2009, the Dental Practice Act was modified to state that in a declared emergency, dentists who are part of their local emergency response teams and/or have received appropriate training can assist during an emergency, providing services for which they have been trained. This could potentially provide Californians an additional 30,000 health care providers in an emergency situation.

The lecture, led by Dr. Joyce Galligan, associate professor at the USC School of Dentistry and director of the Disaster Preparedness Task Force, will discuss how dentists can better prepare themselves to serve as first responders; review the skill set needed to be a triage officer; and how local, state and federal agencies may utilize dental professionals during a disaster.

Friday, May 15 from 9:30-11:30 a.m. in ACC, Room 204 D

Dentistry and Mass Disasters - CSI Anaheim

This course will discuss the evolution of mass disaster management from the perspective of forensic dentistry. Multiple mass disasters will be discussed including earthquakes, firestorms and terrorism. The role of dentists as first responders in a public health emergency will also be examined.

Sunday, May 17 from 8:30-12:30 p.m. in ACC, Ballroom C

Newest High-Tech Products

This seminar will review the latest products needed for a high-tech practice, some of which would be beneficial in a health emergency. For example, dentists should evaluate their clinical documentation and consider using electronic health records so that they have the ability to transfer health records immediately from one office to another. Also, Lexi-com's online Physician Desk Reference is a great resource to check the latest updates on medication and diseases. Consumers can also learn what the latest technologies on the market are for various dental treatments to see if their dentist is on the cutting edge of technology.

Friday, May 15 from 8-11 a.m. and 1-4 p.m. in ACC, Room 304A/B

Creating Balance: At Work, Rest and Play

Former Ms. Fitness Universe, Kary Odiatu, and Dr. Uche Odiatu will provide an entertaining and enthusiastic lecture that will inspire dentists to reclaim their energy. Attendees will learn to recognize the warning signs and implications of being out of balance; discover the mind-body connection; understand the food-mood connection; and experience a chair-yoga routine. Patients will most likely enjoy spending time with a happy and healthy dentist and their dentist can also use this holistic approach to healthcare to further improve their patients' care and experience.

Friday, May 15 from 9:30-noon in ACC, Ballroom C

Legendary Service at the Ritz-Carlton

There is no question that the word "Ritz-Carlton" evokes images of perfectly polished marble and white gloves. Attendees of this course will learn the secrets of legendary service from internationally recognized presenter, Jeff Hargett, of the Ritz- Carlton Leadership Center. They will be able to take these skills to their practice and wow their patients.

Friday, May 15 from 10-noon in ACC, Room 204A

I'm No Good With Names...but I Never Forget a Face!

Memory expert Bob Gray, CSP, will teach dentists how to increase their ability to recall patients name by 300 to 400 percent. He will explain how to utilize the three major memory systems to attain peak performance in the workplace and how to improve networking skills and self-confidence through increased memory potential, all of which will improve patient satisfaction.

Saturday, May 16 from 9:30-noon and 1:30-4:00 p.m. in ACC, Ballroom E

The California Dental Association is the non-profit organization representing organized dentistry in California. Founded in 1870, CDA supports its members in their practices and service to the public through innovation in education, advocacy and related programs. CDA also contributes to the oral health of Californians through various comprehensive programs and advocacy. CDA's membership consists of more than 24,000 dentists, making it the largest constituent of the American Dental Association. For more information, visit cda.org.


SOURCE California Dental Association

Red Cross Urges Families and Communities to Prepare During Swine Flu Outbreak

American Red Cross. (PRNewsFoto/American Red Cross)

WASHINGTON, DC UNITED STATES

Washing Hands, Recognizing Symptoms Key to Prevent Spread

WASHINGTON, April 29 /PRNewswire-USNewswire/ -- Washing hands and paying close attention to symptoms of illness are just some of the things the public can to do help reduce the risk from the swine flu (H1N1) outbreak, the American Red Cross said today.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO)

"This is a serious situation that has the potential to spread, and it is a good time for families, businesses and organizations to follow good public health practices and to review and update their preparedness plans," said Scott Conner, Senior Vice President of Preparedness and Health & Safety Services at the American Red Cross. "Taking steps to prepare for potential emergencies in advance can go a long way in making families feel safer."

The American Red Cross urges the public to remember these simple actions:

Wash your hands often with soap and water, especially after you cough or sneeze. Alcohol-based hand sanitizers are also effective when soap and water aren't available.
Cover your nose and mouth with a tissue or sleeve when you cough or sneeze. Throw the tissue in the trash after you use it.
Avoid close contact with people who are sick and stay home if you are feeling sick.

Children have been greatly impacted by this outbreak, and need to know how to properly wash their hands to prevent the spread of germs. The Red Cross has partnered with NSF International's (NSF) Scrub Club(R) to educate children about the importance of hand washing to protect them against influenza. The Scrub Club Web site (scrubclub.org) is an easy, online tool to teach kids how to wash their hands and why it's important.

If families are asked to stay home during this outbreak, it's important to have a plan and supplies in place before that happens. The Red Cross recommends:

Stock extra food, water and supplies at home to reduce the need to go out should swine flu become more widespread, limiting potential for exposure to the virus.
Be sure to include household necessities such as laundry detergent, toilet paper, etc. Select foods that are easy to prepare and store.
Make sure you have an adequate supply of essential medications and medical items for all family members. Include non-prescription medications as well.

Other preparedness steps that can be taken include:

Plan for what you would do if you had to stay at home for a period of time.

Talk with family members and loved ones about how they would be cared for if they got sick.

Find out your employer's plans to keep the business open if key staff can't come to work.

Ask your child's school or day care if there are plans to encourage sick children to stay home to reduce the spread of the disease.

Identify how you can get information, whether through local radio, TV, internet or other sources.

For more tips on how to prepare yourself, your family and community for this and other potential emergencies, visit www.redcross.org.

About the American Red Cross:

The American Red Cross shelters, feeds and counsels victims of disasters; provides nearly half of the nation's blood supply; teaches lifesaving skills; and supports military members and their families. The Red Cross is a charitable organization -- not a government agency -- and depends on volunteers and the generosity of the American public to perform its humanitarian mission. For more information, please visit www.redcross.org or join our blog at www.redcrosschat.org.


SOURCE American Red Cross

All Natural System Sweeps Swine Flu Out with the Trash

AUCKLAND, New Zealand, April 30 /PRNewswire/ -- As the world mourns the deaths within Mexico and the first death resulting from swine flu outside of Mexican soil, the World Health Organization has raised the worldwide pandemic alert level to Phase 5. With cases being confirmed in California, Texas, New York, Maine and Massachusetts, as well as the far flung corners of Israel and New Zealand, people all over the globe are beginning to panic.

Although most cases of swine flu outside of Mexico to date have been mild, the discovery that the virus is both airborne and extremely contagious has raised several red flags among healthcare professionals - and with good reason. The Swine influenza A (H1N1) virus is native to pigs, not people, and the lack of human immunity is what has made the virus so deadly throughout Mexico. Resolve Back to Health Minerals -- ResolveSwineFlu.com -- contains all natural minerals designed to naturally eliminate viruses from the blood stream so all symptoms subside.

The human body already has a first rate antiviral defense system in place that rapidly and efficiently removes the virus from the body. The efficiency of this system is why so many deaths due to influenza over the years have been associated with weakened immune systems, such as those found in children and the elderly.

Back to Health Minerals natural mineral supplements are designed to boost the body's own protection system and naturally eliminate the presence of Swine Flu and other viruses from the body within 48 hours. Because the system works in the same way as the body's own defenses rather than the artificial chemicals used in antiviral medications, the system has been 100% effective to date.

Back to Health Minerals do not contain any herbs or medication. The mineral detox can be used by all members of the family. One pack is enough for a family of four to prevent winter colds and influenza, including swine flu.

Back to Health Minerals - for more information, visit www.resolveswineflu.com.


SOURCE ResolveSwineFlu.com

Industry Coalition Advises Against Use of Dietary Supplements as Swine Flu Remedy, Cure

WASHINGTON, May 1 /PRNewswire-USNewswire/ -- The dietary supplement industry is aware of public concern regarding H1N1 flu virus ("swine flu") and of the desire of the public to protect itself against this virus. The trade associations of the dietary supplement industry support the responsible sale and use of health-promoting vitamins, minerals, herbs and other dietary supplements. We are unaware of any scientific data supporting the use of dietary supplements to treat swine flu. Furthermore, federal law does not allow dietary supplements to claim to treat any diseases, including swine flu.

The American Herbal Products Association (AHPA), the Consumer Healthcare Products Association (CHPA), the Council for Responsible Nutrition (CRN), the Natural Products Association (NPA) and the United Natural Products Alliance (UNPA) are therefore endorsing the following unified advisory for marketers and retailers, as well as for consumers of dietary supplements:

Marketers and retailers of dietary supplements are urged to refuse to stock or sell any supplements that are presented as treating or curing swine flu, and


Marketers and retailers should refrain from promoting any dietary supplement as a cure or treatment for swine flu.

Anyone who believes they may have swine flu or may have come in contact with the virus should contact a healthcare professional. More information on swine flu and the proper actions to take if you suspect you are ill is available on the Centers for Disease Control Web site: http://www.cdc.gov/swineflu/swineflu_you.htm.

There are dietary supplements that have much to offer in terms of enhancing general immune function. However, therapies for the treatment of swine flu should only be recommended by qualified healthcare professionals or public health authorities.

The organizations supporting this advisory represent the majority of dietary supplement manufacturers. Each of the associations and its member companies remain committed to providing the American public with high quality products for supporting personal health and permitting "self-care" choices. Each of the associations is also committed to recognizing that there are some health conditions for which the choice of self-care should be actively discouraged. The current global outbreak of swine flu is such a condition.

The American Herbal Products Association (AHPA) is the only national trade association devoted to herbal issues. AHPA's mission is to promote the responsible commerce of herbal products, and its committees generate self-regulations to ensure the highest level of quality with respect to the way herbal products are manufactured, labeled, and sold. Website: www.ahpa.org.

Consumer Healthcare Products Association (CHPA) is the 128-year-old, not-for-profit association representing the makers of over-the-counter medicines and nutritional supplements, and the consumers who rely on these healthcare products. Information on the Association can be found at www.chpa-info.org.

Council for Responsible Nutrition (CRN), founded in 1973, is a Washington, D.C.-based trade association representing dietary supplement manufacturers and ingredient suppliers. CRN members agree to adhere to voluntary guidelines for manufacturing, labeling and marketing and CRN's Code of Ethics. Visit www.crnusa.org.

The Natural Products Association, founded in 1936, represents more than 10,000 retailers, manufacturers, wholesalers and distributors of natural products, including foods, dietary supplements, and health/beauty aids. Association members meet annually each July in Las Vegas at the association's official tradeshow, Natural MarketPlace (http://www.naturalmarketplaceshow.com/).

The United Natural Products Alliance (UNPA), founded in 1991, is an association of dietary supplement and functional food companies that share a commitment to provide consumers with natural health products of superior quality, benefit and reliability. Information on the Association may be found at www.unpa.com.


SOURCE NPA, AHPA, CHPA, CRN and UNPA

The Viral Spiral - How A Meme About the Virus May Be More Contagious Than the Virus Itself

PALO ALTO, Calif., May 4 /PRNewswire/ -- The following is a statement by Joon Yun, Director, Palo Alto Institute:

The world is slowly recovering from the fear of a swine flu pandemic, a panic that has proved more widespread than the virus itself.

Perhaps the original fear of swine flu was well grounded. After all, the "Spanish Flu" of 1918-1919 was a global epidemic that killed somewhere between 20 and 40 million people, and it could happen again.

Swine flu was first believed to be highly contagious, with even a brief exposure to someone afflicted producing the condition. For days, world health officials said they expected to see more confirmed cases and more severe forms. Officials across the country stepped up efforts to look for cases, especially among people who had travelled to Mexico. In Egypt last week, the entire pig population was being slaughtered, because of the irrational fear that swine flu was actually transmitted by contact with pigs.

The fear of swine flu has led to hospital emergency rooms overflowing into parking lots, school closings, including all of the schools in Fort Worth, Texas, along with the shutting of stores and numerous travel restrictions. For a while, China stopped all direct flights to Mexico. Vice President Biden warned against confined spaces and travelling in containers, which is never a good idea even in the best of times. The world economies, already fragile, teetered under the added loads of uncertainty, with the potential for lost revenues from cancelled deals, reduced tourism, and other changes in behaviour and spending patterns.

Those mass numbers have yet to materialize. Currently, World Health Organization officials estimate there are 1,003 cases of swine flu in 20 countries. In the United States, the number of confirmed swine flu cases is about 250 in 35 states as of late Sunday. But this should be put into the context of overall flu deaths. In the US, for example, the Centers for Disease Control are estimating that 36,000 people a year die of flu-related causes, out of a current population of just over 300 million. Apparently, the real pandemic was fear.

These fear-fests appear to be cyclical. The last pandemic scare involved Severe Acute Respiratory Syndrome (SARS) which occurred between November 2002 and July 2003, with 8,096 cases and 774 deaths attributed to the SARS virus in Asia. SARS gave us a "pandemic playbook" of sorts, and we are executing against it now because, quite realistically, it represents our most recent, best practices.

Referring to this document may account for renewed fear, because the memories are still fairly recent. In the end, swine flu may reveal more about the viral nature of memes - the transmission of ideas and cultural touchstones from one human to another - than the viral nature of biological viruses in our interconnected world.

We seem to live in an age when information is conveyed rapidly, too often without sufficient context and commentary by relevant experts. With swine flu and other rapidly-developing and so-called "breaking" news, the media need to under-react and over-explain. This need not deaden the relevance and timeliness of a story, but instead make its impact more thoughtful and less fearful. Swine flu coverage could be considered a case study in how a story became a virus, mutating into misinformation and fear that resulted in irrational outcomes, such as the needless slaughter of pigs or the irrational fear of airplane travel.

The head of the CDC, acting director Dr. Richard Besser, is urging continued vigilance against swine flu in the face of its reduced threat. That's fair, but let's make sure we identify the real emergencies, and not re-infect the population with an information flu that has the potential to spiral out of control.

The preceding is a commentary by Joon Yun, Director, Palo Alto Institute - a think tank whose mission is the pursuit of truth through fundamental research.


SOURCE Palo Alto Institute

Taking Control of Your Diabetes Conference Returns to Indianapolis to Bring Answers, Advocacy and Hope for People With Diabetes

INDIANAPOLIS, May 5 /PRNewswire/ -- In partnership with the Indiana University School of Medicine, the not-for-profit Taking Control of Your Diabetes (TCOYD) will hold its critically acclaimed conference for people living with diabetes on May 30 from 9 a.m. to 5 p.m. at the Indiana Convention Center. The TCOYD conference, lunch and health fair brings national and local medical experts in diabetes care to people with all types of diabetes, those at risk for diabetes, and their loved ones for a day of highly informative and motivational programs. Three of the four co-directors for this unique program are personally living with the challenges of this disease.

TCOYD is a San Diego-based 501c3 diabetes education organization dedicated to informing and empowering people with type 1 and type 2 diabetes to take an active role in their health. The organization was founded by Steven V. Edelman, MD, a diabetes specialist who practices and teaches at the VA Medical Center in San Diego, and the University of California, San Diego. This is the 106th event in the national series of conferences that the organization has presented since 1995, and the third in Indianapolis. More than 1500 people are expected to attend.

Leading specialists from across the country, many of whom have diabetes, will offer practical advice and discuss the latest developments in the treatment of diabetes, the complications of the disease, psychological barriers to controlling diabetes, nutritional issues and much more. TCOYD participants can hear lectures, participate in screenings, experiment with some different forms of exercise and speak one-on-one with diabetes specialists including physicians, exercise physiologists, psychologists, pediatricians, researchers, attorneys, dietitians, pharmacists, podiatrists and sleep specialists.

A health fair with 50 informational exhibits from national and local diabetes-related companies and organizations will be open throughout the day. Lunch is included and will feature special guest speaker Nicole Johnson, 1999 Miss America winner and renowned diabetes advocate. Ms. Johnson will share her personal story, living well with type 1 diabetes.

Pre-registration is recommended and financial aid is available for those who need assistance. Early registration fee is $25 per person, before May 27. The registration fee includes lunch, healthy snacks, and all conference activities and materials. FINANCIAL ASSISTANCE IS AVAILABLE BY CALLING TCOYD. Onsite registration begins at 7:30 a.m. and costs $30. The conference is from 9 a.m. to 5 p.m. To register or get more information, call 800-998-2693 or visit www.tcoyd.org.

TCOYD Indianapolis Conference Co-Directors include David G. Marrero, PhD, Professor of Medicine, Department of Medicine, at the Indiana University School of Medicine and Paris Roach, MD, also a professor, and director of endocrinology fellowship training program at Indiana University School of Medicine. Melinda S. Kelly, RN, CDE, Program Coordinator for the Diabetes Prevention Program Outcomes Study at the Indiana University School of Medicine is also co-directing this event. Kelly says, "Education is critical to overcoming this disease and this conference will arm people living with diabetes with the tools to fight back." Dr. Marrero also points out that the best way to improve your diabetes is to learn from others who both share and treat the disease: "Each time I attend a meeting like this, I learn a new approach to dealing with problems that all of us with diabetes experience."

Steven V. Edelman, MD, founder and director of Taking Control of Your Diabetes (TCOYD), was diagnosed with type 1 diabetes at the age of 15. Edelman, an internationally recognized leader in diabetes treatment, research and education, says, "It is my conviction that health care in this country will improve when the people living with diabetes themselves are informed and empowered to take an active role in their own condition."

Contact: Michele Huie
858-755-5683 / huie@tcoyd.org


SOURCE Taking Control of Your Diabetes

Is Age Just a Number?

New Survey Reveals Most People Think They Look Younger Than They Actually Are; Baby Boomers Are Aging Gracefully

FARMINGTON HILLS, Mich., May 4 /PRNewswire/ -- Age may just be a number according to a recent survey conducted by American Laser Centers, the largest provider of non-invasive aesthetic services in the U.S.

The majority of people surveyed (55%) think they look younger than their actual age, while only 9 percent of respondents said they think they look older. More women (58%) than men (48%) think they look younger than their age.

In addition, women appear to be more interested in looking younger than men as 64 percent of women surveyed said they would like to look younger than their actual age compared to 51 percent of men who said they would like to look younger.

The survey also uncovered that the desire to look younger begins after age 25. While 70 percent of people surveyed in the 18-24 age range would like to look "about their age" the trend shifts as you enter the 25-29 age range with more than half of the respondents (51%) expressing they would like to look younger. This trend continued to strengthen as the age of the person surveyed increased. Interestingly, half of all people surveyed (50%) would choose to look like they were in their "20s" if they had a choice.

At 83 percent, Baby Boomers strongly expressed that they would like to look younger than their age, however, many appear to be doing just that as 62 percent said they think they look younger than their age. About one third (31%) of all Baby Boomers surveyed believe they look approximately 10 years younger than their actual age.

24% of 45-50 year olds think they look like they are in their late thirties
38% of 51-54 year olds think they look like they are in their mid forties
30% of 55-60 year olds think they look like they are in their mid forties
33% of 61-63 year olds think they look like they are in their early fifties

Surprisingly, the top reasons people surveyed think they've stayed or become better looking as they've aged have less to do with their physical body and more to do with maturity and mindset:

66% cited a healthier self image
50% cited they are more stylish
46% care less about what people think
28% cited weight loss
15% cited a cosmetic procedure
6% cited weight gain
6% cited plastic surgery

There were approximately 575 total respondents to the independent electronic survey. Complete results can be downloaded at www.americanlaser.com/survey/survey.pdf.

American Laser Centers is the largest and most successful provider of laser hair removal, skin rejuvenation and cellulite reduction therapy, with more than 220 locations in the United States. The company has performed more than two million aesthetic treatments since its founding in 2002. American Laser Centers offers clients laser hair removal, skin rejuvenation, body contouring and cellulite reduction therapy treatments using state-of-the-art-technology under a doctor-supervised regimen. American Laser Centers is proud to offer the industry's only written two-year guarantee for laser hair removal. For a complete list of offerings, visit www.americanlaser.com.


SOURCE American Laser Centers

EO Medicaid Cuts Would Harm People

Health Care for All Michigan Residents Will Suffer

LANSING, Mich., May 4 /PRNewswire-USNewswire/ -- As the recession sends record numbers of Michigan residents onto the Medicaid rolls or into hospital emergency rooms with no health insurance, any mid-year cuts to Medicaid would harm people across the state, health care leaders warned today.

Physicians, hospital executives, long-term-care and mental health providers implored the governor and Legislature to abandon any plans to cut Medicaid from the governor's Executive Order spending reductions to be announced tomorrow.

"We do understand that the state is in dire financial straits, but cuts to Medicaid harm people and we are certain neither the governor nor legislators want to further destabilize the state's fragile health care system," said Spencer Johnson, president of the Michigan Health & Hospital Association (MHA), which represents all 144 nonprofit hospitals in Michigan.

The health care leaders have been told the governor may recommend another 4 percent cut to Medicaid provider rates, which are already grossly inadequate. A 4 percent cut would reduce Medicaid patient care payments by nearly $53 million (this includes federal matching dollars) to save $16 million in general funds between July 1 and Sept. 30. Since 1996, Medicaid hospital patient care funding in Michigan has been slashed by more than $850 million. Currently, Medicaid pays for the health care of nearly 1.7 million Michigan residents, an all-time record high. Most people who rely on Medicaid are children, young families, the elderly and the disabled.

Also straining the health care safety net in Michigan are the rising numbers of people with no health insurance who are seeking care -- for which they cannot pay -- in hospital emergency rooms. According to the U.S. Census Bureau, since 1999, more than 727,000 Michigan residents who had private health insurance, most often provided by an employer, have lost their coverage. The number of Michigan residents with no health insurance now stands at 1.2 million.

Michael A. Sandler, MD, immediate past president, Michigan State Medical Society, said Medicaid cuts in recent years have caused a significant increase in the number of physicians who are being forced to reduce the number of Medicaid patients they can accept. "More cuts to Medicaid would make it even harder for Michigan children, the elderly, and the disabled to see a doctor in our state," Sandler said. "The human toll of cuts, at this time of the year, to an already grossly underfunded Medicaid budget would be significant."

The governor recently noted that cuts to the "important" must be made to "fund the essential." Funding to protect health care is essential, the health care leaders said.

"For generations, Michigan's not-for-profit providers of senior services have been funding programs and services to Michigan's most vulnerable that the state fails to see as essential," said Dave Herbel, president/CEO, Aging Services of Michigan. "When will the administration consider long-term-care programs and services as essential?"

Long-term-care providers in Michigan said more Medicaid cuts will also harm the state's growing population of elderly and disabled residents who need 24-hour skilled health care services.

"The government has a core responsibility to care for Michigan's most frail citizens. Seventy percent of the elderly and disabled residents in nursing facilities are Medicaid beneficiaries," said David LaLumia, president/CEO, Health Care Association of Michigan. "These cuts will result in a loss of jobs, which compromises our ability to provide care at the level they deserve."

"Further Medicaid cuts will close the door to health care, not just for our state's most vulnerable populations, but to everyone," said Dennis Paradis, executive director, Michigan Osteopathic Association. "Our physicians are asking state leaders to protect health care access for all patients."

Within 10 days of the governor proposing Executive Order cuts, the Appropriations Committees of both the House and Senate must approve the cuts or they cannot be implemented.

"Access to behavioral health care is especially essential in times of extraordinary stress and uncertainty for the citizens of Michigan," said Michael Vizena, executive director of the Michigan Association of Community Mental Health Boards. "As we struggle together through this difficult economic downturn, it is not the time to reduce access to supportive mental health and substance use disorder treatment services."

"The Legislature must understand that Medicaid cuts will cause pain and suffering in every one of the state's 110 House districts and in every one of the state's 38 Senate districts," the MHA's Johnson said. "Difficult choices must be made and cuts that do not cause human pain are required. Health care cuts will cause human pain and we urge the governor to abandon those cuts, and we urge the Legislature to reject these cuts if they come before the House and Senate Appropriations Committees."


SOURCE Michigan Health & Hospital Association

Barriers to Health Care, Prescription Choice Hurt Patients, Leading Doctor Says

WASHINGTON, April 28 /PRNewswire/ -- A major barrier to health care is unauthorized prescription drug switching, said Dr. Richard Allen Williams, a leading author and founder of the Minority Health Institute.

In his keynote address to the National Minority Quality Forum in Washington Monday, Williams said the U.S. would be better served if physicians had more say to make decisions based on patient's needs without artificial barriers set by outside parties.

The National Minority Quality Forum, a leader in tackling the issue of health disparities, hosted its Sixth Annual Health Disparities Leadership Summit April 27-28 at the Ritz Carlton Hotel in Washington.

Gary A. Puckrein, PhD, President and CEO of the National Minority Quality Forum (formerly the National Minority Health Month Foundation), founded the organization in 1998 to address the critical need for strengthening national and local efforts to use evidence-based, data-driven initiatives to guide programs to eliminate the disproportionate burden of premature death and preventable illness for racial and ethnic minorities.

Speaking at the event, Williams noted that a survey by the Medical Society of the State of New York shows that more than 90 percent of physicians indicated they had to change patient treatment (or medication) based on restrictions from insurance companies.

Williams said restrictions should be eased so doctors, for example, have more flexibility in ordering diagnostic tests instead of requiring prior authorization; develop formularies based on appropriate clinical evidence; and protection of patients from formulary changes.

Doctors are finding it more difficult to care for patients because of restrictions placed on their decision-making ability. For example, every day physicians have their authority and expertise questioned by insurance companies through "switching" - when an insurance company pressures doctors and patients to switch from a medicine that may be working well to either a less-expensive generic alternative or another cheaper drug that might have different active ingredients. The result for some patients is increased risks and less effective care.

Much of the time, physicians prescribe the least expensive medication or generic equivalent for the best medical outcome. They don't need third parties questioning the drugs they prescribe and the reasons for those prescriptions.

Williams wrote "The Textbook of Black-Related Diseases," which details medical conditions peculiar to African Americans. It's the only book of its kind and is considered the classic seminal work on the medical status of blacks.

Also speaking on the National Minority Quality Forum panel was Tammy Banks of the American Medical Association. Banks, Director of the Practice Management Center and Payment Advocacy, spoke on the "Diagnosis and Cure for the Broken Claims Process."

To help reduce the substantial administrative burden of ensuring accurate insurance payments for physician services, Banks said the AMA launched the Heal the Claims Process campaign to help cure the ailing system of processing medical claims with health insurers and unveiled the first AMA National Health Insurer Report Card on claims processing.

A third panelist, David Satin, MD, spoke on "The impact of Pay For Performance On Health Care Disparities." He discussed the pros and cons of pay for performance and how it might impact health disparities.

Satin is a Postdoctoral Fellow at the University of Minnesota's Center for Bioethics and Assistant Professor in the University's Department of Family Medicine and Community Health. He practices family medicine at Smiley's Family Medicine Residency Program in Minneapolis.


SOURCE National Minority Quality Forum

New Olivia Greets Patient Check-in Solution Streamlines Healthcare Operations

CHICAGO, May 4 /PRNewswire/ -- Olivia Greets, a live, 24-hour, avatar-based virtual receptionist company, has launched a new product targeting the healthcare market. The Olivia Greets Patient Check-in Solution allows busy healthcare clinics, doctors' offices and hospitals to streamline the check-in process similar to how airline companies have added check-in kiosks for customers to use.

The Olivia Greets solution provides patients with different options to check in, allowing them to leverage self-service kiosk. Since the Olivia Greets solution is integrated with the practice management application, the staff is alerted when a patient has arrived and checked in. Additional modules may be added and integrated as required.

Jim Farrell, President of Olivia Greets, said, "Many patients are using self-service technology in other areas of their lives--from ATMs and airlines to supermarkets and fast food restaurants--and often find the Olivia Greets system to be easy to use and more convenient than waiting in line to talk with the receptionist. We felt the time was right to enter the healthcare market as it attempts to consolidate data and improve efficiency and accuracy, as these are all things the Olivia Greets Patient Check-in Solution provides."

The unique feature that distinguishes Olivia Greets is the live, knowledgeable avatar that can walk otherwise computer-weary patients through the touch screen check-in process. The avatar is operated by a call center agent, thus allowing greater flexibility than a standard kiosk in assisting patients.

Today's healthcare organizations are constantly looking for new ways to be more efficient, while at the same time enhancing patient care. While numerous technological patient care advancements have been seen in examination rooms throughout the last ten years, very few have made their way to the waiting room until now. The Olivia Greets patient kiosk can reduce overhead or allow for the reallocation of resources, resulting in a more efficient waiting room.

The Patient Check-in Solution is built off of Olivia Greets' proven virtual receptionist technology, which is currently in use across a variety of companies and organizations in a wide range of industries. The core technology uses a touch-screen device, a customizable avatar to greet visitors and live, back-end interaction with Olivia Greets' call center.

To learn more, visit www.oliviagreets.com.


SOURCE Olivia Greets

Parents: Bottled Water Trend Poses Threat to Dental Health

CHICAGO, April 16 /PRNewswire-USNewswire/ -- Five billion gallons of bottled water were consumed in 2000, an increase of more than 200 percent from a decade earlier. Whether consumers drink more bottled water because it is an alternative to soda, or because it is convenient to do so is unclear, but one thing is certain: they are missing out on the valuable fluoride found in tap water, which helps to protect teeth from cavities, according to a study published in the January/February 2009 issue of General Dentistry, the Academy of General Dentistry's (AGD) clinical, peer-reviewed journal.
Researchers tested the fluoride content in more than 100 different samples of bottled water, which fell into six categories: distilled, drinking/purified, spring/artesian, mineral, fluoride-added and flavor-added. Of the total 105 samples, the fluoride concentrations in the majority of the samples fell below the U.S. government's recommended range of 0.7-1.2 parts per million (ppm), the ideal range to prevent cavities. Only five samples met the recommended range.
Lead author of the study, Ryan L. Quock, DDS, recommends that consumers speak with their dentist about their primary drinking water source. "Understanding consumers' water drinking habits is extremely important," he says. "Determining if they are drinking appropriately fluoridated water, especially when they have or are at risk for cavities, is crucial information, because fluoridated water is an automatic way for them to help improve their oral health. Talking to them also allows us to have a conversation about fluoride's effects, mainly focusing on its relationship to dental caries and fluorosis."
Receiving the appropriate amount of fluoride is critical to consumers' oral health -- especially children's oral health -- as it strengthens the teeth and protects them against cavities. Patricia Meredith, DDS, MS, FAGD, AGD spokesperson, advises parents to do their research before handing their child a water bottle.
"Parents should be in charge of how much bottled water their kids drink, in order to make sure that that they also receive the proper amount of fluoridated water that will keep their teeth healthy," says Dr. Meredith. Fluoride in toothpaste, water supplies and other oral hygiene products is one of the basics of keeping children's mouths healthy, Dr. Meredith adds. "With soda and energy drinks being as popular as they are, not to mention the attractiveness of sugary snacks, children's mouths are constantly fighting cavity-causing bacteria. Something as simple as drinking water from the tap is a no-nonsense and cost-effective way to prevent cavities."
The AGD supports the use of fluoride and adopted a position statement based on the Center for Disease Control's Recommendation for Using Fluoride, which states, "When used appropriately, fluoride is safe and effective in preventing and controlling dental caries. Regular use throughout life will help protect teeth against decay. All water supplies, including bottled water, should have appropriate fluoride levels. All fluoridated items, including toothpaste, should be used as recommended by your dentist."
About the AGD:
The Academy of General Dentistry (AGD) is a professional association of more than 35,000 general dentists dedicated to staying up-to-date in the profession through continuing education. Founded in 1952, the AGD has grown to become the world's second largest dental association, which is the only association that exclusively represents the needs and interests of general dentists. More than 786,000 persons are employed directly in the field of dentistry. A general dentist is the primary care provider for patients of all ages and is responsible for the diagnosis, treatment, management and overall coordination of services related to patients' oral health needs. Learn more about AGD member dentists or find more information on dental health topics at www.knowyourteeth.com.
SOURCE Academy of General Dentistry

Welcome to the Medical Query blog

Welcome to the Medical Query blog.